Status Page  
 
 
 
PROTOCOL 14 -359 
 
   
 
Permanent   
Closed to New  Accrual   
 
 
 
  
 
  
 
  
Closure Effective Date: 06/11/2018  
No new subjects may be enrolled in the study as described above.  Any questions regarding this closure should be directed to the 
study’s Principal Investigator  
 
 
 
 
Page 1 of 1 
Date Submitted:  10/23/2017  
Alert Page  
DF/HCC Protocol #:   14-359 
 
Revised : 07.01.13  
Safety / Drug (includes preparation, administration, dose modifications, 
equations) 
   
Protocol Section 2.7.6, Section 9.7, Section 10, and Appendix F:  The 
research blood draw for cfDNA will occur at baseline and at end of treatment. [Amendment forthcomi ng] 
 Protocol Section 10: The research blood draw for Plasma biomarkers should 
occur at baseline, C1D8, C2D1, C3D1, C4D1, C5D1, C6D1 and then every 2 cycles, and at end of treatment . [Amendment forthcoming]  
 Protocol Section 10: If the research blood draw s are not performed at screening 
then it can be collected on C1D1 prior to the start of treatment.  [Amendment 
forthcoming]  
 Protocol Section 5.2: Urine protein / creatinine ratio (UCPR) is collected at the start every odd cycle beginning C3D1. The UCPR from odd cycles may be used as the criteria to treat on even cycles.  
 
  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 9/ July 17, 2017 
CONFIDENTIAL 
This document is confiden tial. Do not disclose or use except as authorized   
1 Protocol Version/Date:  Version 9/ July 17, 2017  
 
NCI Protocol #: N/A  
 
Local Protocol #:  14-359   
 
Title:   A Phase II study of cabozantinib alone or in combination with trastuzumab in breast 
cancer patients with brain metastases 
 
 
Principal Investigator :  Sara Tolaney, MD, MPH 
             Dana-Farber Cancer Institute              450 Brookline Avenue, Y1257              Boston, MA 02215 
 
Coordinating Center: Dana -Farber Cancer Institute  
 Co-Investigators:  Da n G. Duda, DMD, PhD 
 Steele Laboratory 
 149 Thirteenth Street , MGH East, CNY 3.407 
  Charlestown, MA 02129  Email: dan@steele.mgh.harvard.edu  
 
Nancy Lin, MD 
 450 Brookline Avenue, Yawkey 1237  Dana-Farber Cancer Institute 
 Boston, MA 02215 
 Phone: 617-632-2335  Fax: 617-632-1930 
 Email: nlin@partners.org   
  Eric Winer, MD 
 450 Brookline Avenue, Yawkey 1244  Dana-Farber Cancer Institute  Boston, MA 02215  Phone: 617-632-6876  Fax: 617-632-1930  Email: ewiner@partners.org   
  Sally Tan 
 25 Shattuck Street  Boston, MA 02115   Harvard Medical School  Phone: 917-232-5818  Email: sally_tan@hms.harvard.edu   
 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 9/ July 17, 2017   
CONFIDENTIAL 
This document is confiden tial. Do not disclose or use except as authorized   
2 Study Coordinator:  Madeline Tenenbaum  
  450 Brookline Ave, Dana 157 
  Boston, MA 02215   Phone: 617-632-2342    Fax: 617-632-3550   Email: Madeline_Tenenbaum@DFCI.HARVARD.EDU  
 
 
Responsible Research Nurse:   Elizabeth Kasparian 
  450 Brookline Ave., Yawkey 1220  
  Boston, MA 02215    Phone: 617-632-5046   Fax: 617-632-3380    Email: ekasparian@partners.org   
  
Agent(s):   Cabozantinib (NSC #; IND# 116866) 
 
  
Phase II study of cabozantinib in breast cancer with brain metastases   
Version 9/ July 17, 2017   
CONFIDENTIAL 
This document is confidential. Do not disclose or use except as authorized   
3 SCHEMA 
 
 
Eligibility: 
Metastatic breast cancer 
New or progressive CNS lesions, one of which must be measurable 
 Cohort 2:  
Hormone receptor-
positive  
(ER+ and/or PR+) 
Cohort 3:  
Triple negative 
(ER-, PR-, HER2-) 
REGISTER Treatment 
 
cabozantinib  
(21 day cycle) Imaging every 
6 weeks REGISTER Treatment 
 
cabozantinib  
(21 day cycle) 
+ trastuzumab  
(every 3 weeks) Imaging every 
6 weeks Cohort 1:  
HER2-positive* 
REGISTER Treatment 
 
cabozantinib  
(21 day cycle) Imaging every 
6 weeks 
* Accrual will be paused when 6 patients have recei ved first doses of cabozantinib and trastuzumab in 
this cohort (see section 5. 3 for safety evaluation) 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 9/ July 17, 2017   
CONFIDENTIAL 
This document is confiden tial. Do not disclose or use except as authorized   
4 TABLE OF CONTENTS 
SCHEMA ........................................................................................................................ ............... 3  
1.  OBJECTIVES ................................................................................................................... 8 
1.1 Study Design ........................................................................................................... 8  
1.2 Primary Objectives ................................................................................................. 8  
1.3 Secondary Objectives .............................................................................................. 8  
2.  BACKGROUND ............................................................................................................... 9  
2.1 Cabozantinib ........................................................................................................... 9  
2.2 Cabozantinib Nonclinical Toxicology................................................................... 10  
2.3 Clinical Experience of cabozantinib ..................................................................... 11  
2.4 Trastuzumab .......................................................................................................... 16  
2.5 Brain Metastases in Breast Cancer ...................................................................... 18  
2.6 Rationale ............................................................................................................... 18  
2.7 Correlative Studies Background ........................................................................... 22  
3  PARTICIPANT SELECTION ...................................................................................... 24  
3.1 Inclusion Criteria .................................................................................................. 24  
3.2 Exclusion Criteria ................................................................................................. 28  
3.3 Inclusion of Women, Minorities and Ot her Underrepresented Populations ........ 31  
4  REGISTRATION PROCEDURES ............................................................................... 31  
4.1 General Guidelines for DF/HCC and DF/PCC Institutions ................................. 31  
4.2 Registration for DF/HCC Institutions .................................................................. 32  
5  TREATMENT PLAN ..................................................................................................... 33  
5.1 Treatment Overview ............................................................................................. 33  
5.2 Pre-treatment Criteria ......................................................................................... 35  
5.3 Initial Safety Evaluation of cabozantinib + trastuzumab ................................. 36  
5.4 Agent Administration ........................................................................................... 38  
5.5 General Concomitant Medication an d Supportive Care Guidelines .................... 39  
5.6 Potential Drug Interactions .................................................................................. 40  
5.7 Compliance ........................................................................................................... 42  
5.8 Study Drug Accountability .................................................................................... 43  
5.9 Duration of Therapy .............................................................................................. 43  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 9/ July 17, 2017   
CONFIDENTIAL 
This document is confiden tial. Do not disclose or use except as authorized   
5 5.10 Duration of Follow Up.......................................................................................... 44  
5.11 Criteria for Removal from Study........................................................................... 44  
6  EXPECTED TOXICITIES AND DOSI NG DELAYS/DOSE MODIFICATIONS 
DUE TO CABOZANTINIB ........................................................................................... 45  
6.1 Anticipated Toxicities............................................................................................ 45  
6.2 Dose Modifications/Delays and Toxicity Management ........................................ 45  
6.3 Management of Adverse Events ............................................................................ 46  
7  EXPECTED TOXICITIES AND DOSI NG DELAYS/DOSE MODIFICATIONS 
DUE TO TRASTUZUMAB ........................................................................................... 65  
7.1 Recommendations for Dose Modificati on of Trastuzumab Based on Cardiac 
Monitoring ............................................................................................................. 65  
7.2 Management of Acute Infusion Syndrome ............................................................ 66  
8  DRUG FORMULATION AND STORAGE ................................................................. 67  
8.1 Cabozantinib ......................................................................................................... 67  
8.2 Trastuzumab .......................................................................................................... 69  
9  CORRELATIVE / SPECIAL STUDIES METHODS ................................................. 70  
9.1 Evaluate c-Met and phosphor-c-Met exp ression in FFPE tumor tissue (and 
optional baseline tumor biopsies, if available) ..................................................... 70  
9.2 Evaluate the incidence of c -Met positive circulating tumor cells at baseline ...... 70  
9.3 Evaluate potential plasma bi omarkers of cabozantinib ........................................ 71  
9.4 Cerebral blood volume, blood flow, ve ssel size, tumor infiltration ...................... 72  
9.5 Pain Assessments .................................................................................................. 73  
9.6 Tumor biopsies ...................................................................................................... 74  
9.7 Blood sample collection ........................................................................................ 74  
10  STUDY CALENDAR ..................................................................................................... 76  
11  MEASUREMENT OF EFFECT ................................................................................... 80  
11.1 Definitions ............................................................................................................. 80  
11.2 Disease Parameters .............................................................................................. 80  
11.3 Methods for Evaluation of Measurable Disease ................................................... 82  
11.4 Response Criteria.................................................................................................. 84  
11.5 Neurological Signs and Symptoms (NSS) ............................................................. 89  
12  ADVERSE EVENT REPORT ING REQUIREMENTS.............................................. 90  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 9/ July 17, 2017   
CONFIDENTIAL 
This document is confiden tial. Do not disclose or use except as authorized   
6 12.1 Definitions ............................................................................................................. 90  
12.2 Procedures for AE and SAE Recording and Reporting ........................................ 92  
12.3 Expedited SAE Reporting Guidelines ................................................................... 93  
12.4 Reporting to the Institutional  Review Board (IRB)............................................... 94  
12.5 Reporting to the Food and Drug Administration (FDA) ...................................... 94  
12.6 Reporting to the Hospital Risk Management ........................................................ 95  
12.7 Monitoring of Adverse Events and Period of Observation ................................... 95  
13  DATA AND SAFETY MONITORING ........................................................................ 95  
13.1 Data Reporting...................................................................................................... 95  
13.2 Safety Meetings ..................................................................................................... 96  
13.3 Monitoring ............................................................................................................ 97  
14  REGULATORY CONSIDERATIONS ........................................................................ 97  
14.1 Protocol Review and Amendments........................................................................ 97  
14.2 Informed Consent .................................................................................................. 97  
14.3 Ethics..................................................................................................................... 98  
14.4 Study Documentation ............................................................................................ 98  
14.5 Records Retention ................................................................................................. 99  
15  STATISTICAL CONSIDERATIONS .......................................................................... 99  
15.1 Study Design / Endpoints ...................................................................................... 99  
15.2 Sample Size / Accrual Rate ................................................................................... 99  
16  PUBLICATION PLAN ................................................................................................ 102  
REFERENCES .................................................................................................................... ...... 103 
APPENDIX A:  PERFORMANCE STATUS CRITERIA.................................................... 107  
APPENDIX B:  PAIN QUESTIONNAIRE ............................................................................ 109  
APPENDIX D:  PARTICIPANT’S MEDICATION DIARY ............................................... 112  
APPENDIX E:  NEUROLOGICAL  SIGNS AND SYMPTOMS ......................................... 113  
APPENDIX F:  RESEARCH SPECIMEN COLLECTION/SHIPPING GUIDELINES .. 115  
APPENDIX G:  STUDY D RUG ORDER FORM ................................................................. 119  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 9/ July 17, 2017   
CONFIDENTIAL 
This document is confiden tial. Do not disclose or use except as authorized   
7 APPENDIX H:  STRECK COLLECTION AND PROCESSING INSTRUCTIONS – FOR 
OUTSIDE OF DFCI LAB USE ONLY ....................................................................... 120  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
8 1. OBJECTIVES 
1.1 Study Design 
This is a two-stage Phase 2 study assessing th e efficacy of cabozantinib (alone or in 
combination with trastuzumab) in patients  with metastatic breast cancer and brain 
metastases. Cabozantinib is a small molecule inhibitor of multiple receptor tyrosine 
kinases (RTKs) including MET, VEGF r eceptor-2 (VEGFR2), RET, and KIT, when 
given as monotherapy.  The population to be studied will consist of patients with 
metastatic breast cancer with measurable central nervous system (CNS) lesions.  
Treatment will consist of once daily oral dos ing of cabozantinib (60 mg po day), during 
a 21 day cycle.  Patients will also receive trastuzumab (8 mg/kg IV loading dose followed by 6 mg/kg IV every 3 weeks) if th ey have a HER2-positive breast cancer.  
Patients will undergo restaging scans at 6 week s.  Patients with stable or responsive 
disease after completion of 6 cycles may have  the frequency of restaging scans reduced 
to once every 3 cycles. Patients with complete or partial responses, or stable disease, will continue to receive cabozantinib.  Patients with progressive disease will be taken off study.  Archival tissue from patients will be obtained if possible ( please refer to 
Appendix F  for archival tissue guidelines); however, if archival tissue is not 
available the patient may still participate in the study.  The patient will have an 
opportunity to participate in an optional tumor biopsy study;  however, the biopsy is not 
mandatory to participate in the study.  Goal accrual is 37 patients (up to 40 patients will be enrolled), including 21 HER2-positive patients, 8 ER-positive patients, and 8 triple-negative patients.  
1.2 Primary Objectives 
1) To evaluate the CNS objective response rate (ORR), defined by RECIST 1.1, in patients with HER2-positive metastatic breast cancer and brain metastases  
1.3 Secondary Objectives 
1) To evaluate the CNS ORR in patients with  hormone receptor positive metastatic 
breast cancer and brain metastases by RECIST 1.1 
2) To evaluate the CNS ORR in patients with triple-negative metastatic breast cancer 
and brain metastases by RECIST 1.1 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
9 3) To evaluate the CNS ORR in patients with HER2-positive, hormone receptor 
positive, and triple-negative metastatic breast cancer and brain metastases by 
volumetric criteria and composite criteria 
4) To evaluate ORR in non- CNS sites (by RECIST 1.1) 
5) To evaluate Progression-Free Survival (PFS) 
6) To evaluate the clinical benefit rate 
7) To evaluate site of first progression (CNS versus non-CNS) 
8) To evaluate overall survival (OS)  in total study population.  
9) To evaluate c-Met and phospho c-Met expression in archival tumor tissue 
10) To evaluate the incidence of c-Met amplif ied circulating tumor cells at baseline 
11) To evaluate potential plasma biomarkers of  cabozantinib when given in combination 
with trastuzumab 
12) To assess vascularity of CNS tumors, thro ugh descriptive analysis of tumor vessel 
size, cerebral blood volume, cerebral blood flow, perfusion, and diffusion before and 
after exposure to cabozantinib 
13) To assess the safety and tolerability of cabozantinib wh en given in co mbination with 
trastuzumab 
14) To collect blood to study cell-free DNA for comparison to tumor specimens 
 
2. BACKGROUND 
2.1 Cabozantinib 
A summary of cabozantinib clinical and nonc linical experience is contained in the 
Investigator’s Brochure supplied by Exelixis . The Investigator’s Brochure should be 
reviewed in conjunction w ith this study protocol. 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
10 Cabozantinib is a new chemical entity that inhibits multiple RTKs with 
growth-promoting and angiogenic properties. The primary targets of cabozantinib are 
RET, MET, VEGFR2/KDR, and KIT (see below).   
Table 1.  Cabozantinib IC 50 Values in Biochemica l, Enzymatic Assays 
 
Kinase IC 50 (biochemical) [nM] 
RET 3.8 
MET 1.8 
VEGFR2/KDR 0.035 
KIT 4.6 
IC50, concentration required for 50 % target inhibition. 
In vivo data from pharmacodynamic experiments show that cabozantinib inhibits key RTKs that promote tumor cell proliferat ion and/or angiogenesis (RET, MET, and 
VEGFR2). In xenograft tumor models, cabo zantinib inhibited VE GFR2 phosphorylation 
in lung tissue, with an ED
50 of 26 mg/kg. The duration of  action for cabozantinib was 
sustained with > 50 % inhibition observed 10-24 hours post-dose at a dose level of 
100 mg/kg for all targets studied.  
Treatment with cabozantinib shows rapid eff ects on the tumor endothelium, resulting in 
breakdown of the vasculature beginning 24 hour s after administration of cabozantinib, 
thus suggesting potent anti-angiogenic effects of cabozantinib. These effects translate 
into significant tumor growth inhibition after cabozantinib treatment in multiple tumor 
models including human MTC, human breast cancer, human lung carcinoma, and rat glioblastoma. Overall, the data generated in vivo demonstrate that the target profile of 
cabozantinib translates to potent anti-angioge nic activity and potent anti-tumor efficacy. 
 
2.2 Cabozantinib Nonclinical Toxicology 
In nonclinical toxicity studies in rodent s and non-rodents, histopathological changes 
associated with cabozantinib administration were observed in gastroin testinal (GI) tract, 
bone marrow, lymphoid tissues, kidney, adrenal, and reproductive tract tissues. 
Histopathological changes present in bone and pancreas were considered secondary to 
cabozantinib administration. Cabozantinib was negative in in vitro  bacterial, in vitro 
mammalian cell, and in vivo mammalian genotoxicity bioassays . In reproductive toxicity 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
11 studies, cabozantinib was embryotoxic in rats, produced fetal soft tissue changes in 
rabbits, and decreased fertility in male and female rats. 
Safety pharmacology studies of cabozantinib administration did not demonstrate adverse 
effects on neurobehavioral or respiratory-system function in rats; furthermore, no 
significant changes in electrocardiographic parameters (including corrected QT [QTc] interval) were observed by telemetry in dogs. 
Cabozantinib was not an inhibi tor of cytochrome P450 (CYP) 3A4 in vitro and is not 
predicted to have signifi cant effects on CYP3A4 inducti on. Cabozantinib was shown to 
be an inhibitor of CYP2C8, CYP2C9*3, and CYP2C19 isozymes, in vitro and was also a 
substrate of CYP3A4-mediated metabolism.  The mean plasma protein binding by 
cabozantinib in vitro was greater than 98%. 
Additional toxicology information may be found in the Investig ator’s Brochure. 
2.3 Clinical Experience of cabozantinib 
2.3.1 Clinical Summary 
The single agent maximum tolerated dose (MTD ) on the once daily (qday) oral dosing 
schedule has been determined to be 60 mg po qday. Details of all studies may be found 
in the Investigator’s Brochure. 2.3.2 Clinical Safety Profile 
The adverse event (AE) and serious adverse event (SAE) data summarized in the 
following section includes those reported and en tered in the clinical database and safety 
database published as of July 2013 (IBv9). The clinical studies with cabozantinib are 
ongoing, thus the AE data from the clinical da tabase does not yet include all SAEs. Data 
from double-blinded studies are not presented. The severity of AEs was assessed using the Common Terminology Criteria for A dverse Events (CTCAE) version 3.0.  
2.3.3 Adverse Events 
As of February 28, 2013, 1311 subjects have be en studied in open-la bel clinical trials 
with cabozantinib, including treatment with cab ozantinib as a single agent. The available 
pooled data in this database in clude studies XL184-001, XL184-008, XL184-201, 
XL184-203, XL184-205, and XL184-301 cabozantinib  arm. The most frequently ( ≥ 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
12 20%) observed AEs, regardless of causality, were fatigue (66.7%), diarrhea (63.1%), 
decreased appetite (51.9%), nausea (51.9%), weight decreased (36.0%), PPES (35.9%), vomiting (34.1%), constipation (33.2%), dys geusia (28.0%), hypertension (27.8%), 
dysphonia (26.3%), abdominal pain (23.3%),  aspartate aminotransferase (AST) 
increased (23.0%), dyspnea (21.3%), head ache (20.9%), rash (20.4%), and ALT 
increased (20.2%). The safety profile of si ngle-agent cabozantinib is consistent across 
tumor types. 
The most frequently ( ≥ 20%) observed AEs reported as related to cabozantinib, were 
fatigue (60.0%), diarrhea (56.1%), decreased appetite (44.1%), nausea (42.4%), PPES 
(35.6%), weight decreased (29.1%), dysgeus ia (27.1%), hypertensi on (24.0%), vomiting 
(23.5%), dysphonia (22.0%), and AST increased (20.1%). 
The most common AEs (≥  5%) reported at severity of Gr ade 3 and above include fatigue 
(15.9%), diarrhea (11.1%), hypertension (9.7%),  PPES (8.9%), lipase increased (6.8%), 
PE (5.9%), abdominal pain (5.5%), decrea sed appetite (5.3%), and asthenia (5.0%).   
Serious Adverse Events Out of all 1311 subjects enrolled in open -label, single-agent clinical trials with 
cabozantinib, 688 subjects (52.5%) experienced  one or more SAEs recorded in the 
Argus Safety Database, and 300 (22.4%) subj ects experienced one or more SAEs that 
were assessed to be related to treatment with cabozantinib. The most commonly reported 
SAEs (≥ 2%) were pulmonary embolism (5.1%),  vomiting (3.4%), dehydration (3.2%), 
pneumonia (3.0%), nausea (3.0%), abdominal pa in (2.4%), diarrhea (2.4%), deep vein 
thrombosis (DVT; 2.1%), and convulsion (2.0%). subjects), abdomi nal pain (in three 
subjects), and perirectal abscess (in three subj ects). In addition, one late-breaking case of 
reversible posterior leukoencephalopathy s yndrome (RPLS) was reported after the data 
cut-off in the double-blinded placebo-controlled Study XL184-301. As of 28 February 2013, 192 fatal SAEs  were reported (182 on single-agent 
cabozantinib or cabozantinib in combination w ith other therapies, 10 on placebo) across 
all open-label or unblinded company-sponsor ed studies (Studies  evaluated include 
XL184-001, XL184- 002, XL184-008, XL184-014, XL184-201, XL184-202, XL184-
203, XL184-205, XL184-209, XL184-900, and all clin ical pharmacology studies, for a 
total N = 1754). The majority of these SAEs  were attributed to disease progression 
(70.3%). Fifty-seven subjects had fatal SAEs  that were not attributed to disease 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
13 progression, and of these 27 subjects had ev ents related to cabozantinib (24 as single 
agent, 3 in combination with erlotinib). 
Detailed information regarding the safety profile of Cabozantinib from all studies may 
be found in the Investigator’s Brochure (version 9).  
2.3.4 Clinical Pharmacokinetics 
Pharmacokinetic (PK) analysis showed dos e proportional increases in maximum plasma 
concentration (C max) and area under the plasma concentration-vs-time curve (AUC) both 
for the powder-in-bottle (PIB) formulati on (dose range: 0.08 to 11.52 mg/kg) and the 
capsule formulation (dose ra nge: 125 mg to 175 mg). Terminal-phase half-life (t 1/2, z) 
values were 59.1 to 136 hours. More detailed  information regarding cabozantinib PK 
from all studies and product metabolism in humans may be found in the Investigator’s 
Brochure. 2.3.5 Blood Brain Barrier 
No studies of cabozantinib exposure in cer ebrospinal fluid in humans have been 
performed. Two preclinical studi es evaluating tissue distributi on of cabozantinib in brain 
or CNS tissue have been conducted. In a study employing nude mice dosed orally with 
10 mg/kg cabozantinib, exposure in brain tissue was 1.32 ± 0.083 µM four hours post-
dose, compared to 8.19 ± 0.709 µM in plasma at the same time point. A cabozantinib tissue distribution study in pigmented and al bino rats has also been performed using 
radiolabeled cabozantinib. The exposure of  CNS tissue to cabo zantinib-associated 
radioactivity was relatively lo w (tissue to blood ratio of 0.09- 0.10 µg equiv/g) compared 
to most other tissues (e.g. tissue to blood ratios of 2.65 µg equiv/g for liver, 1.28 µg 
equiv/g for lung, and 0.43 µg equi v/g for prostate gland).  
2.3.6 Clinical Activity 
In addition to MTC, cabozantinib has dem onstrated findings consistent with broad 
clinical anti-tumor activity in early Phase 1 and Phase 2 studies in several other tumor 
types. In a randomized discontinuation trial (RDT) XL184-203, th e following disease 
control rates (DCR = complete response [CR] + partial response [PR]  + stable disease 
[SD]) at Week 12 were observed in tumor types including non- small cell lung cancer 
(NSCLC), 38%; breast cancer, 48%; melanoma, 46%; ovarian cancer, 53%; 
hepatocellular carcinoma (HCC), 66%; a nd CRPC, 66%. In Study XL184-008, clinical 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
14 activity was also observed in differentia ted thyroid cancer (DTC; DCR = 73% at 24 
weeks) and renal cell carcinoma (RCC; medi an progression-free survival [PFS] = 12.9 
months). Observations of clinical activity have included decrease of soft tissue tumor 
lesions including visceral metastases, effects on metastatic lesions on bone scan (partial or complete bone scan resolution), reducti on in serum markers of bone resorption and 
formation, reduction in circulat ing tumor cells (CTCs; subjec ts with prostate cancer), 
increases in hemoglobin, and improvements in bone pain and reductions in narcotic use 
in subjects with bone metastases. Activity in MTC and CRPC subject s is described in 
more detail below. 
In the placebo-controlled Phase 3 study XL 184-301 in 330 MTC subjects, a significant 
increase in median PFS was seen in the ca bozantinib arm compared  with placebo (11.2 
vs 4.0 months; hazard ratio [HR] =0.28; 95 CIs: 0.19, 0.40). Confirmed PRs occurred in 
28% of cabozantinib-treated subjects and none  in the placebo arm; responses were 
durable (median duration 14.6 months). An unpla nned administrative analysis of overall 
survival (OS) performed at the request of the FDA with a data cut-off of 15 June 2012 
(75% of required deaths) showed a tr end for improved duration of OS in the 
cabozantinib arm compared with placebo (26.0 months vs 20.3 months; HR = 0.83; 95% 
CI: 0.60, 1.14). In the Phase 1 Study XL184- 001, with an enriched MTC population, 
PRs were reported in 29% of 35 MTC subjects with measurable disease across all dose levels and in 28% of 25 MTC subjects treat ed at the MTD. The median duration of 
treatment for the subjects in Study XL 184-001 with PRs was 17.7 months with one 
subject receiving treatment for 68.4 months on XL184-001 before rolling over onto maintenance trial XL184-900 to cont inue to receive cabozantinib. 
In the Phase 2 study XL184-203, cabozantinib de monstrated broad cl inical activity in 
men with CRPC (Smith et al. 2013). Duri ng the RDT phase, the majority of CRPC 
subjects with bone metastases and elevated to tal alkaline phosphatase  (t-ALP) levels at 
baseline showed reductions in t-ALP (S mith et al. 2013). Similarly, during the non-
randomized expansion (NRE) phase, the majo rity of CRPC subj ects at the 100 mg 
assigned dose showed reductions in circul ating bone specific alkaline phosphatase 
(BSAP) (Smith et al. 2012). These effects were independent of prior or concomitant bisphosphonate treatment. Reductions in bone bi omarkers were also evident in the 40 
mg CRPC NRE cohort (de Bono et al, 2012). Effects on bone scan were assessed by an independent reader, and pain and narcotic use were prospectively assessed using an 
interactive voice recording system (IVRS) and a diary. Subjects achieved a bone scan 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
15 response (BSR) in both the 100 mg and 40 mg assigned NRE dose cohorts (67% and 
49%, respectively). Among subjects with baselin e pain of at least 4 (0-10 scale by Brief 
Pain Inventory [BPI]), a majority had at least a decrease of 30% in the average daily 
worst pain compared with baseline in both cohorts (100 mg: 64% of subjects; 40 mg: 69% of subjects). In addition, more than half of subjects decreased narcotic use.  
Table 2.  Summary of Clinical Studies of Cabozantinib in Cancer Patients 
Protocol 
Number Study Population Study Title Study 
Status 
Phase 1 
XL184-001 Advanced 
tumors, MTC A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to 
Subjects with Advanced Malignancies Complete 
XL184-002 GB A Phase 1 Dose Finding Study of the Safety and 
Pharmacokinetics of XL184 Administered Orally in 
Combination with Temozolomide and Radiation 
Therapy in the First Line Treatment of Subjects with 
Glioblastoma Complete – analysis pending 
XL184-008 Solid tumors, 
RCC, DTC A Phase 1 Drug-Drug Interaction Study of the Effects 
of XL184 on the Pharmacokinetics of a Single Oral 
Dose of Rosiglitazone in Subjects with Solid Tumors Complete – 
analysis 
pending 
XL184-014 Solid tumors Phase 1 Multip le Ascending Dose Study of XL184 
Monotherapy in Japanese Subjects with Advanced or 
Metastatic Solid Tumors Active, 
enrollment 
ongoing 
Phase 1/2  
XL184-202 NSCLC A Phase 1b/2 Study of XL184 with or without Erlotinib 
in Subjects with Non-Small Cell Lung Cancer Complete 
Phase 2  
XL184-201 GB A Phase 2 Study of XL184 in Subjects with Progressive 
or Recurrent Glioblastoma Multiforme in First or Second Relapse Complete – 
analysis 
pending 
XL184-203 CRPC, ovarian, 
NSCLC, HCC, 
melanoma, 
breast, 
gastric/GEJ, SCLC, 
pancreatic A Randomized Discontinuation Study of XL184 in 
Subjects with Advanced Solid Tumors Active, enrollment completed 
XL184-205 GB A Phase 2 Non-Comp arative Randomized Open-Label 
Study of Multiple Regimens of Single-Agent XL184 in 
Subjects with Grade IV Astrocytic Tumors in First or 
Second Relapse Complete – analysis 
pending 
XL184-301 MTC An International, Randomized, Double-Blinded, Phase 
3 Efficacy Study of XL184 Ve rsus Placebo in Subjects 
with Unresectable, Locally Advanced or Metastatic 
Medullary Thyroid Cancer (EXAM) Active, enrollment 
completed 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
16 XL184-307 CRPC A Phase 3, Randomized, Double-Blind, Controlled 
Study of Cabozantinib (XL184) vs. Prednisone in 
Metastatic Castration-Resistant Prostate Cancer 
Patients who have Received Prior Docetaxel and Prior 
Abiraterone or Enzalutamide [COMET-1] Active, enrollment ongoing 
XL184-306 CRPC A Phase 3, Randomized, Double-Blind, Controlled 
Trial of Cabozantinib (XL184) vs. Mitoxantrone Plus Prednisone in Men with Previously Treated 
Symptomatic Castration-Resistant Prostate Cancer 
[COMET-2] Active, enrollment ongoing 
Maintenance “Roll Over” Study 
XL184-900 Advanced 
malignancies A Maintenance Study Evaluating the Long Term Safety of XL184 in Subjects with Advanced Malignancies 
Previously Enrolled in Other XL184 Studies Active, 
enrollment 
ongoing 
 
Expanded Access Study 
XL184-209 MTC An Open-Label, Expanded Access Study of 
Cabozantinib (XL184) in Subjects with Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer Active, 
enrollment 
completed 
 
2.4 Trastuzumab 
2.4.1 Overview 
Trastuzumab is a humanized an ti-HER2 antibody that  binds to the subdomain IV of the 
HER2 extracellular domain an d exerts its antitumor effects by blocking HER2 cleavage, 
stimulating antibody-dependent, cell-mediated cytotoxicity and inhibiting ligand-
independent, HER2-mediated mitogenic signaling.  
2.4.2 Safety profile 
Trastuzumab is a humanized murine antibody. It was engineered so that conserved units of the antibody molecule were transcribed from human DNA sequences, while the specific anti-HER2 domain remained of mouse DNA origin. As a result of these modifications, the antibody is not immunogeni c in the vast majority of people. The 
resulting antibody (Herceptin®, Trastuzumab;  Genentech) has been studied both as a 
single agent and in combination ther apy for metastatic breast cancer. 
Trastuzumab is associated with the potential  for left ventricular cardiac dysfunction and 
congestive heart failure (CHF).  In the pivotal  trial of trastuzumab for metastatic breast 
cancer, the rate of cardiac dysfunction was highest when given concurrently with 
doxorubicin, with a rate of NYHA class II I/IV CHF of 4% in patients receiving 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
17 trastuzumab with paclitaxel (D. Slamon & Leyl and-Jones, 2001). In an adjuvant study of 
carboplatin, docetaxel, and tras tuzumab (BCIRG 006), the rate of grade 3 or 4 left 
ventricular cardiac dysfunction was 0.3% and no cardiac deaths were observed (D. 
Slamon, Eiermann, Robert, & Al., 2006). 
Other reported adverse events  include infusion reactions, characterized by fever, chills, 
nausea, vomiting, headache, dyspnea, hypotensi on, and rash. Trastuzumab may also 
exacerbate chemotherapy-induced neutropenia.  Very rarely, trastuzumab can result in 
serious and fatal pulmonary toxicity. 
2.4.3 Rationale for Trastuzumab in HER2-positive Breast Cancer 
The HER2/ neu oncogene lies on chromosome 17q, and encodes a transmembrane 
glycoprotein (p185) with homology to the epidermal growth  factor receptor. 
Overexpression of HER2 at the genetic or prot ein level is observed in 20 to 25% of all 
breast cancers, and is primarily a consequence of gene amplification (D. J. Slamon et al., 
1987, 1989). Trastuzumab has been studied as first-line ther apy for metastatic breast cancer. In a study 
of 114 women with HER2-positiv e tumors who had not previ ously received chemotherapy 
for advanced breast cancer, a response rate  of 26% was observed with single agent 
trastuzumab (Vogel, 2002). Trastuzumab has al so been used in co mbination with other 
chemotherapy to treat women wi th metastatic breast cancer. In  a phase III clinical trial, 
patients with HER2-positive metastatic br east cancer were randomized to receive 
treatment with either chemotherapy, or chem otherapy and trastuzuma b given concurrently 
(Slamon et al., 2001). A subsequent analysis of this phase III study has demonstrated that 
initial therapy with trastuzumab and chemothe rapy, as opposed to chemotherapy alone, is 
associated with both higher response rates, as well as improved time-to-progression and, 
most significantly, improved overall survival. In patients who have progressed on trastuzumab,  data from one study supports the concept 
that continuation of trastuzumab beyond progression improves the efficacy of 
chemotherapy on systemic (i.e. extra-CNS) me tastases. In a study of 156 patients who had 
previously progressed on trastuzumab-based th erapy, the continuation of trastuzumab with 
capecitabine was associated with a doubling of  the response rate an d improvement in PFS 
compared to capecitabine alone (Von Mi nckwitz, Vogel, Schmidt, & Al., 2007).  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
18 Trastuzumab does not cross the blood-brain barrier (Pestalozzi & Brignoli, 2000) and no 
CNS responses to trastuzumab, given intr avenously, have been documented in the 
literature. The rationale for including trastuzumab is to maintain maximum disease 
control systematically (i.e. outside of the CNS). It is anticipated that the addition of 
trastuzumab to patients with HER2-positiv e breast cancer will not alter the primary 
endpoint of CNS objective response.  
2.5 Brain Metastases in Breast Cancer 
It is estimated that approximately 10-15% of  women with metastatic breast cancer will 
eventually develop brain metastases (Tsuka da, Fouad, Pickren, & Lane, 1983; Tsukada, 
Hurwitz, Kashi, & Al., 1983). It has been noted that several features predict an increased 
risk of CNS recurrence, including young age, African American ethnicity, HER2 
positive or ER-negative primary breast cancer, and the presence of visceral metastases (Barnholtz-Sloan et al., 2004). Our group and Da na-Farber was the first to describe an 
increased incidence in women with HER2-pos itive metastatic breas t cancer, of whom up 
to one-third will be diagnosed with brain metastases (Lin, Bellon, & Winer, 2004). More recently, a high rate of brain metastases has al so been described in patients with triple-
negative (ER, PR, and HER2-negative) tumors with an incidence of 46% (Lin et al., 
2008). Brain metastases are associated with  considerable morbidity and mortality. 
   
2.6 Rationale 
Few treatments exist for such brain metastases  from breast cancer. Treatment is mainly 
aimed at palliation, and genera lly includes whole brain radi ation (WBRT), stereotactic 
radiosurgery (SRS), and/or surgical resect ion.  As systemic therapies have improved, 
CNS progression after WBRT and/or SRS is becoming a significant problem.  Currently 
there is no optimal therapy once this occu rs.  Unfortunately, very few prospective 
studies have examined the role of chemothe rapy in the treatment of brain metastases 
from breast cancer, and most studies of novel agents have excluded patients with brain 
metastases.  Developing effective agents for the treatment of brain metastases from breast cancer is critical. 
Recently, data suggests that anti-angiogenic therapy can be given safely to patients with 
brain metastases, and that clinical activity has been demonstrated.  Norden and colleagues reported a retrospective case series of 55 patients treated with bevacizumab and chemotherapy in patients with glioma (Norden et al., 2008). Of these patients, 2.3% 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
19 achieved a complete response, 31.8% partia l response, 29.5% minimal response, and 
29.5% stable disease.  Vredenburgh and colleagues treated a total of 35 patients with 
recurrent glioma with irinotecan and bevaci zumab and demonstrated a 57% ORR.    
Given the postulated importance of the VE GF pathway in the pathogenesis of brain 
metastases from breast cancer, exploration of anti-angiogenesis approaches for CNS 
metastases from breast cancer is warrante d.  Nancy Lin and colleagues have conducted a 
trial of carboplatin + bevacizumab +/- trastuzumab for patient with metastatic breast cancer and brain metastases and demonstrated  a composite CNS ORR of 63% (Lin et al, 
2013).  
A pre-clinical study in mice by Kodack a nd colleagues found th at treating HER2-
amplified breast cancer patients with a combination of trastuzumab and anti-VEGF 
receptor-2 (VEGFR2) antibody slowed tumor growth in the brain and conferred a significant survival benefit. This benef it was postulated to be due to enhanced 
antiangiogenic effects of these two drugs reducing total and func tional microvascular 
density in the brain, resulting in more necrosis of brain lesions (Kodack et al., 2012). 
Taken together, these evidence suggest some clinical efficacy of anti-angiogenic therapy 
in treating brain tumors and metastases that warrant further clinical study. 
Evidence shows that inhibiting VEGF alone  may only produce a temporary clinical 
response, but that simultaneously inhibiti ng both VEGF and MET with cabozantinib can 
achieve a more durable clinical bene fit. Though VEGF inhibitors alone are 
therapeutically effective for ma ny types of cancer, their clin ical benefit often only last 
for several weeks or months before tumor progression recurs. Precl inical studies have 
found that VEGF pathway inhibition initiall y slows tumor growth and reduces tumor 
vasculature, this is followed by a refract ory period of rapid revascularization and 
increased tumor invasiveness (Casanovas, Hi cklin, Bergers, & Hanahan, 2005; Ebos et 
al., 2009). Resistance to VEGF pathway inhibition may devel op in response to hypoxia. 
Under hypoxic conditions, hypoxi a-inducible factor 1 α is upregulated, which in turn 
increases expression of both VEGF and M ET (Kitajima, Ide, Ohtsuka, & Miyazaki, 
2008; Pennacchietti et al., 2003). These res ponses are a compensatory mechanism 
during periods of hypoxia, and result in more angiogenesis or migration away from the 
hypoxic zone. Because VEGF pathway inhibi tion can result in hypoxia, it may also 
subsequently trigger MET expression. Several studies have shown that the MET 
pathway plays an important role in development of resistance to VEGF pathway inhibition by sunitinib treatment (Pàez-Ribes et al., 2009; Sh ojaei et al., 2010). 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
20 Moreover, additional evidence demonstrates that  VEGF inhibitors such as cediranib can 
lead to increased tumor invasiveness and me tastasis and higher MET expression levels 
(di Tomaso et al., 2011). Taken together, this suggests that simultaneously targeting both 
MET and VEGF can critically disrupt angiogenesis, tumorigenesis and cancer 
progression. 
Evidence from studies suggests that cabozantinib has anti-angi ogenic (anti-VEGFR2) 
activity, CNS penetration, and activity in br east cancer, and could be efficacious in 
treatment of brain metastases from breast ca ncer.  Cabozantinib inhibits c-met, RET, 
VEGFR2/KDR, and KIT.  The safety and to lerability of cabo zantinib have been 
established in a Phase I, single-arm, dose- escalation studies in adult patients with 
advanced solid tumors, and in another Phas e Ib trial evaluating the combination of 
cabozantinib and erlotinib.  The most commonly reported drug-related adverse events 
were diarrhea (40%), fatigue (37%), anor exia (31%), nausea (29%), PPE syndrome 
(20%), increased AST (19%), and rash (18 %).  Data from a randomized discontinuation 
study in heavily pretreated patients with me tastatic breast cancer demonstrated an ORR 
of 14% and a clinical benef it rate at 12 weeks of 48%.  Additionally, there are two 
ongoing studies of cabozantinib in metastatic breast cancer, one in ER+ disease, and one 
in triple-negative breast cancer.  We have  noted two patients who likely had brain 
metastases at time of enrollment onto st udy, though it was unknown at the time, and 
noted that there was treatment effect in the brain with cabozantinib.  One of these 
patients had TNBC, and another ha d ER+, HER2- breast cancer.  
The c-Met receptor is the only high-affinity receptor for hepatocyte growth factor 
(HGF), also known as scatter factor.  Bindi ng of HGF to the c-Met extracellular ligand-
binding domain results in receptor multimer ization and phosphorylation of multiple 
tyrosine kinase residues in the intracellular po rtion of c-Met.  Activ ation of c-Met results 
in the binding and phosphorylation of adaptor proteins, such as Gab-1, Grb-2, Shc, and 
c-Cbl, and subsequent activation of signal tr ansducers such as PI3K, STATs, ERK1 and 
2, and FAK (Christensen et al., 2003; Truso lino, Bertotti, & Comoglio, 2001). c-Met and 
HGF are expressed in numerous tissues, and their expression is pr edominantly confined 
to cells of epithelial and mesenchymal origin, respectively (Trusolino et al., 2001). HGF and Met promote cell proliferation, motility, invasion, and stimulate tissue repair and 
tumor growth (Bottaro et al., 1991; Gherardi  & Stoker, 1990; Ma, Maulik, Christensen, 
& Salgia, 2003; Nakamura et al., 1989; St oker, Gherardi, Marion, & Gray, 1987). c-Met 
overexpression, with or without gene amplifi cation, has been reported in a variety of 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
21 malignancies, including breast,  colorectal, lung, gastric, and hepatocellular carcinoma 
(Boix et al., 1994; Kuniyasu, Yasui, Yoko zaki, Kitadai, & Tahara, 1993). Elevated 
expression of c-Met has been associated w ith poor prognosis in br east cancer (Kang et 
al., 2003; Lengyel et al., 2005). Interestingl y, data suggests the HGF and c-Met are 
expressed to a greater degree in triple-neg ative and HER2-positive breast cancer (Camp, 
Rimm, & Rimm, 1999; Sheen-Chen, Liu, Eng, & Al, 2005; Toi et al., 1998; Yamashita 
et al., 1994).  
Mouse models also suggest a critical role of the c-Met pathway during the development 
of triple-negative breas t cancer.  Mice harboring mutant c-Met knock-in or mutant c-Met 
transgene under mouse mammary tumor virus pr omoter, developed breast cancers with a 
triple-negative phenotype (Graveel, DeGroot, Su, & Al, 2009; Ponzo, Lesurf, 
Petkiewicz, & Al, 2009). Additionally, a c-Met- driven pathway signature clustered with 
basal and triple-negative breast cancer from  human tissue samples and correlated with 
worse patient outcome (Graveel et al., 2009; Ponzo et al., 2009). These studies suggest 
that c-Met expression an d activation is important for init iation and progres sion of triple-
negative breast cancer. C-Met has been found to frequently be coe xpressed in HER2+ breas t cancer and appears 
to contribute to resistance through sustained AKT activation. Resistance to trastuzumab 
presents a significant barrier to effective tr eatment of HER2+ breast cancer.  Loss of Met 
function, either through RNA interference-m ediate depletion or small molecular 
mediated inhibition, significantly improve s the response to trastuzumab (Shattuck, 
Miller, & Carraway, 2008). Conversely, Met activation protects the cells against 
trastuzumab.  The mechanism of resistance li kely lies in the ability of Met to drive 
EGFR-independent/ERbB3-dependent PI3K/AKT activation.   In ER-positive breast cancer ce lls, activation of the receptor tyrosine kinase by its ligand 
results in increased ER phosphorylation on Ser118 and Ser167 and estrogen-independent 
activation of ER transcriptional activity (Pl aza-Menacho, Morandi, Robertson, & Al, 
2010). Expression of RET protein is significantly associated with ER positive tumors 
and with the development of recurrent diseas e after adjuvant tamoxifen treatment, thus 
along with MET, cotargeting RET may be a po tentially important th erapeutic target in 
ER-positive and hormone-resistant breast cancers.  
Given the data suggesting the c-Met expression is increased in the triple-negative breast 
cancer, may be important in trastuzumab -resistant HER2+ breast cancer, and RET 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
22 inhibition may be important in hormone refractory ER+ breast cancer, cabozantinib may 
have benefit in all subtypes of breast cancer .  Moreover, data sugge sts that cabozantinib 
penetrates the blood brain barri er, and with its anti-angioge nic activity, may be critical 
for treatment of brain metastases.  We will assess the efficacy of cabozantinib in patients with metastatic breast cancer with known brain metastases.  Patients with HER2+ breast cancer will receive trastuzumab in combination with cabozantinib. 
2.7 Correlative Studies Background 
2.7.1 Evaluate c-Met and phospho-c-Met expression in FFPE tumor tissue 
Since cabozantinib inhibits MET expression, it is hypothesized that tumors in patients who 
express higher levels of c-Me t will respond more robustly to cabozantinib therapy. Testing 
c-Met and phospho-c-Met expression in prev iously collected FFPE  tumor tissue is one 
method to genotype patient tumors. Caveats to this technique are that patients’ malignant 
cells may have acquired additional mutations since these tissues were collected, and this 
sampling may not detect the heterogeneity of gene expression within  a tumor. However, 
this technique is an accessible option to profile  genetic expression, especially when paired 
with additional profiling approaches. In this study, patients will be dichotomized as to 
whether or not their tumor expresses c-Met and the association between expression and 
response to cabozantinib will be explored. 
2.7.2 Evaluate the incidence of c-Met amplification in circulating tumor cells at baseline  
Simultaneously, we will also use another approach to determin e c-Met amplification levels 
based on circulating tumor cells. These results may corroborate the c-Met and phospho-c-
Met expression studies with FFPE tumor tissu e samples. The primary advantage of this 
technique is that malignant ce lls are collected via purificati on of circulating tumor cells 
(CTCs) from whole blood, which is a far less invasive technique for malignant cell 
sampling than traditional biopsies. Interesti ngly, these CTCs are indicative of tumor 
metastases and predictive of c linical outcomes in breast cancer  patients (Cristofanilli et al., 
2004). Patients will be grouped as to whether or  not their tumor has amplified c-Met and 
the association between amplification and re sponse to cabozantinib  will be evaluated.  
2.7.3 Evaluate potential plasma bi omarkers of cabozantinib 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
23 Exploratory analyses of poten tial biomarkers of cabozanti nib activity will be performed 
by measuring proteins in the pl asma and circulating cells at baseline, on days 1 and 8 of 
each cycle of therapy, and, if available, at th e end of treatment. Plasma analysis will be 
carried out for a panel of circulating angioge nic and inflammatory molecules previously 
identified as potential biomarkers of res ponse to anti-VEGF therapy in breast cancer 
patients (Boucher et al., ASCO 2013). They in clude vascular endothelial growth factor 
(VEGF), placental-derived grow th factor (PlGF), soluble (s)VEGFR1, basic fibroblast 
growth factor (bFGF), and stromal-derived factor 1  (SDF1 ). In addition, we will 
measure the plasma concentration of biomarke rs that are related to cabozantinib activity: 
HGF, s-MET, s-c-KIT and sVEGFR2. Finally, we will evaluate biomarkers of tumor 
hypoxia, by measuring plasma carbonic anhydrase IX  (CAIX) levels as well as 
biomarkers of osteoclast and osteoblast activ ity (plasma C-telopeptide and total alkaline 
phosphatase). Baseline and on treatment biomarker values will be correlated with 
patient’s response to cabozantinib therapy. 
2.7.4 Vessel density and tortuosity 
Visualization of vessel density and tortuos ity enables longitudi nal assessment of 
cabozantinib’s impact on tumor a ngiogenesis within brain tumors. 
The feasibility of this technique has been previously demonstrat ed in a prospective trial of 
lapatinib for patients with brain metastases from HER2-positive breast cancer (Bullitt et 
al., 2007). This study demonstrated widespr ead abnormalities in vessel shape in the brain 
at baseline, in some cases extending far beyond the visible tumors. Vessel tortuosity 
measurements enabled correct prediction of tr eatment failure earlier than other methods. 
In that small study, of the three patients who had quantitative impr ovements in vessel 
tortuosity at 2-month follow-up, each of the two patients for whom further follow up data 
were available remained on protocol-based th erapy for 6 months or longer. Particularly 
given the postulated mechanism of action of cabozantinib, visualization of changes in 
vessel tortuosity is of great interest. 
2.7.5 Cerebral blood volume, bloo d flow, and vessel size 
Vascularity of tumors indicates active angiogenesis, a pro cess that cabozantinib targets 
through its inhibitory effects on VEGFR and c-MET. Patients on this study will receive 
routine brain MRIs to assess the vascularity of their br ain tumors – blood flow, blood 
volume, permeability and surface area of capill ary bed. In a previous study of AZD2171, 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
24 a small molecule inhibitor of VEGFRs, th ese techniques successfully demonstrated 
normalization of tumor vessels and reducti on of vasogenic edema in patients with 
gliomas. Furthermore, early changes in vasc ular parameters were predictive of improved 
overall outcomes in these patien ts (Batchelor TT et al., 2007). 
2.7.6 Blood sample collection 
Blood will be collected at baseline and at  the end of treatment for cell-free DNA 
(cfDNA).  The cfDNA will be processed by the Clinical Trial Core Laboratory at DFCI 
and then banked in the DF/HCC Clinical Trials Core laboratory for future research 
purposes.  The banked samples will be used to analyze DNA, RNA and protein in future studies.   
3 PARTICIPANT SELECTION 
3.1 Inclusion Criteria 
Participants must meet the following criteria  on screening examination to be eligible to 
participate in the study: 3.1.1 Patients must have histologically or cytologically confirmed invasive breast 
cancer, with stage IV disease.  Patie nts without pathologic or cytologic 
confirmation of metastatic di sease should have unequivo cal evidence of metastasis 
from physical examination or radiologic evaluation. (i) Measurable disease: patients must have measurable CNS disease, defined as 
at least one parenchymal brain lesion that  can be accurately measured in at 
least one dimension with the longest diameter ≥10 mm by local radiology 
review (measurable non-CNS disease is not required for study participation) 
(ii) Patients will be defined as HER2+ if either the primary tumor and/or the metastasis are HER2-positive, defined as 3+ by IHC or FISH ≥2.0 
3.1.2 New or progressive CNS lesions, as assessed by the patient’s treating physician.  
(i) It is anticipated that some patients may have multiple progressive CNS 
lesions, one or several of which are treated with SRS or surgery with 
residual untreated lesions remaining.  Such patients are eligible for enrollment on this study providing that at least one lesion is measurable 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
25 (≥10 mm) per RECIST 1.1.  The location of the measurable lesion should 
be documented in the patient chart and case report form. 
(ii) Patients who have had prior cranial surgery are eligible provided that there 
is evidence of measurable residual or  progressive lesions, and at least 3 
months have passed since surgery.  If a patient has surgical resection followed by WBRT, then there must be evidence of progressive CNS 
disease after the completion of WBRT 
(iii) Patients who had had prior WBRT and/or  SRS and then whose lesions have 
progressed thereafter are also eligible.  In this case, lesions that have been 
treated with SRS may be considered as target lesions if there is unequivocal 
evidence, in the opinion of the tr eating physician, of progression. 
(iv) Patient who have not prev iously been treated with  cranial radiation (e.g. 
WBRT or SRS) are eligib le to enter the study, but such patients must be 
asymptomatic or minimally symptoma tic from their CN S metastases and 
not requiring corticosteroids. 
3.1.3 For patients who have received prio r cranial radiation, no increase in 
corticosteroid dose in the week prior to the baseline brain MRI 
3.1.4 Prior therapy: Patients mu st have discontinued all chemotherapy, investigational 
therapy or biologic therapy at least 14 days prior to ini tiating study treatment 
(with the exception of trastuzumab for patients with HER2+ breast cancer) 
3.1.5 Recovery to baseline or ≤  Grade 1 CTCAE v.4.0 from t oxicities related to any 
prior treatments, unless AE(s) are clini cally nonsignificant and/or stable on 
supportive therapy; 
3.1.6 Cohort 1: HER2-positive, defined by ASCO CAP 2013 guidelines:  
 IHC 3+ based on circumferential memb rane staining that is complete, 
intense  
-OR- 
 FISH positive based on one of the three following criteria: 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
26 o Single-probe average HER2 copy number ≥ 6.0 signals/cell; OR 
o Dual-probe HER2/CEP17 ratio < 2.0 with an average HER2 copy 
number ≥ 6.0 signals/cell; OR 
o Dual-probe HER2/CEP17 ratio ≥ 2.0 
Cohort 2: Hormone receptor positive (ER-positive and/or PR-positive, defined as 
≥ 1% staining by immunohistochemistry) and HER2-negative 
Cohort 3: Triple negative (ER-negativ e, PR-negative, HER2-negative) 
3.1.7 The subject is 18 years old on the day of consent 
3.1.8 The subject has an Eastern Cooperativ e Oncology Group (ECOG) performance 
status of 0 or 1 
3.1.9 Patients must have normal organ and marrow function and laboratory values as follows within 14 days before the first dose of cabozantinib: 
(i) Absolute neutrophil count  1000/mm
3 without colony stimulating factor 
support 
(ii) Platelets  100,000/mm3 
(iii) Hemoglobin  9 g/dL 
(iv) Total Bilirubin  1.5 mg/dL × the ULN 
(v) Serum albumin  2.8 g/dl 
(vi) Serum creatinine ≤ 1.5  ULN or creatinine clearance (CrCl) ≥  50 mL/min. 
For creatinine clearance estimation, the Cockcroft and Gault equation 
should be used: 
 Male: CrCl (mL/min) = (140 - age) × wt (kg) / (serum creatinine 
× 72); 
 Female: Multiply above result by 0.85; 
(vii) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)   3 
× the ULN.  For patients with doc umented liver metastases, AST/ALT ≤ 5.0 
times the upper li mit of normal.  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
27 (viii) Lipase < 2.0 x the upper limit of normal and no radiologic or clinical 
evidence of pancreatitis 
(ix) Urine protein:creatinine ratio ≤ 1 
(x) Serum phosphorus, calcium, magnesium and potassium ≥ LLN 
3.1.10 The subject is capable of understanding and complying with the protocol and has 
signed the informed consent document 
3.1.11 Sexually active subjects (men and women)  must agree to use medically accepted 
barrier methods of contraception (e.g., male or female condom) during the course 
of the study and for 4 months  after the last dose of st udy drug(s), even if oral 
contraceptives are also used. All subjects of reproductive potential must agree to 
use both a barrier method and a second met hod of birth control during the course 
of the study and for 4 months afte r the last dose of study drug(s); 
3.1.12 Female subjects of childbearing potential must not be pregnant at screening. Females of childbearing poten tial are defined as prem enopausal females capable 
of becoming pregnant (ie, females who ha ve had any evidence of menses in the 
past 12 months, with the exception of those who had prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing poten tial if the amenorrhea is possibly due to 
prior chemotherapy, antiestrogens, lo w body weight, ovarian suppression or 
other reasons. 
3.1.13 Patients on bisphosphonates may conti nue receiving bisphosphonate therapy 
during study.  Patients wanting to initiate bisphosphonate therapy may do so. 
3.1.14 The subject has had an assessment of all known non-CNS disease sites eg, by 
computerized tomography (CT) scan, ma gnetic resonance imaging (MRI), bone 
scan as appropriate, within 28 days before the first dose of cabozantinib 
3.1.15 Research MRI sequences performed at Massachusetts General Hospital 
Charlestown Navy Yard must be completed ≤ 7 days of Cycle 1 Day 1 
3.1.16 Clinical MRIs performed at baseline must  be completed within 28 days of the 
first dose of cabozantinib 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
28 3.2 Exclusion Criteria 
Participants who exhibit any of the following co nditions at screening wi ll not be eligible 
for admission into the study: 3.2.1 The subject has received cabozantinib or  another c-Met inhi bitor (please note 
ARQ 197 is not considered a MET inhibitor for purposes of this study given data 
to suggest it inhibits tubulin) 
3.2.2 The subject has uncontrolled, significant inte rcurrent or recent illness including, 
but not limited to, the following conditions: a. Cardiovascular di sorders including: 
i. Congestive heart failure (CHF): New York Heart Association (NYHA) 
Class III (moderate) or Class IV (sev ere) at the time of screening; 
ii. Concurrent uncontrolled hyperten sion defined as sustained blood 
pressure (BP) > 150 mm Hg systolic or > 90 mm Hg diastolic despite optimal antihypertensive treatment with in 7 days of the first dose of 
cabozantinib; 
iii. Any history of congenital long QT syndrome; iv. Any of the following within 6 months before the first dose of 
cabozantinib: unstable angina pector is; clinically-significant cardiac 
arrhythmias; stroke (inc luding transient ischemic attack (TIA), or other 
ischemic event); myocardial infarction; thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter (eg, vena 
cava filter) are not eligible for this study). 
b. GI disorders particularly those associated with a high risk of perforation or 
fistula formation including: 
i. Any of the following within 28 days before the first dose of cabozantinib: intra-abdominal tumo r/metastases invading GI mucosa; 
patients must be completely recovered from any evidence of active peptic ulcer disease; patients must be comple tely recovered from these conditions - 
any evidence or inflammatory bowel disease (including ul cerative colitis 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
29 and Crohn’s disease), diverticulitis, c holecystitis, symptomatic cholangitis 
or appendicitis; malabsorption syndrome. 
ii. Any of the following within 6 months before the first dose of 
cabozantinib: abdominal fistula; ga strointestinal perforation; bowel 
obstruction or gastric outlet obstructi on; intra-abdominal abscess. Note: 
Complete resolution of an intra-abdomi nal abscess must be confirmed prior 
to initiating treatment with cabozantini b even if the abscess occurred more 
than 6 months before the first dose of cabozantinib. 
c. Other disorders associated with a high  risk of fistula formation including PEG 
tube placement within 3 months before the first dose of study therapy 
d. Other clinically significant disorders such as: 
i. active infection requiring systemic treatment within 28 days before the 
first dose of cabozantinib; ii. serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of cabozantinib; iii. history of organ transplant; iv. concurrent uncompensated hypothyroi dism or thyroid dysfunction within 
7 days before the first dose of cabozantinib.  
3.2.3 Leptomeningeal disease as the only site of CNS involvement 
3.2.4 Known contraindication to  MRI with gadolinium c ontrast, such as cardiac 
pacemaker, shrapnel, or ocular foreign body 
3.2.5 More than 2 seizures over the last 4 weeks prior to study entry 
3.2.6 Grade 1 or higher CNS hemorrhage on baseli ne brain MRI, or history of grade 2 
or higher CNS hemorrhage within 12 months 
3.2.7 The subject has experienced  any of the following: 
a. clinically-significant GI bleeding with in 6 months before the first dose of 
cabozantinib; 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
30 b. hemoptysis of ≥ 0.5 teaspoon (2.5ml) of red blood within 3 months before the 
first dose of cabozantinib; 
c. any other signs indicative of pulmona ry hemorrhage within 3 months before 
the first dose of cabozantinib. 
3.2.8 The subject has tumor in contact wit h, invading or encasing any major blood 
vessels 
3.2.9 The subject has evidence of tumor i nvading the GI tract (esophagus, stomach, 
small or large bowel, rectum or anus),  or any evidence of endotracheal or 
endobronchial tumor within 28 days be fore the first dose of cabozantinib 
3.2.10 The subject requires concomitant treatment, in therapeutic doses, with 
anticoagulants such as warfarin or warf arin-related agents, heparin, thrombin or 
Factor Xa inhibitors, or antiplatelet agents (eg, clopi dogrel). Low dose aspirin ( ≤ 
81 mg/day), low-dose warfarin ( ≤ 1 mg/day), and prophylactic LMWH are 
permitted; 
3.2.11 The subject has prothrombin time (PT)/INR  or partial thromboplastin time (PTT) 
test ≥ 1.3 × the laboratory ULN within 7 days before the first dose of 
cabozantinib. 
3.2.12  Inability to swallow intact tablets  
3.2.13 Pregnant or lactating females  
3.2.14 Diagnosis of another malignancy within 2 years before the first dose of cabozantinib, except for superficial skin cancers, or localized, low grade tumors 
deemed cured and not treated with systemic therapy 
3.2.15 Radiation therapy with in 7 days before the first dose of cabozantinib. Subjects 
with clinically relevant ongoing complic ations from prior radiation therapy are 
not eligible 
3.2.16 The subject is known to be positive for the human immunodeficiency virus 
(HIV) 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
31 3.2.17 Major surgery within 12 weeks before th e first dose of cabozantinib. Complete 
wound healing from major surgery must have occurred 1 month before the first 
dose of cabozantinib. Minor surgery (inc luding uncomplicated tooth extractions) 
is allowed if it occurred 28 days before  the first dose of cabozantinib with 
complete wound healing at least 10 days before the first dos e of cabozantinib. 
Subjects with clinically relevant ongoi ng complications from prior surgery are 
not eligible 
3.2.18 QTcF > 500 msec on average of screening EKGs performed within 28 days of 
first dose of cabozantinib. Three EKGs mu st be performed at screening. If the 
average of these three consecutive results for QTcF is > 500 msec, the subject is 
ineligible. 
3.2.19 Active infection requiring IV an tibiotics at Day 1 of cycle 1 
3.2.20 No prior lapatinib within 7 days prior to initiation of protocol treatment 
3.2.21 Patients may not receive any concurrent  investigational agents while on study 
3.2.22 Patients may not receive any cancer-dire cted concurrent therapy, such as 
concurrent chemotherapy, radiotherapy, or hormonal therapy while on study.  
3.2.23 Previously identified allergy or hype rsensitivity to components of the 
cabozantinib formulations 
3.2.24 The subject requires chronic concomita nt treatment with strong CYP3A4 
inducers (eg, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, 
phenobarbital, and St. John’s Wort). 
3.3 Inclusion of Women, Minorities and Other Underrepresented Populations 
 Both men and women of all races and ethnic groups are eligible for this trial.   
4 REGISTRATION PROCEDURES 
4.1 General Guidelines for DF/H CC and DF/PCC Institutions 
Institutions will register eligible partic ipants with the DF/HCC Quality Assurance 
Office for Clinical Trials (QACT) central registration system. Re gistration must occur 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
32 prior to the initiation of ther apy. Any participant not registered to the protocol before 
treatment begins will be considered ine ligible and registration will be denied. 
  
An investigator will confirm eligibility cr iteria and a member of the study team will 
complete the QACT the protocol-specific eligibility checklist.  Following registration, participants may begin protocol treatment. Issues that would 
cause treatment delays should be discussed w ith the Overall Principa l Investigator (PI). 
If a participant does not receive protocol th erapy following registration, the participant’s 
registration on the study must  be canceled. Notify the QACT Registrar of registration 
cancellations as soon as possible.  
4.2 Registration for DF/HCC Institutions 
The QACT registration staff is accessible on Mond ay through Friday, from 8:00 AM to 5:00 
PM Eastern Standard Time. In emergency si tuations when a participant must begin 
treatment during off-hours or holidays, call the QACT registration line at 617-632-3761 and 
follow the instructions for regist ering participants after hours. 
The registration procedures are as follows: 
 Obtain written informed consent from the participant prior to the performance of 
any protocol specific procedures or assessments.  
 Complete the QACT protocol-specific elig ibility checklist using the eligibility 
assessment documented in the participant’s medical record and/or research chart. 
To be eligible for registration to the protocol, the particip ant must meet all 
inclusion and exclusion criterion as de scribed in the protocol and reflected 
on the eligibility checklist.  
Reminder: Confirm eligibility fo r ancillary studies at the same time as eligibility for a 
treatment protocol. Registration to both tr eatment and ancillary protocols will not be 
completed if eligibility requirements are not met for all studies.  
 
 Fax the eligibility checklist(s) and all pa ges of the consent form(s) to the QACT 
at 617-632-2295. For Phase I protocols, att ach participant dose level assignment 
confirmation from the sponsor. 
 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
33  The QACT Registrar will (a) review the el igibility checklist, (b) register the 
participant on the protocol, and (c) ra ndomize the participant when applicable. 
 
 An email confirmation of the registration and/or randomization will be sent to 
the Overall PI, study coordina tor(s) from the Lead Site, treating investigator and 
registering person immediately following the registration and/or randomization. 
5 TREATMENT PLAN   
5.1 Treatment Overview 
Treatment will be administered on an outpatien t basis. Expected toxicities and potential 
risks as well as dose modifications for cabo zantinib are described in Section 6 (Expected 
Toxicities and Dosing Delays/Dose Modificat ion). No investigational or commercial 
agents or therapies other than those describe d below may be administ ered with the intent 
to treat the participant’s malignancy. The target accrual is up to a maximum of 40 patients who receive at least one dose of 
protocol-based therapy in order to enter 37 patients who have “asse ssable” CNS disease. 
Assessable disease is defined as at least one parenchymal brain lesion that can be 
accurately measured in at least one dimension with the longest dimension ≥ 10 mm by 
local radiology review (measureable non- CNS disease is not required for study 
participation). The estimated rate of accrua l is 1-2 patients per month. Patients will be 
followed for up to two years after removal from study or until death, whichever comes 
first. Exelixis will provide each investigator w ith adequate supplies of cabozantinib, which 
will be supplied as 60-mg, and 20-mg yellow film-coated tablets. The 60-mg tablets are 
oval, and the 20-mg tablets are round.  
Subjects will receive cabozantinib orally ad ministered daily and continuously. Dosing 
will begin at 60 mg cabozantinib per day ta ken orally for all patients with dosing 
delays/dose modifications as  outlined in Section 6.  
A full cycle length will be defined as 21 days  (3 weeks). Cabozantinib will be given on 
day 1 and taken daily for 21 day cycle. Patients with HER2 positive disease will 
concurrently receive 6 mg/kg intravenous trastuzumab on Day 1 of each cycle. HER2 positive patients naïve to trastuzumab receive an 8 mg/kg loading dose during cycle 1, and resume the 6 mg/kg dosing for every subsequent cycle.  Correlative imaging studies 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
34 will be done 21 days post dose of cabozantinib at the Cycle 2 Day 1 timepoint (day 22), 
prior to patient receiving Cycle 2 Day 1 dose. 
Cycle 2 of treatment will begin 21 days following the first dose of  cabozantinib. Starting 
with cycle 2, minor deviations to the treatment schedule are allowed for patient 
scheduling requests with a + 4 days window (i.e. infusion chair availability, weather-
related issues, vacation, etc.). Additionally, minor deviations to  the scan schedule will be 
allowed (i.e. Day 22 brain MRI, CT, MUGA) for patient scheduling requests with a + 7 
days window. 
Subjects will be provided with a sufficient supply of cabozantinib and instructions for 
taking the cabozantinib on days without scheduled clinic visits. After fasting (with 
exception of water) for 2 hours, participants  will take cabozantinib daily each morning 
with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour 
after each dose of cabozantinib. Participants sh ould be instructed to swallow the tablets 
whole and not crush, chew or dissolve in wa ter prior to swallowing. Participants should 
record dosing time and doses taken in a study drug dosing diary while on cabozantinib. If doses are withheld, the or iginal schedule of assessments  should be maintained when 
cabozantinib is restarted. The participant shoul d be instructed to not make up the missed 
doses and to maintain the planned dosing schedule. As described in Appendix D, 
Participant’s Medication Diary, if it has b een more than 12 hours since missing their 
scheduled dose, then the participants should not take the missed dose. However, if it has 
been less than 12 hours since the missed dose, then the dose should be taken 
immediately and the participant should continue taking their dose at the regular time the 
next day.  Participants must be instructed to not make up missed doses that are vomited. 
Participants should be instructed to wait unt il the next day to take  the next scheduled 
dose and should be reminded to tell their doctor or nurse at their next  visit which dose(s) 
were missed. 
At study sites, all study medication will be stor ed as described in the local institution’s 
pharmacy policies (or SOPs) and inventoried in accordance with applicable state and 
federal regulations.     
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
35  
  Table 3. Cycle 1 and beyond 
REGIMEN DESCRIPTION 
Agent Dose Route Schedule Cycle 
Length 
Cabozantinib 60 po qday Oral Daily 3 weeks (21 
days) 
Trastuzumab* 6 mg/kg 
(8mg/kg 
loading dose) 
  IV Day 1 
*Trastuzumab will only be administered to patients with HER2-positive disease. 
Loading dose of trastuzumab not required if patients have received a weekly 
trastuzumab dose (2 mg/kg) within 3 weeks of  anticipated trastuzumab start date on this 
protocol, or if patients have received a Q3 weekly dose (6 mg/kg) of trastuzumab within 
6 weeks of anticipated trastuzu mab start date on this protocol. In such cases, patients 
should receive 6 mg/kg IV starting on Cycle 1 Day 1. 
5.2 Pre-treatment Criteria 
The following pre-treatment criteria must be  met in order to begin cabozantinib on 
Cycle 1, Day 1 :   
 Absolute neutrophil count (ANC) ≥ 1000/mm3 
 Platelets ≥ 100,000/mm3 
 Total bilirubin ≤ 1.5   the upper limit of normal 
 Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤  3 the 
upper limit of normal for patients with no liver involvement; or ≤ 5  the upper 
limit of normal for patients with liver involvement 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
36  Urine protein/creatin ine ratio (UPCR) ≤ 1. 
The following pre-treatment criteria must be  met in order to begin cabozantinib on Day 
1 of each subsequent cycle :   
 Absolute neutrophil count (ANC) ≥ 1000/mm3 
 Platelets ≥ 100,000/mm3 
 Total bilirubin ≤ 1.5   the upper limit of normal 
 Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤  3  the 
upper limit of normal if no liver involvement; or ≤ 5  the upper limit of normal 
for patients with ≤ 3  the upper limit of normal  (i.e . Grade 1) LFTs at baseline 
or liver involvement 
 Urine protein/creatin ine ratio (UPCR) ≤ 1. 
5.3 Initial Safety Evaluation of  cabozantinib + trastuzumab 
As an extra safety precaution, accrual will be paused when 6 patients have received first 
doses of cabozantinib and tras tuzumab in this cohort. Thes e 6 patients will be observed 
for 3 weeks and assessed for DLTs (dose- limiting toxicities), defined below. A 
teleconference call with all investigators will be  held at the end of this period to discuss 
any unexpected SAEs that may have been observed. Accrual will be suspended either temporarily or permanently to the combina tion of cabozantinib and trastuzumab, if, in 
the opinion of the principal i nvestigator, any such SAE wa rrants further evaluation or 
discontinuation of the cohort. If DLTs are observed in 1 or fewer patients, accrual will 
continue at a starting cabozantinib dosage  of 60 mg po qday. If 2 or more patients 
experience a DLT, cabozantinib dosage w ill be reduced to 40 mg po qday, and an 
additional DLT safety assessment will be done after enrollment of another 6 patients. If 
DLTs are observed in 1 or fewer patients, accrual will continue at a starting cabozantinib dosage of 40 mg po qday. If 2 or more patients experience a DLT, accrual to the HER2-positive cohort will be stopped permanently. Management for these patients is illustrated below. 
 
Phase II study of cabozantinib in breast cancer with brain metastases   
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidential. Do not disclose or use except as authorized. 
37  
 
 
 
 
  
 
 Definition of Dose-Limiting Toxicity All adverse events will be reported, with se verity assessed according to the NCI CTCAE 
v4.0.  Dose limiting toxicity (DLT) refers  to both non-hematologic and hematologic 
toxicities experience during the first cy cle (i.e., first 3 weeks) of treatment. 
A DLT will be defined as any of the following assessed by the investigator to be 
possibly related to cabozantinib  occurring during cycl e 1 (for the first 6 patients in the 
trastuzumab/cabozantinib pilot cohort: 
1. Any AE that results in a dose redu ction during the DLT evaluation period 
2. Non-Hematologic Toxicity 
Any Grade 3 or 4 event, excluding: 
a. Grade 3 nausea and/or vomiting contro lled with supportive measures within 24 
hours 
b. Grade 3 diarrhea controlled with  supportive measures within 24 hours 
c. Grade 3 fatigue that resolves within 24 hours d. Grade 3 constipation controlled with  supportive measures within 24 hours  Cabozantinib dose Trastuzumab dose 
Dose Level 1 (D1) 60 mg po qday 6 mg/kg IV (every 3 weeks)
Dose Level -1 (D-1) 40 mg po qday 6 mg/kg IV (every 3 weeks)

Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
38 e. Grade 3 hypophosphatemia 
f. Grade 3 hyponatremia g. Grade 3 hypomagnesemia h. Grade 3 hypokalemia i.  Grade 3 hypertension contro lled with medical management 
j.  Grade 3 hepatic transaminase (A LT or AST) lasting less than 72 hours 
Note: For patients with Grade 1 hepatic transaminase at baseline as a result of liver or bone metastases, a ≥ 1.5 fold increase in AS T or ALT, or hepatic 
transaminase ≥ 5 x the upper limit of normal (ULN) lasting more than 72 hours 
will be considered a DLT.  For patients with grade 2 hepatic tranasminases at baseline as a result of liver or bone metastases, hepatic transaminase >7.5x ULN 
lasting more than 72 hours will be considered a DLT. 
3. Hematologic Toxicity 
a. Grade 3 neutropenia with infection requi ring intervention or lasting > 7 days, or 
Grade 4 neutropenia b. Grade 3 or 4 febrile neutropenia  c. Grade 4 thrombocytopenia or grade 3 thrombocytopenia with clinically significant bleeding d. Other Grade 4 hematologi c toxicities (e.g., anemia) 
4. Failure to take more than 7 days of treatment within Cycle 1 due to treatment-related adverse effects 5. Any cabozantinib-related death 
 
5.4 Agent Administration  
5.4.1 Cabozantinib  
Subjects will receive cabozantinib orally ad ministered daily and continuously. Dosing 
will begin at 60 mg cabozantinib per day ta ken orally for all patients with dosing 
delays/dose modifications as  outlined in Section 6.  
Participants will be provided with a sufficien t supply of cabozantinib and instructions 
for taking the cabozantinib on days without  scheduled visits. After fasting (with 
exception of water) for 2 hours, participants  will take cabozantinib daily each morning 
with a full glass of water (minimum of 8 oz  / 240 mL) and continue to fast for 1 hour 
after each dose of cabozantinib. Participants sh ould be instructed to swallow the tablets 
whole and not chew them prior to swallowi ng. Participants should record dosing time 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
39 and doses taken in a study drug dosing di ary while on cabozantinib. If doses are 
withheld, the original schedul e of assessments should be ma intained when cabozantinib 
is restarted. The participant s hould be instructed to not make up the missed doses and to 
maintain the planned dosing schedule. As described in Appendix D, Participant’s 
Medication Diary, if it has been more than 12 hours since missing their scheduled dose, 
then the participants should not take the mi ssed dose. However, if it has been less than 
12 hours since the missed dose, then the dose should be taken immediately and the participant should continue  taking their dose at the regular time the next day. 
Participants must be instructed to not  make up missed doses that are vomited. 
Participants should be instructed to wait unt il the next day to take  the next scheduled 
dose and should be reminded to tell their doctor or nurse at their next  visit which dose(s) 
were missed. 
5.4.2 Trastuzumab  
For HER2-positive patients, trastuzumab is ad ministered intravenously in the outpatient 
setting. The dose for initial treatment with tr astuzumab is 8 mg/kg IV unless the patient 
has received qweek dose (2mg/kg) trastuzumab ≤ 21 days or q3 week dose (6mg/kg) ≤ 
42 days from day 1 of treatment; patients w ho have received trastuzumab within these 
windows of initiation of therapy should rece ive an initial dose of 6 mg/kg IV. All 
subsequent doses are 6 mg/kg IV. There s hould be no dose adjustment for trastuzumab. 
Trastuzumab is administered concurrently wi th cabozantinib on Day 1 of each cycle. For 
patients who have not previously received trastuzumab, the initial infusion time of 
trastuzumab (loading dose 8 mg/kg) is approximately 90 minutes. 
  
The initial dose of trastuzumab will be administered over approximately 
90 minutes. If this first dose is well tolerated, subsequent infusion times may be shortened to approximately 30 minutes or given per participating site’s institutional SOP for trastuzumab administration. If the initial or a subsequent dose is not well tolerated (i.e. fevers, chills, or rigors), subsequent infusion times may be shortened only after a dose is well tolerated.  
 
5.5 General Concomitant Medication and Supportive Care Guidelines 
If a participant requires additional systemic  anticancer treatment, cabozantinib must be 
discontinued. These treatments include, but  are not restricted to the following: 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
40  Chemotherapy 
 Radiopharmaceuticals 
 Steroids (not including physio logical replacement doses of  steroids, equivalent to 
≤ 10 mg/day prednisone, or megestrol acetate used to treat constitutional 
symptoms) 
 Endocrine therapy for breast cancer (e g, tamoxifen, aromatase inhibitors) 
 Radiation therapy 
If the participant must use other concomitant medications  during the study (including 
vitamins, herbal and nutritional supplements, and over-the-counter medications), it is the 
responsibility of the principa l investigator (PI) to ensure  that details regarding the 
medication are documented. 
At the discretion of the investigator and after the onset of symptoms, treatment (or 
prophylaxis) with anti-emetic and anti-diar rheal medications may be undertaken per 
standard clinical practice.  
Treatment with denosumab or a bisphosphonate  is allowed while patient is on study. 
Colony stimulating factors (eg, erythropoietin, granulocyte colony-stimulating factors, 
and peg-filgrastim) are not allo wed while patient is on study.  
Pain medications, transfusions, short-term  systemic steroid treatment, and other 
supportive measures should be utilized as dictated by standard clinical practice while the participant is enrolled in the study.  
No concurrent investigational agents are permitted. 
5.6 Potential Drug Interactions 5.6.1 Cytochrome P450  
Data from a clinical drug interaction study (Study XL184 008) sh ow that clinically 
relevant steady state concentrations of cabozan tinib appear to have no marked effect on 
the area under the plasma drug concentrati on time curve (AUC) of co administered 
rosiglitazone, a CYP2C8 substrat e. Therefore, cabozantinib is  not anticipated to markedly 
inhibit CYP2C8 in the clinic, an d by inference, is not anticipated to markedly inhibit other 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
41 CYP450 isozymes that have lower [I]/Ki va lues compared with CYP2C8 (ie, CYP2C9, 
CYP2C19, CYP2D6, CYP1A 2, and CYP3A4). In vitro data indicate that cabozantinib is 
unlikely to induce cytochrome P450 enzymes, excep t for possible induction of CYP1A1 at 
high cabozantinib concentrations (30 μM).  
Cabozantinib is a CYP3A4 substrate and a weak substrate for CYP2C9 (but not a 
CYP2D6, CYP2C8, CYP2C19, CY P2B6, or CYP1A2 substrate) , based on data from in 
vitro studies. Results from a clinical pharmacology study,  XL184 006, showed that 
concurrent administration of cabozantinib wi th the strong CYP3A4 inducer, rifampin, 
resulted in an approximately 77% reduction in cabozantinib exposure (AUC values) after 
a single dose of cabozantinib in healthy volunteers. Chronic co-administration of 
cabozantinib with strong indu cers of the CYP3A4 family (e g, dexamethasone, phenytoin, 
carbamazepine, rifampin, rifabutin, rifapentin e, phenobarbital, and St. John’s Wort) may 
significantly decrease cabozantinib concentra tions. The chronic us e of strong CYP3A4 
inducers should be avoided. Other drugs that induce CYP3A4 should be used with caution 
because these drugs have the potential to decrease exposure (AUC) to cabozantinib. 
Selection of alternate concomitant medicati ons with no or minimal CYP3A4 enzyme 
induction potential is recommended.  
Results from a clinical pharmacology st udy, XL184 007, showed that concurrent 
administration of cabozantinib w ith the strong CYP3A4 inhibitor, ketoconazole, resulted 
in a 38% increase in the cabozantinib exposure (AUC values) after a single dose of 
cabozantinib in healthy volunteers. Co-adm inistration of cabozantinib with strong 
inhibitors of the CYP3A4 family (eg, ketoconazole, itraconazole, clarithromycin, 
indinavir, nefazodone, nelfinavir, and ritonavir) may increase cabozantinib concentrations. Grapefruit and Seville oranges may also increase plasma co ncentrations of cabozantinib 
and should be avoided. Strong CYP3A4 inhibitors  should be avoided and other drugs that 
inhibit CYP3A4 should be used  with caution because these drugs have the potential to 
increase exposure (AUC) to cabozantinib. Sel ection of alternate concomitant medications 
with no or minimal CYP3 A4 enzyme inhibition po tential is recommended.  
In addition, cimetidine should be avoided because of its potential to interfere with CYP3A4 mediated meta bolism of cabozantinib. 
Please refer to the drug interaction tables at the following webs ites for lists of substrates, 
inducers, and inhibitors of sele cted CYP450 isozyme pathways: 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
42 http://medicine.iupui.edu/clinpharm/ddis/table.aspx 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Developm entResources/DrugInt
eractionsLabeling/ucm080499.htm   
5.6.2 Drugs Associated with QTc Prolongation  
Treatment with cabozantinib has been associ ated with a mild pr olongation of the QTc 
interval.  Caution should be used when treati ng subjects on cabozantinib with other drugs 
associated with QTc prolongation (see http://www.qtdrugs.org ).  Additional QTc 
monitoring is suggested for subjects who are treated concomitantly with QTc prolonging 
drugs.  
5.6.3 Protein Binding 
Cabozantinib is highly bound (≥  99.7%) to human plasma pr oteins. Therefore, highly 
protein bound drugs should be used with ca ution with cabozantinib because there is a 
potential displacement  interaction that could incr ease free concen trations of 
cabozantinib and/or a co-administere d highly protein bound drug (and a 
corresponding increase in pharmacologic effect). 5.6.4 Other Interactions  
Food may increase exposure levels of cabo zantinib by 57%, fasting recommendations 
should be followed. In vitro data suggest that  cabozantinib is unlikely to be a substrate 
for P glycoprotein, but it does appear to have the potential to inhi bit the P-glycoprotein 
transport activity. Therefore, cabozantinib may have the potential to increase plasma 
concentrations of co-administered substrat es of P-glycoprotein. Additional details 
related to these overall conclusions can be found in the investigator brochure. 
 Additional details regarding potential drug interactions with cabozantinib can be found 
in the investigator brochure.  
5.7 Compliance 
Drug accountability and subject compliance w ill be assessed with drug dispensing and 
return records.  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
43 5.8 Study Drug Accountability 
The investigator will maintain accurate records of receipt of all cabozantinib, including 
dates of receipt. In addition, accurate records will be kept regarding when and how much 
cabozantinib is dispensed and used by each subject in the study. Reasons for deviation from the expected dispensing regimen must also be recorded. At completion of the 
study, to satisfy regulatory requirements regarding drug accountability, all unused 
cabozantinib will be reconciled and destroyed in accordance with applicable state and 
federal regulations. 
5.9 Duration of Therapy 
Duration of therapy will depend on individual response, evidence of disease progression 
and tolerance. In the absence of treatment delays due to adverse events, treatment may 
continue until one of the fo llowing criteria applies: 
 Intolerable side effects the investigat or feels may be due to cabozantinib 
 Specific conditions described in th e medical management Section 6.2. 
 The investigator feels it is not in the best interest of the subject to continue on 
study  
 Necessity for treatment with non-protocol approved systemic anticancer therapy  
 If the subject does not recover from hi s or her toxicities to tolerable Grade ≤ 2 
within 6 weeks, the subject will have cabozantinib discontinued unless there is 
unequivocal evidence that the subject is benefitting.  In  this situation, a subject 
may be able to restart therapy with  a dose reduction upon resolution of the 
toxicity 
 Request by regulatory agencies for termin ation of treatment of an individual 
subject or all subjects under the protocol 
 Subject request to discontinue cabozan tinib (with or without concurrent 
withdrawal of informed consent)  
 Significant noncompliance with the prot ocol schedule in the opinion of the 
investigator. 
 The minimum dose of cabozantinib will be 20 mg po qday. Subjects who cannot tolerate 20 mg po qday will have cabozantinib discontinued. 
 Disease progression 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
44  Death 
 Intercurrent illness that prevents further administration of treatment 
 General or specific changes in the participant's condition render the participant 
unacceptable for further treatment in the opinion of the treating investigator . 
Participants will be removed from the protocol  therapy when any of these criteria apply.  
The reason for removal from protocol thera py, and the date the pa rticipant was removed, 
must be documented in the case report form  (CRF). Alternative care options will be 
discussed with the participant. 
 
A QACT Treatment Ended/Off Study Form will be filled out when a participant is 
removed from protocol therapy. This form can be found on the QACT website or obtained 
from the QACT registration staff. In the event of unusual or lif e-threatening complications, treating investigators must 
immediately notify the Principal Investig ator, Sara Tolaney, phone: 617-632-2335, or 
email: stolaney@partners.org . 
 
5.10 Duration of Follow Up  
Patients who are alive and free of disease pr ogression when they are taken off protocol 
therapy will be followed until earliest occurrence of disease progression or death, 
whichever occurs first.  Patients who come  off cabozantinib for reasons other than 
disease progression should have a staging scan  at the time they go off cabozantinib, and 
scans should be performed every 9 weeks to look for disease progression. Patients 
removed from protocol therapy for unacceptable adverse event(s) will be followed until 
resolution or stabilization of the adverse even t.  Patients will be followed up for survival 
after progression until deat h or lost to follow-up.   
5.11 Criteria for Removal from Study 
Participants will be removed from study wh en any of the following criteria apply: 
 
 Lost to follow-up 
 Withdrawal of consent for data submission 
 Death 
 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
45 The reason for taking a participant off study, and the date the participant was removed, 
must be documented in the case report form (CRF). 
 
A QACT Treatment Ended/Off Study Form will be filled ou t when a participant comes 
off study. This form can be found on the QAC T website or obtained from the QACT 
registration staff.  
 
6 EXPECTED TOXICITIES AND DOSI NG DELAYS/DOSE MODIFICATIONS 
DUE TO CABOZANTINIB 
Dose delays and modifications will be made using the following recommendations. 
Toxicity assessments will be done using the CTCAE Version 4.0 of the NCI Common 
Terminology Criteria for Adverse Events (CTC AE) which is identified and located on 
the CTEP website at: http://ctep.cancer.gov/protocolDevelopment/electroni c_applications/ctc.htm . 
  If possible, symptoms should be managed symptomatically. In the case of toxicity, 
appropriate medical treatment should be used (including anti-emetics, anti-diarrheals, etc.). All adverse events experienced by participants will be collected from the time of the first 
dose of cabozantinib, through th e study and until the final study visit. Participants 
continuing to experience toxicity at the off study visit may be contacted for additional assessments until the toxicity has resolved or is deemed irreversible.  
6.1 Anticipated Toxicities 
The general adverse event profile of cabo zantinib includes GI symptoms (such as 
nausea, vomiting, and diarrhea), fatigue, anor exia, palmar-plantar erythrodysesthesia 
(PPE) syndrome, skin rash, elevated ALT and AST, increased pancreatic enzymes with rare cases of  pancreatitis, as well as side effects associated with  inhibition of VEGF 
signaling such as thrombotic events (eg, pulmonary embolism [PE] and deep vein 
thrombosis [DVT]), hypertension, proteinuria,  hemorrhagic events, and rare cases of 
gastrointestinal [GI] perforation and rectal/perirectal abscess. Arterial thromboembolism (transient ischemic attack [TIA], myocardial  infarction [MI]) have been reported rarely. 
   
6.2 Dose Modifications/Delays and Toxicity Management 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
46 Subjects will be monitored continuously for AEs throughout the study and for 30 days 
after the last dose of cabozantinib, and for any serious adverse event (SAE) assessed as 
related to cabozantinib or st udy procedures, even if the SAE occurs more than 30 days 
after the last dose of cabozantinib.  Subjects will be instructed to notify thei r physician immediately of any and all AEs.
 
Subjects experiencing one or more AEs due to the cabozantinib may require a dosing delay 
or reduction(s) in their dose in order to continue with cabozantinib.   
Re-escalating cabozantinib after a dose reduction: 
 
 Subjects who required a dose reduction for Grade 4 non-hematologic toxicity should not be re-escalated 
 For other related AEs, subjects may be re -escalated to the previous dose at the 
discretion of the investigator but not sooner than 2 weeks beyond the resolution 
to Grade ≤  1 or to the base line value of AEs. 
 If a subject has been dose-re duced , dose re-escalation can  only occur to the next 
higher dose level. Further dose escalation to higher well-tolerated dose levels is 
allowed only if clinically indicated per investigator’s judgment and dose escalation criteria are met w ith each escalation (e.g. a minimum 2 week interval 
between escalations)  
 If the AEs that previously  led to dose reduction(s) recur upon re-es calation, the 
dose should be reduced again and no furt her dose escalation will be permitted.  
 
Dose re-escalation is not allowed for dose reduction triggered by neutropenia or 
thrombocytopenia.  
Additional information for dose delays or dose reductions: 
 Dose delays for reason(s) other than AEs related to cabozantinib, such as 
surgical procedures with no anticancer therapy intent, may be allowed with 
investigator approval. The acceptable length of interruption will be determined 
by the investigator. 
6.3 Management of Adverse Events 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
47 In the absence of an unacceptable cabozantinib- related toxicity and/or clinical signs of 
disease progression, subjects may continue treatment at the di scretion of the investigator. 
Subjects must be instructed to notify their phys ician immediately for any and all toxicities. 
Guidelines for the management of AEs (ie,  dose interruptions a nd dose reductions) are 
presented in the next sections. Each dose reduction of cabozantinib  should be to one 
dose level lower that the current dose (see Ta ble 4 below).  Dose reductions of more 
than one dose level are acceptabl e if agreed to by the Inve stigator. If cabozantinib of 
cabozantinib is restarted after being withheld or interru pted, the subject should be 
instructed not to make up the missed doses of cabozantinib.  
The reason for treatment delay and reduced dose must be recorded on the case report form 
(CRF). 
Dosing may need to be interrupted for AEs cons idered not related to cabozantinib if this 
is clinically indicated or if causality is initially uncertain. Cabozantinib may be resumed 
at the same dose (or a lower dos e per investigator judgment) if the AE is determined not 
to be related to cabozantinib once the inve stigator determines that retreatment is 
clinically appropriate and the subject meets the protoc ol re-treatment criteria. 
Table 4: Dose Reductions 
Starting Dose First Level dose  Reduction Second Level dose 
Reduction 
60 mg cabozantinib Reduce to 40 mg 
cabozantinib Reduce to 20 mg  
cabozantinib 
 
6.3.1 General Guidelines for Non-Hematologic and Hematologic Adverse Events  
Guidelines for the management of AEs (ie,  dose interruptions a nd dose reductions) are 
presented in the next sections. Each dose reduction of cabozantinib  should be to one 
dose level lower that the current dose. Dose reductions of more than one dose level are 
acceptable if agreed to by the Investigat or. All AEs should also be managed with 
supportive care at the earliest signs of toxicity  considered related to  the study treatment.  
If study treatment of cabozantinib is restarte d after being withheld or interrupted, the 
subject should be instructed not to ma ke up the missed doses of cabozantinib. The 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
48 reason for treatment delay and reduced dose must be recorded on the case report form 
(CRF). 
Dosing may need to be interrupted for AEs cons idered not related to cabozantinib if this 
is clinically indicated or if causality is  initially uncertain. Study treatment may be 
resumed at the same dose (or a lower dose pe r investigator judgment) if the AE is 
determined not to be related to cabozantinib once the investigator determines that 
retreatment is clinically appropriate and th e subject meets the protocol re-treatment 
criteria. 
Subjects receiving a daily dose of 20 mg may be restarted at the same dose if deemed 
safe at the discretion of the investigator. S ubjects unable to tolera te a daily dose of 20 
mg should discontinue study treatment. Re-escalation to the previous dose, (but not  higher than 60 mg/day) may be allowed at 
the discretion of the inves tigator but no sooner than 2 weeks beyond resolution of AEs 
that led to the dose re duction. Dose re-escalation is not allowed for a drug-related dose 
reduction triggered by myelosuppression or by Grade 4 AEs affecting major organs (eg, 
central nervous system, cardiac, hepatic, renal). 
The predicted effective plasma half-life of cabozantinib is 55 hours. Thus, when 
initiating therapy with cabozantinib, it will ta ke most subjects 2 to 3 weeks to reach 
steady state. If AEs attributable  to cabozantinib occur within the initial 3-week period of 
dosing, early intervention with dose modifica tions may be justified for AEs that, if 
worsened, could potentially be dangerous or debilitating, because without a dose 
adjustment, systemic exposure of cabozantinib  might be expected to increase after the 
onset of the AE. 
Table 5: General Approach to the Management of Cabozantinib-Related Non-Hematologic Toxicities 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
49 CTCAE v4.0   Guidelines/Intervention  
Grade 1:  Add supportive care as indicated. Continue cabozantinib at the 
current dose level if the AE is manageable and tolerable.  
Grade 2 AEs which are tolerable and are easily managed
 Continue cabozantinib treatment at the current dose level with supportive care.
 
Grade 2 AEs which are intolerable and cannot be adequately managed
 Interrupt cabozantinib treatment or dose reduction. Add supportive care as indicated.
 
 If cabozantinib dosing is inte rrupted, then upon resolution 
of the AE to baseline or Grade ≤ 1, cabozantinib may be 
resumed at either the same dose or with a dose reduction at the discretion of the investigator unless this is a recurring event at which time the dose should be reduced
 
Grade 3 AEs which occurred without optimal prophylaxis or which is easily managed by medical intervention or resolved 
quickly 
 Interrupt cabozantinib treatment and add supportive care as 
indicated:  
 For AEs that are easily managed (eg, correction of electrolytes) with resolution to baseline or Grade ≤ 1 within 
24 hours, cabozantinib may be resumed at either the same 
dose or with a dose reduction at the discretion of the 
investigator unless this is a r ecurring event at which time the 
dose should be reduced
 
 For AEs that require supportive care, the dose should be held 
while supportive care is initia ted and optimized. Then upon 
resolution of the AE to baseline or Grade ≤ 1, cabozantinib 
may be resumed at either the same dose or with a dose reduction at the discretion of the investigator unless this is a 
recurring event at which time the dose should be reduced
 
Grade 3 AEs which occurred despite optimal prophylaxis or is 
not easily managed by medical 
intervention 
 Interrupt cabozantinib treatment until recovery to ≤ Grade 1 or 
baseline.  Then resume treatment with a dose reduction.  
Grade 4 AEs (except easily corrected laboratory abnormalities)
 Permanently discontinue study treatment unless determined that the subject is unequivocally deriving clinical benefit. In this 
case, upon recovery to Grade ≤ 1 or baseline, the subject may be 
re-treated at a reduced dose that  is to be determined by the 
treating investigator and Principal Investigator, but only with PI 
approval.
 
Dose reductions or delays may occur in the setting of lower grade toxicity than defined above if 
the investigator believes that it is in the interest of the subject’s safety.  
 
 
  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
50 Table 6. General Approach to the Man agement of Hematologic Toxicities 
 
CTCAE v4.0  Intervention  
Neutropenia  
 Grade 3 neutropenia with 
infection requiring IV antibiotic, antifungal, or antiviral 
intervention
 
 Grade 3 neutropenia ≥ 7 days  
 Grade 4 neutropenia  Interrupt cabozantinib treatment until resolution to Grade ≤ 1, 
and resume cabozantinib treatment at a reduced dose.  
Thrombocytopenia  
Grade 3 thrombocytopenia with 
clinically significant bleeding or Grade 4 thrombocytopenia
 Interrupt cabozantinib treatment until platelet count is ≥ 100,000/mm
3, and resume cabozantinib treatment at a 
reduced dose.  
Febrile Neutropenia  
Grade 3 febrile neutropenia  Interrupt cabozantinib treatment until recovery of ANC to Grade ≤ 1 and temperature to ≤ 38.0°C and resume 
cabozantinib treatment at a reduced dose.
 
Grade 4 febrile neutropenia  Permanently discontinue study treatment unless determined that the subject is unequivocally deriving clinical benefit. In 
this case, upon recovery to Grade ≤ 1 or baseline, the subject 
may be re-treated at a reduced dose that is to be determined by 
the investigator and Sponsor but only with Sponsor approval.
 
Other Grade 4 Hematologic Toxicities  
Grade 4 hematologic toxicities  
other than anemia  Permanently discontinue study treatment unless determined that the subject is clearly deriving clinical benefit. In this case, upon recovery to Grade ≤ 1 or baseline, the subject may be 
re-treated at a reduced dose that  is to be determined by the 
treating investigator and Principal Investigator, and only with approval by the PI.
 
Grade 4 anemia  Permanent discontinuation for Grade 4 anemia is not mandated. Dose reductions or dose delays for anemia should be applied as clinically indicated. Supportive care such as red 
blood cell transfusions should be managed in accordance with 
institutional guidelines.
 
ANC, absolute neutrophil count; LLN, lower limit of normalNeutropenia: Grade 1 (ANC < LLN –  1.5  10
9/L); Grade 2 (ANC <1.5 x 109/L  – 1   109/L);  
Grade 3 (ANC <1  109/L –  0.5  109/L); Grade 4 (ANC <0.5  109/L ). 
Febrile Neutropenia: Grade 3 (present); Grade 4 (L ife-threatening consequences; urgent intervention 
indicated).  
Thrombocytopenia: Grade 1 (Platelet count <LLN – 75 x 109/L); Grade 2 (Platelet count <75.0 – 50.0 x 
109/L); Grade 3 (Platelet count < 50 - 25  109/L); Grade 4 (Platelet count < 25  109/L). 
 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
51 6.3.2 Gastrointestinal Disorders  
The most common GI AEs report ed in clinical studies with cabozantinib are diarrhea, oral 
pain, dyspepsia, stomatitis, and dysphagia.  
Diarrhea 
Subjects should be instructed to notify their physician immediately at the first signs of 
poorly formed or loose stool or an increased frequency of bowel movements. 
Administration of antidiarrheal/antimotility agen ts is recommended at  the first sign of 
diarrhea as initial management . Some subjects may require concomitant treatment with 
more than one antidiarrheal agent. When th erapy with antidiarrheal agents does not 
control the diarrhea to tolerable levels, study treatment should be temporarily interrupted or dose reduced. 
In addition, general supportive measures should  be implemented includ ing continuous oral 
hydration, correction of fluid and electrolyt e abnormalities, small frequent meals, and 
stopping lactose-containing products, high fat meals, and alcohol.  Nausea and Vomiting 
Antiemetic agents are recommended as clinically  appropriate at the first sign of nausea 
and vomiting or as prophylaxis to prevent emesis, along with supportive care in 
accordance to clinical practice guideline s. The 5-HT3 receptor antagonists are 
recommended over chronic use of NK-1 recep tor antagonists and dexamethasone (NK-1 
receptor antagonists can induce or inhibit CY P3A4, and glucocorticoids induce CYP3A4 
and thus could lower cabozantinib exposure). Caution is also recommended with the use 
of nabilone, which is a weak inhibitor of CYP3A4. When therapy with antiemetic agents 
does not control the nausea or vomiting to tolerable levels, study treatment should be 
temporarily interrupted or dose reduced. 
Stomatitis and Mucositis 
Preventive measures include a comprehensive dental examination to identify any potential 
complications before study treatment is in itiated. Removal of local factors should be 
instituted as indicated, such as  modification of ill-fitting dent ures and appropriate care of 
gingivitis.  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
52 During treatment with cabozantinib good oral hygiene and standard local treatments such 
as nontraumatic cleansing and oral rinses (e g, with a weak solution of salt and baking 
soda) should be maintained. The oral cavity sh ould be rinsed after meals, and dentures 
should be cleaned and brushed often to re move plaque. Local treatment should be 
instituted at the earliest onset of symptoms. Obta in bacterial/viral culture if oral infection 
is suspected and treat infection as indicated by local guidelines. When  stomatitis interferes 
with adequate nutrition and local therapy is not adequately effective, dose reduction or 
temporary withholding of cabozantinib should be considered. 
6.3.3 Hepatobiliary Disorders  
Elevations of transaminases have also  been observed during treatment with 
cabozantinib. In general, it is recommended th at subjects with elev ation of ALT, AST, 
and/or bilirubin have more frequent laboratory monitoring of these parameters. Other 
causes that may contribute to transaminase elev ations should be considered.  If possible, 
hepatotoxic concomitant medications and al cohol should be discont inued in subjects 
who develop elevated transaminases.  Because subjects may enter the study with elevations of AST/ALT at baseline, the 
following guidelines in Table 5 should  be used for dose modifications: 
Table 7: Management of Transaminase Elevation 
Transaminase 
elevation CTCAE v4.0  
Intervention 
Subjects with AST and ALT less than or equal to the ULN at baseline 
Grade 1  Continue cabozantinib with week ly monitoring of  liver function 
tests (LFTs) for at least 4 weeks. Then resume the standard protocol-defined monitoring of  liver function tests (LFTs). 
Grade 2 Continue cabozantinib with at l east twice weekly monitoring of 
LFTs for 2 weeks. Then weekly for 4 weeks. If LFTs continue to rise within Grade 2, interrupt caboz antinib treatment. Then continue 
with at least weekly LFTs  until resolution to Grade ≤ 1. Study 
treatment may then be resumed at  a one-dose-leve l reduction of 
cabozantinib 
Grade 3  Interrupt cabozantinib treatment a nd monitor with at least twice 
weekly LFTs until Grade ≤ 2. Then continue with at least weekly 
LFTs until resolution to Grade ≤ 1. Cabozantinib may then be 
resumed at a one-dose-level reduction.  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
53  
Cabozantinib treatment should also be inte rrupted when AST or ALT increases are 
accompanied by progressive elevations of tota l bilirubin, and/or elevations of coagulation 
tests (eg, International Norma lized Ratio [INR]). Monitoring  of transaminases should be 
intensified (2–3 times per week) and cabozantin ib should be held until the etiology of the 
abnormalities is determined and these abnormalitie s are corrected or stabilize at clinically 
acceptable levels (INR < 1.5  upper limit of normal [ULN ], total bilirubin < 1.5  ULN, 
aminotransferases ≤ baseline grade).  
Subjects must have cabozantinib permanently di scontinued if transaminase elevations are 
accompanied by evidence of impaired he patic function (bilirubin elevation > 2  ULN), in 
the absence of evidence of b iliary obstruction (ie, signifi cant elevation of alkaline 
phosphatase) or some other explanation of the injury (eg, viral hepatitis, alcohol hepatitis), 
because the combined fi nding (ie, Hy’s Law cas es) represents a signal of a potential for 
the drug to cause severe liver injury. Grade 4  Discontinue study treatment permanently. LFTs should be 
monitored as clinically indicated, at least 2 to 3 times per week, 
until resolution to Grade ≤ 1. If the subject was unequivocally 
deriving clinical benefit, the s ubject may be able to resume 
treatment at a lower dose of cabozantinib as determined by the treating investigator and Principa l Investigator but only with PI 
approval. 
Subjects with AST or ALT above the ULN but ≤ 3.0 x ULN (ie, Grade 1) at baseline  
≥ 1.5 fold increase of 
AST or ALT AND 
both AST and ALT 
are ≤ 5.0 x ULN Continue cabozantinib treatment with at least twice weekly monitoring of LFTs for 4 weeks a nd weekly for 4 weeks. If LFTs 
continue to rise, interrupt study tr eatment. Then continue with at 
least weekly LFTs until resolution to Grade ≤ 1. Study treatment 
may then be resumed at a one-dose-level reduction of cabozantinib. 
≥ 1.5 fold increase of 
AST or ALT and at least one of AST or ALT is Grade 3 (ie, 
AST or ALT > 5.0 but 
≤ 20.0 x ULN) Interrupt study treatment and monitor with at least twice weekly LFTs until Grade ≤ 2. Then continue with at least weekly LFTs 
until resolution to Grade ≤ 1. Study treatment may then be resumed 
at a one-dose-level redu ction of cabozantinib. 
Grade 4  Discontinue study treatment permanently. LFTs should be monitored as clinically indicated, at least 2 to 3 times per week, 
until resolution to Grade ≤ 1. If the subject was unequivocally 
deriving clinical benefit, the s ubject may be able to resume 
treatment at a lower dose as determ ined by the treating investigator 
and Principal Investigator, but only with PI approval. 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
54 All subjects who develop isolated bilirubin  elevations of Grade 3 should have study 
treatment held until recovered to Grade ≤ 1 or baseline (or lower). If this occurs within 
6 weeks of the dosing delay, study treatment ma y continue at a reduced dose. In subjects 
without biliary obstruction and Grade 4 bilir ubin elevation, or with  recurrence of Grade 
3 bilirubin elevation after a dose reducti on, study treatment must be permanently 
discontinued.  
6.3.4 Fatigue, Anorexia and Weight Loss  
Fatigue has been reported during treatment with cabozantinib. Common  causes of fatigue 
such as anemia, deconditioning, emotional dist ress (depression and/or anxiety), nutrition, 
sleep disturbance, and hypothyroidism should be  ruled out and/or these causes treated in 
accordance to standard of care. Individual non-pharmacological and/or pharmacologic 
interventions directed to the contributi ng and treatable factors should be given. 
Pharmacological management with psychostimul ants such as methylphenidate should be 
considered after disease specific morbidities have been excluded. Note: Chronic use of 
modafinil should be avoided because of its potential to  reduce cabozantinib exposure (see 
Investigator’s Brochure).   
Anorexia and weight loss should be manage d in accordance to loca l standard of care 
including nutritional support. Ph armacologic therapy such as megestrol acetate should be 
considered for appetite enhancement.  If fa tigue, anorexia, or weight loss cannot be 
adequately managed, study treatment should be temporarily interrupted or dose reduced. 
6.3.5 Pancreatic Conditions  
Amylase and lipase elevations have been obser ved in clinical studies with cabozantinib. 
The clinical significance of asymptomatic elevations of enzymes is not known, but in 
general have not been associated with clini cally apparent sequelae. It is recommended 
that subjects with lipase elevation and/or sy mptoms of pancreatitis have more frequent 
laboratory monitoring of lipase and/or amylas e. Subjects with symptomatic pancreatitis 
should be treated with standard supportive measures. 
 
     
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
55 Table 8: Asymptomatic Lipase or Amylase Elevations 
 
Asymptomatic Lipase or  Amylase  Elevations 
Grade 1 or Grade 2 Continue at current dose level.  Mo re frequent monitoring is 
recommended 
Grade 3  Interrupt treatment 
 Monitor lipase and amylase weekly 
 Upon resolution to Grade ≤ 1 or baseline, cabozantinib may 
be restarted at the same dose or at a reduced dose provided 
that this occurs within 6 weeks. 
 If retreatment following Grade 3 lipase or amylase elevation 
is at the same dose and Grade 3 elevations recur, then 
treatment must be interrupted again until lipase and amylase  levels have resolved to Grade ≤ 1 or baseline and 
retreatment must be at a reduced dose. 
Grade 4  Interrupt treatment 
 Monitor lipase and amylase weekly 
 Upon resolution to Grade ≤ 1 or baseline and if resolution 
occurred within 4 days, cabozantinib may be restarted at the same dose or a reduced dose.  If resolution took more than 4 
days, the dose must be reduced upon retreatment provided that resolution occurred within 6 weeks. 
 If retreatment following Grade 4 lipase or amylase elevation is at the same dose and Grade 3 or 4 elevations recur, then treatment must be interrupted again until lipase and amylase have resolved to Grade ≤ 1 or baseline and retreatment must 
be at a reduced dose. 
 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
56 Table 9:  Symptomatic Pancreatitis 
Pancreatitis 
Grade 2  Interrupt treatment 
 Monitor lipase and amylase weekly 
 Upon resolution to Grade ≤ 1 or baseline, cabozantinib may 
be restarted at the same dose or at a reduced dose provided 
that this occurs within 6 weeks. 
 If retreatment following Grade 2 pancreatitis is at the same 
dose and Grade 2 pancreatitis r ecurs, then treatment must be 
interrupted again until resolution to Grade ≤ 1 or baseline 
and retreatment must be at a reduced dose. 
Grade 3  Interrupt treatment 
 Monitor lipase and amylase weekly 
 Upon resolution to Grade ≤ 1 or baseline, cabozantinib may 
be restarted at a reduced dose if  resolution occurred within 6 
weeks 
Grade 4 Permanently discontinue treatm ent.  However, if the subject was 
unequivocally deriving benefit from cabozantinib therapy, 
treatment may resume at a reduced dose per investigator judgment. 
 
6.3.6 Skin Disorders  
Palmar-plantar erythrodysesthesia syndrom e (also known as hand-foot syndrome), skin 
rash (including blisters, erythematous ras h, macular rash, skin exfoliation, dermatitis 
acneiform, and papular rash), pruritus, dry skin, and erythema have been reported in 
cabozantinib-treated subjects. All subject s on study should be advised on prophylactic 
skin care. This includes the use of hypoallerg enic moisturizing creams, ointment for dry 
skin, and sunscreen with sun protection factor ≥  30, avoidance of exposure of hands and 
feet to hot water, protection of pressure-sen sitive areas of hands and feet, and use of 
thick cotton gloves and socks to  prevent injury and to k eep the palms and soles dry. 
Subjects with skin disorders should be careful ly monitored for signs of infection (eg, 
abscess, cellulitis, or impetigo). 
Early signs of hand-foot syndrome could be  tingling, numbness, and slight redness or 
mild hyperkeratosis. Early manifestations in clude painful, symmetr ical red and swollen 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
57 areas on the palms and soles. The lateral sides of the fingers or peri-ungual zones may 
also be affected. Adequate interventions are required to preven t worsening of skin 
symptoms such as blisters, desquamations, ul cerations, or necrosis of affected areas. 
Aggressive management of symptoms is  recommended, including early dermatology 
referral. Treatment guidelines for PPE relate d to study treatment are presented in Table 
10. 
In the case of study treatment-related skin changes (eg, rash, hand-foot syndrome), the 
investigator may request that  additional assessments be conducted with the subject’s 
consent. These assessments may include digita l photographs of the skin changes and/or 
a biopsy of the affected skin and may be repeated until the skin changes resolve.  
Table 10: Hand-Foot Syndrome  
Hand-Foot Skin Reaction a nd Hand Foot Syndrome (PPE) 
Grade 1 Continue cabozantinib at curr ent dose. Start urea 20% cream twice 
daily and clobetasol 0.05% cream once daily. Assess subject at 
least weekly for changes in sever ity. Subjects should be instructed 
to notify investigator immediately if severity worsens. 
Grade 2 If tolerable, continue cabozantinib at current dose. 
 
If intolerable, reduce cabozantinib dose to next lower level and/or 
interrupt dosing. Start/continue urea 20% cream twice daily and 
clobetasol 0.05% cream once daily. A dd analgesics for pain control 
with NSAIDs/GABA agonists/narcotics if needed. Assess subject at 
least weekly for changes in severity. If treatment was interrupted (but not reduced), treatment may be restarted at the same dose or at 
one dose level lower when reaction d ecreases to Grade 1 or 0. If a 
treatment interruption is again re quired, the dose must be reduced 
when treatment resumes. 
 
Subjects should be instructed to notify investigator immediately if severity worsens. If severity worsens at any time, or affects 
self-care, proceed to the manage ment guidelines for Grade 3 PPE. 
Grade 3 Interrupt study treatment until severity decreases to Grade 1 or 0. 
Start/continue urea 20% cream twice daily and clobetasol 0.05% 
cream once daily. Pain control with NSAIDs/GABA agonists/narcotics. Treatment may restart at one dose level lower 
when reaction decreases to Grade 1 or 0. Permanently discontinue 
subject from study if reactions worsen or do not improve within 6 weeks.  
GABA, γ-aminobutyric acid; NSAID, nonsteroidal anti-inflammatory drugs; PPE, palmar-plantar erythrodysesthesia 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
58 6.3.7 Thromboembolic Events 
Thromboembolic complications are frequent  in cancer patients due to procoagulant 
changes induced by the malignancy or antican cer therapy including inhibitors of VEGF 
pathways. Deep vein thrombosis and PE have  been observed in clinical studies with 
cabozantinib; including fatal events (pleas e refer to the Investigator’s Brochure). 
Subjects who develop a PE or DVT should have cabozantinib treatment held until 
therapeutic anticoagulation with heparins (eg, low molecular weight heparin [LMWH]) 
is established. (Note: Therapeu tic anticoagulation with oral anticoagulants, eg, warfarin, 
or oral platelet inhibitors su ch as clopidogrel is not allo wed in this study). Cabozantinib 
treatment may be resumed in subjects who ar e stable and have uncomplicated PE or 
DVT and are deriving clinical benefit from cabozantinib treatment. During 
anticoagulation treatment, subjects need to be monitored on an ongoing basis for 
bleeding risk and signs of bleeding which may require a dditional or more frequent 
laboratory tests in accordance to instituti onal guidelines. If there are any signs of 
clinically significant bleedings, cabozan tinib treatment should be permanently 
discontinued. 
Arterial thrombotic events (eg, transient is chemic attack, myocardial infarction) have 
been observed in studies with cabozantinib. Su bjects should be evaluated for preexisting 
risk factors for arterial thrombotic events  such as diabetes mellitus, hyperlipidemia, 
hypertension, coronary artery disease, history of tobacco use, and cardiac or 
thromboembolic events that occurred before initiation of study treatment. Cabozantinib 
treatment should be discontinued in subjects who develop an acute myocardial infarction 
or any other clinically relevant arterial thromboembolic complication. 
 
6.3.8 Hypertension  
Hypertension is a common class effect of drugs that inhibit VEGF pathways and has 
been reported among subjects treated with cabozantinib. 
Blood pressure should be monitored in a consta nt position at each visit (either sitting or 
supine). Treatment guidelines for hyperten sion deemed related to cabozantinib are 
presented in Table 11. In general, subjects with known hypertension should be optimally 
managed before study entry. Decisions to d ecrease or hold the dose of study treatment 
must be based on blood pressure readings taken by a medical professional and must be 
confirmed with a second measurement at leas t 5 minutes after the first measurement. 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
59 Other than for hypertension requiring imme diate therapy, the presence of new or 
worsened hypertension should be confirmed at  a second visit before taking therapeutic 
action. It is recommended that this second visit occurs  within 1 week. 
 
Table 11:  Management of Hypertension Related to Cabozantinib 
Criteria for Dose Modifications Treatment/cabozantinib Dose Modification 
Subjects not receiving optimized anti-hypertensive therapy 
> 150 mm Hg (systolic) and < 160 
mm Hg 
or > 100 mm Hg (diastolic) and < 110 
mm Hg 
 
  Increase antihypertension therapy (ie, increase 
dose of existing medications and/or add new 
antihypertensive medications) ; 
 Maintain dose of cabozantinib; 
 If optimal antihypertensive therapy (usually to 
include 3 agents) does not result in blood pressure 
< 140 systolic or < 90 diastoli c, or if the subject is 
symptomatic, the dose of cabozantinib should be interrupted and/or reduced. 
≥ 160 mm Hg (systolic) and < 180 
mm Hg 
or ≥ 110 mm Hg (diastolic) and < 120 
mm Hg  Interrupt and/or reduce cabozantinib by one dose 
level; 
 Increase antihypertension therapy (ie, increase 
dose of existing medications and/or add new 
antihypertensive medications) ; 
 Monitor subject closely for hypotension; 
 If optimal antihypertensive therapy (usually to 
include 3 agents) does not result in blood pressure 
< 150 systolic or < 100 diastolic, dose of 
cabozantinib should be reduced further. 
≥ 180 mm Hg (systolic) 
or 
≥ 120 mm Hg (diastolic )  Interrupt treatment with cabozantinib Add new or 
additional anti-hypertensive medications and/or 
increase dose of existing medications; 
 Monitor subject closely for hypotension; 
 When SBP < 150 and DBP < 100, restart 
cabozantinib treatment at one dose level lower; 
 If optimal antihypertensive therapy (usually to include 3 agents) does not result in blood pressure 
< 150 systolic or < 100 diastolic, dose of 
cabozantinib should be reduced further.  
Hypertensive emergency or hypertensive encephalopathy Discontinue all study treatment 
BP, blood pressure, SBP systolic blood pressure, DBP diastolic blood pressure 
NOTE: If SBP and DBP meet different criteria in table, manage per higher dose-modification criteria  
 
 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
60 6.3.9 Proteinuria  
Proteinuria is an anticipated AE with the inhibition of VEGF pa thways and has been 
observed in cabozantinib clin ical studies, and nephrotic syndrome has been reported 
with cabozantinib and other inhibitors of VEGF pathways. Management guidelines are 
provided in Table 12. 
  Table 12: Management of Treatment Emergent Proteinuria 
Severity of 
Proteinuria 
(UPCR) Action To Be Taken 
≤ 1 mg/mg  
(≤ 113.1 mg/mmol)  No change in cabozantinib treatment or monitoring. 
> 1 and < 3.5 mg/mg 
(> 113.1 and 
< 395.9 mg/mmol)  No change in cabozantini b treatment required;  
 Consider confirming with a 24-hour protein assessment 
within 7 days; 
 Repeat UPCR within 7 days and once per week. If 
UPCR < 1 on 2 consecutive readings, UPCR monitoring 
can revert to protocol-speci fic times. (Second reading is 
confirmatory and can be done  within 1 week of first 
reading). 
≥ 3.5 mg/mg 
(≥ 395.9 mg/mmol) 
  Hold cabozantinib treatment pending repeat UPCR within 7 days and/or 24-hour urine protein; 
 If ≥ 3.5 on repeat UPCR, continue to hold cabozantinib 
treatment and check UPCR every 7 days. If UPCR decreases to < 2, restart cabozantinib treatment at a reduced dose and monitoring of urine protein/creatinine 
should continue weekly until the UPCR decreases to < 1. 
Nephrotic syndrome  Discontinue cabozantinib treatment. 
UPCR, urine protein to creatinine ratio. 
 
6.3.10  Hemorrhage 
Hemorrhagic events have been reported with approved drugs that inhibit VEGF 
pathways as well as with cabo zantinib. In order to mitigate risk of severe hemorrhage, 
subjects should be evaluate d for potential bleeding risk  factors before initiating 
cabozantinib treatment and monitored for bleeding events  with serial complete blood 
counts and physical examinat ion while on study. Risk fact ors for hemorrhagic events 
may include (but may not be limited to) the following: 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
61  Tumor of the lung with cavitary lesions or tumo r lesions which invades, 
encases, or abuts major blood ve ssels. The anatom ic location and 
characteristics of tumor as  well as the medical history must be carefully 
reviewed in the selection of subj ects for treatment with cabozantinib; 
 Recent or concurrent radiation to the thoracic cavity; 
 Active peptic ulcer disease, ulcera tive colitis, an d other infla mmatory GI 
diseases; 
 Underlying medical  conditions which affect normal hemostasis (eg, 
deficiencies in clotting fa ctors and/or platelet func tion, or thrombocytopenia); 
 Concomitant medication with anticoagulants or other drugs which affect 
normal hemostasis; 
 History of clinically significant hemoptysis. 
Discontinue cabozantinib trea tment in subjects who have  been diagnosed with a 
severe bleeding complication. 
6.3.11  Rectal and Perirectal Abscess  
Rectal and perirectal abscesses have been  reported, sometimes in subjects with 
concurrent diarrhea. These should be treate d with appropriate lo cal care and antibiotic 
therapy. Cabozantinib should be held until adequate healing has taken place. 
6.3.12  GI Perforation/Fistula and Non-GI Fistula Formation  
GI perforation/fistula and no n-GI fistula formation have been reported with approved 
drugs that inhibit VEGF pathways as well as with cabozantinib. Carefully monitor for 
episodes of abdominal pain, especially am ong subjects with know n risk factors for 
developing GI perforation/fistul a, and carefully monitor subj ects with known risk factors 
for non-GI fistula, to allow for early diagnosis. Such risk  factors include (but may not be 
limited to) the following: 
GI perforation/fistula: 
 Intra-abdominal tumor/metast ases invading GI mucosa; 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
62  Active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis 
or symptomatic cholan gitis, or appendicitis; 
 History of abdominal fistula, GI perfora tion, bowel obstruction, or intra-abdominal 
abscess; 
 Prior GI surgery (particularly when associat ed with delayed or incomplete healing). 
Complete healing after abdominal surgery or resolution of intra-abdominal abscess 
must be confirmed be fore initiating treatmen t with cabozantinib. 
Additional risk factors include concurrent chronic use of ster oid treatment or nonsteroidal 
anti-inflammatory drugs. Constipation indi cative of bowel obstruction should be 
monitored and effectively managed.  
Non-GI fistula: 
Complications from radiation therapy has been  identified as a possible predisposing risk 
factor for non-GI fistula formation among subjects undergoing treatment with VEGF 
pathway inhibitors (eg, bevacizumab). Patient s with endotracheal or endobronchial tumor 
should not be treated with cabozantinib 
Discontinue cabozantinib treatment in subject s who have been diagnosed with GI or 
non-GI perforation/fistula. 6.3.13  Wound Healing and Surgery  
VEGFR inhibitors can cause wound healing complications and wou nd dehiscence which 
may occur even long after a wound has been co nsidered healed. Ther efore, surgical and 
traumatic wounds must have completely healed  before starting cabozantinib treatment and 
be monitored for wound dehiscen ce or wound infection while the subject is being treated 
with cabozantinib. If possible, cabozantinib tr eatment should be stopped for at least 28 
days prior to major surgery. 6.3.14  Hypophosphatemia  
Hypophosphatemia has been reported during treatment with cabozantinib. Serum 
phosphorus should be monitored frequently wh ile receiving cabozantinib. Other causes of 
hypophosphatemia should be ruled out and/or these causes treated in accordance to standard of care. Mild to moderate hy pophosphatemia should be managed by oral 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
63 replacement including food that are high in phosphate (diary items, meats, beans) and/or 
oral phosphate supplements in accordance to  standard clinical practice guidelines.  
Clinically relevant hypophosphatemia shoul d be managed in accordance to the dose 
modification guidelines. 
6.3.15  Thyroid Function Disorders  
Changes in thyroid function tests (TFTs) an d hypothyroidism have been reported with 
cabozantinib and other tyrosine kinase inhibitor treatment as a result of altered thyroid 
hormone regulation by mechanisms that seem to  be specific for each agent (Torino et al. 
2009). Preliminary data from ongoing studies indicate that treatment-emergent elevation 
of thyroid stimulating hormone (TSH) by caboz antinib may be dose-dependent in fashion. 
Hyperthyroidism has also been reported. Currently available data are insufficient to determine the mechanism of TFT alterations and its clinical relevance. Routine monitoring 
of thyroid function and assess ments for signs and symptoms associated with thyroid 
dysfunction is recommended before initiati on and during treatment with cabozantinib. 
Management of thyroid dysfunction (eg, symptomatic hypothyroidism) should follow accepted clinical practice guidelines and dose modification guidelines.  
6.3.16  Guidelines for Prevention of Osteonecrosis of the Jaw  
Osteonecrosis of the jaw (ONJ ) has been reported with us e of anti-angiogenic drugs and 
bisphosphonates and denosumab in cancer patie nts. Additional risk factors for ONJ have 
been identified such as use of corticosteroids, chemotherapy, local radiotherapy, poor oral hygiene, smoking, dental or orofacial surgery procedures, and cancer disease itself. Osteonecrosis has been reported among subject s treated with cabozan tinib, the details of 
which are provided in the current version of  Investigator’s Brochure. As a preventive 
measure, invasive dental procedures should be avoided if possible in subjects who have previously been treated with or concomita ntly receive bisphosphonates or denosumab. 
In cases where dental procedures are unavoidable, the risks and benefits of a dental procedure and the extent of the procedure as well  as the risk of develo ping ONJ need to be 
considered when deciding on the duration of a temporary treatment interruption of 
cabozantinib. If clinically possible, treatm ent with cabozantinib should be held for 
approximately 4 weeks before a dental proced ure and resumed after complete healing has 
occurred. 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
64 Subjects with any documented case of oste onecrosis should have study treatment 
interrupted, and appropriate c linical management should be initiated. Reinitiation of 
study treatment must be discussed with a nd approved by the Sponsor on a case-by-case 
basis.  
6.3.17  Guidelines for Management of Trea tment-Emergent Corrected QT (QTc)  
The effect of orally administ ered cabozantinib at 140 mg/day  (free-base equivalent) on 
QTc interval was evaluated in a randomi zed, double-blinded, placebo-controlled phase 3 
study in patients with medulla ry thyroid carcinoma. A mean increase in QTcF of 10 - 15 
ms was observed at 4 weeks after init iating cabozantinib. A concentration-QTc 
relationship could not be definitively established. Changes in cardiac wave form 
morphology or new rhythms were not observed. Accordingly, subjects in this study will 
be monitored for potential QT effects. 
Other factors which may contri bute to QTc prolongation include: 
 Treatment with other drugs associated with QTc prolongation (see 
http://www.qtdrugs.org); 
 Treatment with CyP 3A4 inhibitors (which may increase cabozantinib drug 
levels); 
 Electrolyte changes (hypokalemia, hypocalcemia, hypomagnesemia); 
 Medical conditions which can alter electro lyte status eg, severe or prolonged 
diarrhea. 
Subjects having any of these additional risk  factors while on cabozantinib must have 
electrocardiograms (ECGs) performed approxima tely one week after the onset of these 
factors. 
If at any time on study there is an increase in QTc to an absolute value > 500 msec, two 
additional ECGs should be performed within  30 minutes after th e initial ECG with 
intervals not less than 3 minut es apart. If the average QTc calculated by the Friderica 
formula (QTcF) from the three ECGs is > 500 msec, study treatment must be withheld 
and the following actions should be taken: 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
65  Check electrolytes, especially potas sium, magnesium and calcium. Correct 
abnormalities as clinically indicated; 
 If possible, discontinue any QTc- prolonging concomitant medications; 
 Repeat ECG triplets hourly until the average QTcF is ≤ 500 msec or otherwise 
determined by consultation with a cardiologist. 
The Sponsor should be notified immedi ately of any QTc prolongation event: 
Subjects with QTc prolongation and symptoms must be monitored closely until the QTc 
elevation has resolved. Cardiology consul tation is recommended for evaluation and 
subject management. Symptomatic subjects must  be treated in accordance with standard 
clinical practice. No additional study treatment is to be given to the subject until after the event has resolved, the subject has been thoroughly evaluated, and further treatment has been agreed to by the Sponsor. If any a dditional study treatment is given (eg, after 
correction of electrolyte abnormalities and normalization of QTcF), it will be at a reduced dose as agreed to by th e investigator and the Sponsor. 
7 EXPECTED TOXICITIES AND DOSI NG DELAYS/DOSE MODIFICATIONS 
DUE TO TRASTUZUMAB 
There are no reductions in the trastuzumab dose. If adverse events occur that require 
holding trastuzumab, the dose will remain the same once treatment resumes. 
7.1 Recommendations for Dose Modification of Trastuzumab Based on Cardiac Monitoring 
 Asymptomatic 
LVEF drop CTCv3 Grade 3 CTCv4 Grade 4 
Trastuzumab ≥10% AND below 
LLN-Hold, repeat EF in 4-6 weeks, restart if in normal range Discontinue permanently Discontinue permanently 
 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
66  LVEF can be determined by echocardiogr am or MUGA but the same method 
should be used for that patie nt for all determinations. 
 LVEF of greater than 75% at baseline sh ould be re-reviewed and/or at least 
repeated as it may be falsely elevated. 
 Trastuzumab may be restarted if the 4- 6 week repeat LVEF has improved such 
that the hold parameters would no longer apply. 
 Patients who have two consecu tive or three intermittent  “holds” of trastuzumab 
should have trastuzumab discontinued permanently. 
 If trastuzumab is discontinued, patient s may still remain on  study and receive 
cabozantinib, if parameters are met for administration of this agent. 
7.2 Management of Acute Infusion Syndrome 
During the first infusion with  trastuzumab, a symp tom complex consisting of chills and/or 
fever is observed commonly in patients. Other signs and/or symptoms may include 
nausea, vomiting, pain, rigors, headache, c ough, dizziness, rash, and asthenia. These 
symptoms are usually mild to moderate in severity, a nd occur infrequently with 
subsequent trastuzumab infusion. Thes e symptoms can be treated with an 
analgesic/antipyretic such as meperidine, or  an antihistamine such as diphenhydramine. 
Serious adverse reactions to trastuzumab infusion including dyspnea, hypotension, 
wheezing, bronchospasm, tachycar dia, reduced oxygen saturation and respiratory distress 
have been reported infrequently. In rare cases, these events were associ ated with a clinical 
course culminating in a fatal outcome. Serious reactions have been treated with supportive 
therapy such as oxygen, beta-agonists, corticos teroids, and withdrawal of trastuzumab as 
indicated. If patients develop an infusion reaction: 
 Stop trastuzumab infusion and notify physician. 
 Assess vital signs. 
 Administer acetam inophen 650 mg PO. 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
67  Consider administration of: meperidine (Demerol®) 50 mg IM, Benadryl® 50 mg 
IV, Ranitidine 50 mg IV or  cimetidine 300 mg IV, and dexamethasone 10 mg IV.  
It is acceptable to administer meperidine (Demerol®) intravenously. 
 If vital signs stable, resu me trastuzumab infusion. 
 Patients tend not to develop infusion syndromes with subsequent cycles. No standard premedication is required for future treatments if patients have developed an infusion syndrome. Patients may be gi ven acetaminophen prior to treatments. 
 If a grade 3 or 4 toxicity occurs during an infusion of  trastuzumab, the infusion 
must be immediately stopped. The patient must be monitored for a minimum of 1 
hour after the infusion is stopped. If an outpatient, the patient must be admitted to the hospital for monitoring if the toxi city does not resolve within 3 hours. 
 If a grade 3 or 4 toxicity occurs durin g the post-infusion observation period, the 
patient must be evaluated for a minimum of  1 hour from the time the toxicity was 
first noticed. If an outpatient, the patient  must be admitted to the hospital for 
monitoring if the toxicity does not resolve within that hour. 
8 DRUG FORMULATION AND STORAGE 
8.1 Cabozantinib 
8.1.1  Description  
Chemical Name: N-{4-[(6,7-dimethoxyquino lin-4-yl)oxy]phenyl}- N’-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate  
8.1.2 Form – Cabozantinib Tablets  
Exelixis internal number: XL184 Exelixis will provide each investigator w ith adequate supplies of cabozantinib, which 
will be supplied as 60-mg, and 20-mg yellow film-coated tablets. The 60-mg tablets are 
oval, and the 20-mg tablets are round. The co mponents of the tablets are listed in Table 
13. 
  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
68 Table 13: Cabozantinib Tablet Components and Composition 
 
        8.1.3 Storage & Stability  
Cabozantinib must be stored at controlled room temperature  
8.1.4 Compatibility  Ingredient  Function % w/w
Cabozantinib Drug Substance (25% drug load 
as free base) Active Ingredient 31.7 
Microcrystalline Cellulose (Avicel PH-102) Filler 38.9 
Lactose Anhydrous (60M) Filler 19.4 Hydroxypropyl Cellulose (EXF) Binder 3.0 Croscarmellose Sodium (Ac-Di-Sol) Disenegrant 6.0 Colloidal Silicon Dioxide, Glidant 0.3 Magnesium Stearate Lubricant 0.75 Opadry Yellow Film Coating which includes: 
- HPMC 2910 / Hypromellose 6 cp  
- Titanium dioxide  
- Triacetin  
- Iron Oxide Yellow Film Coating 4.00 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
69 Not applicable  
8.1.5 Availability  
Cabozantinib is an investigational agent a nd will be supplied free-of-charge from 
Exelixis. 
8.1.6 Preparation 
Not applicable 8.1.7 Ordering  
Cabozantinib will be provided by Exelixis. 8.1.8 Accountability  
The investigator, or a responsible party designated by the investigator, must maintain 
a careful record of the inventory and dis position of cabozantinib using the NCI Drug 
Accountability Record or another co mparable drug accountability form.  
8.1.9 Destruction and Return 
At the end of the study, unused supplies of cabozantinib should be destroyed according to institutional policies. Dest ruction will be documented in the Drug 
Accountability Record Form. 
8.2 Trastuzumab 
8.2.1 Product Description Trastuzumab is commercially available.  Trastuzumab Lyophilized Formulation is 
supplied as a freeze-dried preparation at a nom inal content of either 440 mg or 150 mg 
per vial for parenteral admi nistration (may vary based upon commercial availability). 
The drug is formulated in histidine, trehalose, and polysorbate 20. 
8.2.2 Formulation 
 
Each 440 mg vial is reconstituted with 20m L of Bacteriostatic Water for Injection 
(BWI), USP (containing 1.1% benzyl alcohol), which is supplied with each vial. The 
reconstituted solution contains 21 mg/mL Herceptin and will be added to 250 mL of 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
70 0.9% Sodium Chloride Injection, USP.  The reconstituted formulation (440 mg vial) is 
designed for multiple use.  Unused drug may be stored for 28 days at 2ºC-8ºC (36ºF-
46ºF).   
Each 150 mg vial is reconstituted with 7.4 mL  of Sterile Water for Injection (SWFI). 
The reconstituted solution contains 21 mg/mL trastuzumab and will be added to 250 ml 
of 0.9% Sodium Chloride Injection, USP.  Use the Herceptin solution immediately 
following reconstitution with SWFI, as it contains no preserva tive. If not used 
immediately, store the reconstituted Hercepti n solution for up to 24 hours at 2º C-8ºC  ; 
discard any unused Herc eptin after 24 hours. 
8.2.3 Storage 
 
DO NOT FREEZE. Trastuzumab may be sensitive to shear-induced stress (e.g. agitation or rapid expulsion from a syringe). DO NOT SHAKE. Vigor ous handling of solutions 
trastuzumab results in aggr egation of the protein and may create cloudy solutions. 
 
Reconstituted trastuzumab shoul d be clear to slightly opalescent and colorless to pale 
yellow. 
 
9 CORRELATIVE / SPECIAL STUDIES METHODS 
9.1 Evaluate c-Met and phosphor-c-Met expres sion in FFPE tumor tissue (and optional 
baseline tumor biopsies, if available) 
FFPE tissue sections will be deparaffinized prior to antigen retrieval, blocking, and 
incubation with primary antibodies. Patients wi ll be dichotomized as to whether or not 
their tumor expresses c-Met and the association between expression and response to 
cabozantinib will be evaluated. 
 Please refer to Appendix F for archival tissue guidelines. 
 
9.2 Evaluate the incidence of c-Met positi ve circulating tumor cells at baseline 
Peripheral blood will be collected at baseline  for evaluation of c-met amplification in 
circulating tumor cells (CTCs). Two tubes of  whole blood will be co llected in CellSave 
tubes.  CTCs will be collected using the automated CellSearch processing technique 
(Veridex).  The captured cells are permeabilized and labeled with cytokeratin CD45 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
71 specific antibodies, and the nuclear stain ‘4-6-Diamidino-2-phenylindole (DAPI), and 
analyzed by semi-automated c ounting of appropriately labe led CTCs (Riethdorf et al, 
2007). CTCs are defined as CD45 negative and positive for cytokeratin and DAPI. 
Stained cells are collected by the Veridex system in a “MagNest” cartridge. This 
cartridge is automatically scanned. Semi-aut omated counting is performed according to 
the manufacturer’s instructions by a trai ned pathologist. The MET/CEP 7 bacterial 
artificial chromosome (BAC) probe will be obtained from Vysis Molecular (Abbot Park, 
Illinois). BAC MET (RP11-95I20) will be obtained from CHORI (Children’s Hospital of Oakland Research Hospital). Labeling will be completed with the Nick Translation 
Kit (Vysis Molecular (Abbot Park, Illinois). Slides will be maintained in a horizontal 
position throughout the entire hybrid ization and washing proce dure.  Briefly, cells are 
fixed with methanol-acetic acid  (3:1), dehydrated in an al cohol series (50%, 75%, 90%, 
100%) and air-dried. Five microliters of the pr obe mixture are applied, and the slides are 
covered with cover glass and sealed with rubber cement. Pre-hybridization is done with 
hybridization buffer without dextran sulfate for 1 hour at 37 oC. Denaturation is 
performed at 94
oC for 5 minutes. Hybridization is completed overnight at 37oC. 
Following hybridization, slides are washed in 1x SSC 3 times for 10 minutes each at 
37oC (maintaining the horizontal position), br iefly air dried, and counterstained with 
Vectashield/DAPI (Vector). Two-color FISH  slides will be created for each MET 
amplification analysis. Manual quantification of tumor cells will be performed by determining the total number of whole nuclei (DAPI-positive signals).  This will be performed in Dr. Cloud Paweletz’s laborat ory at Dana-Farber Cancer Institute.  
Patients will be grouped as to whether or not their tumor has amplified Met and the association between amplific ation and response to cabozantinib will be evaluated. 
Please refer to Appendix F for specimen collection and shipping guidelines. 
 
9.3 Evaluate potential plasma bi omarkers of cabozantinib 
Exploratory analyses of potenti al biomarkers of cabozantini b activity will be performed by 
measuring proteins in the plasma and circulatin g cells at baseline, on day 8, day 1 of each cycle 
of therapy, and, if available, at the end of treatment. 8cc of bl ood will be collected in purple top 
(plasma EDTA) vacutainers, with a minimum of 5cc required. Each sample will be shipped on 
wet ice to the Steele Laboratory at MGH. Blood will be separated by centrifugation into plasma 
and a cellular phase by standard methods. The plasma will be prepared in standard fashion and 
stored at –78 degrees Celsius until analysis . After plasma separation, we will use the cellular 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
72 fraction for flow cytometric analyses of ly mphocytes and myeloid cell populations. We will 
enumerate cells using CD3, CD4, CD8, CD14, CD25, CD34, CD45, CD56, CD117, CD127 and 
CD133, using established protocols and an LSR -II flow cytometer available in the Steele 
Lanboratories. Plasma analysis will be carried out for a panel of circulating angiogenic and 
inflammatory molecules previously identified as potential biomarkers of response to anti-VEGF 
therapy in breast cancer patients. They includ e vascular endothelial growth factor (VEGF), 
placental-derived growth factor (PlGF), soluble (s)VEGFR1, and basic fibroblast growth factor (bFGF), using 1 multiplex (4-plex) protein ar ray from Meso-Scale Discovery (Gaithersburg, 
MD), and stromal-derived factor 1  (SDF1 ) using ELISA from R&D Systems (Minneapolis, 
MN). In addition, we will measure the plasma c oncentration of biomarkers  that are related to 
cabozantinib activity: HGF, s-MET, s-c-KIT a nd sVEGFR2 using ELISA from R&D Systems 
(Minneapolis, MN). Finally, we  will evaluate biomarkers of tumor hypoxia, by measuring 
plasma carbonic anhydrase IX  (CAIX) levels as well as biomarke rs of osteoclast and osteoblast 
activity (plasma C-telopeptide and total alkali ne phosphatase) using ELISA from R&D Systems 
(Minneapolis, MN). Samples will be run in duplicate. The number of circulating cells will be evaluated by using cell counters at routine visits and by flow cytometry in fresh blood samples 
collected at the same time-points as for plasma measurements.  
 
Please refer to Appendix F for specimen collection and shipping 
guidelines. 
 
9.4 Cerebral blood volume, blood flow, vessel size, tumor infiltration 
Two broad approaches have been taken to assess the vascularity of tumors: T1-based, 
dynamic contrast enhanced (DCE) MRI; and T2-based, termed dynamic susceptibility 
contrast (DSC) MRI. There are limitations to DCE-MRI, because enhancement depends 
on multiple factors (blood flow, blood volume, permeability and surface area of the 
capillary bed). It is therefore important to measure both blood flow  and blood volume.  
The following measurements will be described at baseline and following the first cycle of 
cabozantinib (on Cycle 2 Day 1). These an alyses are exploratory and hypothesis-
generating only. Any promising findings will be further studied in future clinical trials. 
 Perfusion MRI Markers 
We will quantitatively describe relative cerebral blood volume/flow (rCBS, rCBF), mean transit time (MTT), and mean vessel diameter from perfusion-weighted MRI (PWI) and arterial spin labeling.  
 Permeability 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
73 We will measure the permeability surface area product on a voxel-by-voxel basis 
as well other permeability imaging para meters such as Ve, the volume of 
extravascular extracellular space.  
 Diffusion 
We will measure the full water self-diffu sion tensor on a voxe l-by-voxel basis. 
Water mobility can regionally increase due to tissue edema, increased matrix 
degradation caused by tumor invasion, and/or  tumor necrosis. We will also 
measure tensor fractional anisotropy (FA); FA can be used to define white matter 
tract directions, and tumor invasion may induce effects like displacement, 
infiltration, or disruptio n of white matter tracts. 
 Resting State (optional) 
We will measure the default mode connec tivity using functiona l MRI to assess the 
infiltration, or disruptio n of white matter tracts. 
 MR Spectroscopy (optional) 
We will obtain MRS to look at tumo r metabolites and tumor infiltration 
9.5 Pain Assessments 
For the purpose of determining the effect of cabozantinib treatment on pain and 
analgesic medication usage, pain will be assessed by a part icipant-reported 
questionnaire, and daily analgesic medication usage will be recorded during regular intervals.  All participants are required to complete assessments, regardless of whether 
pain is present or analgesic medica tions are being taken at baseline. 
Pain assessments will consist of patient-re ported responses to a questionnaire (see 
Appendix B), administered by paper, in which participants will be asked to rate their pain and degree of interference in daily act ivities due to pain over the prior 24 hours. 
The participant will complete this pain que stionnaire each day for a 7-day interval 
within 14 days before the fi rst dose of cabozantinib and at  7-day intervals during Week 
3
 and the last week of the cycles that patients are s canned on ( ie end of cycle 2, 4, 6, 9, 12, etc.)  
until the date of the participant’s last follow-up visit.    
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
74 Analgesic medications will be recorded on a daily participant diary matching the dates 
of the pain questionnaire (described above). Analgesic medications to be recorded on the 
diary include narcotics and corticosteroids used to trea t pain symptoms.  Every effort 
should be made to collect responses for ever y day during the 7 day assessment interval.  
However, collection of a minimum of 4 out of  the 7 days in the interval (need not be 
consecutive) will be deemed sufficient for assessment completion. 
The pain questionnaire and analgesic medication diary will be due on  the last 
week of the cycles that patients are scanned on ( ie end of cycle 2, 4, 6, 9, 12, etc.) until the date 
of the participant’s last follow-up visit . The first pain questionnaire completed can be used 
to report pain that the participant experienced th e week prior to the date of the study consent 
signature.   
9.6 Tumor biopsies With agreement of the investigator and w ith the participant’s consent tumor tissue 
samples may be optionally collected, pref erentially, during the screening period 
(preferably 1-2 weeks prior to initi ation of cabozantin ib treatment).  
Please refer to Appendix F  for specimen collection and shipping guidelines. 
 
Tumor analyses may involve evaluation of the signaling pathways related to 
cabozantinib targets (eg, VEGF R, MET, KIT, RET) and include methods such as 
genotyping, fluorescence in situ hybridizati on (FISH) and/or Immuno-histochemistry 
(IHC). Mutation and/or amplification status  of disease-specific tumor-promoters or 
suppressors may also be determined to char acterize the potential impact on response or 
resistance to cabozantinib (eg, HER2, EGFR, KRAS, NRAS, BRAF, PTEN, PIK3CA, 
TP53). Broader genome-wide copy number  and mutation profiling may also be 
conducted. For paired tumor biopsies pharm acodynamic markers such as pMET/MET, 
pVEGFR2/VEGFR2, pERK/ERK, pAKT/AKT and pKIT/KIT may also be analyzed by 
IHC. 
9.7 Blood sample collection Blood will be collected at baseline and the e nd of treatment for the analysis of cfDNA 
and to be processed by the DF/HCC Clinical Tr ials Core Laboratory and then banked in 
the DF/HCC Clinical Trials Core laboratory for future research purposes.   
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
75 One 10 ml of whole blood will be collected in  Streck Tubes.  The blood sample will be 
collected and processed at base line and at the end of treatmen t for evaluation of cfDNA.  
Tubes are provided by the Sponsor as needed.   
If the blood collection is misse d at baseline or at the time of progression, then the blood 
will be collected at a future appointment.  The banked samples will be used to analyze 
DNA, RNA and protein in  future studies. 
Please refer to Appendix F  for specimen collection and shipping guidelines and 
Appendix H  for additional processing details specifi c to the laboratorie s at Dana-Farber 
Cancer Institute.       
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
76 10 STUDY CALENDAR 
All assessments must be perf ormed prior to administration  of any study medication.  
Table 14: Study Calendar 
 Pre-
treatment 21 Day Cycles 
Assessments/ 
Procedures  ScreeningA   C1 D1 
 C1 D8  
(± 2 days) C 2 D1 
(± 4 days) C3 D1 and Subsequent 
Odd Cycles Day 1  
(± 4 days) C4 D1 
(± 4 days) C6 D1 and Subsequent 
Even Cycles Day 1  
(± 4 days) Every 2 
Cycles  
(days 16-22) Every 4 
Cycles 
(days 16-22) End of 
Cabozantinib 
Informed consent X          
Inclusion/ 
exclusion criteria X           
Demographics X          
Medical and 
cancer history X   X X X X   X 
Concomitant medications X X X X X X X   X 
Complete physical examination X X
B X X X X X   X 
Height X          
Weight X X X X X X X    
Vital signsC X XB X X X X X   X 
ECOG performance 
status X X
B X X X X X   X 
12-lead EKG D X   X  X     
MUGA or 
echocardiogramE X         XE  
Neurological examination
F X  X X X X X   X 
CBC w/ differential and platelets X X
B X X X X X   X 
Coagulation studies (PT/INR 
and PTT) X X
B  X X X  
X   X  
Serum 
chemistryG X XB X X X X X   X 
Amylase/lipase X XB  X X X X   X 
Urine protein and creatinine
H X XB   X     X 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
77  Pre-
treatment 21 Day Cycles 
Assessments/ 
Procedures  ScreeningA   C1 D1 
 C1 D8  
(± 2 days) C 2 D1 
(± 4 days) C3 D1 and Subsequent 
Odd Cycles Day 1  
(± 4 days) C4 D1 
(± 4 days) C6 D1 and Subsequent 
Even Cycles Day 1  
(± 4 days) Every 2 
Cycles  
(days 16-22) Every 4 
Cycles 
(days 16-22) End of 
Cabozantinib 
TSH X XB   X     X 
Research blood 
draw for CTC 
collectionI X          
Research blood draw for Plasma biomarkers
J X  X X XJ XJ  XJ  XJ 
Research blood draw for cfDNA
K X          XK 
Serum/urine pregnancy test
L X          
Baseline Findings  (CTCAE v.4.0) X           
Brain MRIM X    X   XM   
Research MRI  sequences
N X   X       
Non-CNS tumor evaluation (MRI 
or CT and 
clinical assessment of 
visible, palpable 
lesions)
M X    X   XM   
Bone scan O     X   X M  X M 
CA 27.29 or 
CA15.3 X XB  X X X X   X 
Adverse eventsP X X X X X X X   X 
Drug diary   X X X X X X    
Survival 
 follow-up          XQ 
Optional biopsyR X           
7-day pain questionnaire
S X   X X S      
7-day analgesic medication 
 diary 
S X   X X S      
CabozantinibT  X X X X X X    
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
78  Pre-
treatment 21 Day Cycles 
Assessments/ 
Procedures  ScreeningA   C1 D1 
 C1 D8  
(± 2 days) C 2 D1 
(± 4 days) C3 D1 and Subsequent 
Odd Cycles Day 1  
(± 4 days) C4 D1 
(± 4 days) C6 D1 and Subsequent 
Even Cycles Day 1  
(± 4 days) Every 2 
Cycles  
(days 16-22) Every 4 
Cycles 
(days 16-22) End of 
Cabozantinib 
TrastuzumabU  X  X X X X    
A   Laboratory tests must occur within 14 days before initial dose of cabozantinib. All other sc reening assessments must occur w ithin 28 days 
before initial dose of cabozantinib (with th e exception of the baseline research MRI sequences, which must be < 7 days of C1D1 dose).  
Informed consent must be provided before any study-specific proc edures are performed and within 28 days of registration.    
B  If performed <7 days before the first dose of cabozantinib, these screening procedures do not need to be repeated on Cycle 1 Day 1. If these 
procedures are performed on Cycle 1 Day 1, th en the results must be available and revi ewed by the treating physician prior to a dministering 
cabozantinib.  All pre-treatment criteria listed in Section 5.2 must  be met in order to begin cabozantinib on Cycle 1 of Day 1.  
C  Includes blood pressure, pulse, respiratory rate, temperature, weight 
D  Three EKGs must be performed at screening. To be eligible, the patient must have an average QTcF of ≤ 500 msec on three consecutive 
results. 
E Only performed in HER2-positive patients currently taking trastuz umab. Evaluation of LVEF to occur at baseline and every 4 cyc les. When 
possible, the same modality (e.g. MUGA or ECHO) shoul d be performed for consis tency in measurements. 
F    Neurologic examination worksheet (Appendix E) to be complete d at baseline and at each study visit, except for Cycle 1 Day 1 the neurological 
examination will be on Cycle 1 Day 8. 
G   Complete serum chemistry panel includes albumin, alkaline phos phatase, ALT, AST, BUN, calcium, chloride, creatinine, glucose , magnesium, 
potassium, phosphorus, sodium, total bilirubin, total protein.  Electrolytes do not need to be collected as part of the eligibility assessment (K, 
Phos, Ca, Mg). 
H Spot urine protein and urine creatinine 
I  At baseline, 2 tubes of whole blood will be collected in 10 ml Ce llSave tubes for CTC analysis.  If this is not performed at sc reening, then it can 
be collected on C1D1 prior to the start of treatment. 
J    At baseline and at C1D8, C2D1, C3D1, C4D1, C5D1, C6D1 and then every 2 cycles, and at end of treatment, two 10 ml purple top tubes 
(plasma EDTA) will be collected (minimum of 5 cc of blood in each ) at each visit.  The purple top tubes will be shipped on wet ice to the 
Steele Laboratory at MGH.  If this is not performed at screening, then it can be collected on C1D1 prior to the start of treatm ent.  After 18 
weeks (6 cycles) research blood collection for plasma biomarkers s hould occur at the same time scans are reviewed after a resta ging. After 18 
weeks, frequency of restaging scans is redu ced to once every 3 cycles (item M above), therefore draws will occur on C7D1, C10D1 , C13D1, 
etc. 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
79 K At baseline and at the end of treatment, 1 tube of whole blood w ill be collected in a 10 ml Streck tube for cfDNA analysis.  If  sample collection 
is missed for any reason at baseline or at the end of treatment then the sample should be drawn at a future appointment.   
L   For women of child bearing potential.  This  must be performed within 14 days of C1D1. 
M  Clinical Brain MRI at screening and non-CNS tumor evaluation must be performed within 28 days of Cycle 1 Day 1.  Clinical Bra in MRI and 
non-CNS tumor evaluation scans will then be completed within 7 days  prior to Cycle 3 Day 1, Cycle 5 Day 1, and Cycle 7 Day 1. Patients 
with stable or responsive diseas e after completion of 6 cycles may have the frequency of restaging scan s reduced to once every 3 
cycles.  For patients who come off cabozantinib for any reason other th an disease progression, they will need to undergo a scan at the t ime 
they come off cabozantinib, and continue undergoing scans every 9 weeks.  They will also need to have a follow-up visit every 6  months. 
N  The research MRI sequences will be performed at Massachusetts Genera l Hospital, Charlestown Navy Yard at Baseline (< 7 days of Cycle 1 
Day 1), and at Cycle 2 day 1 (prior to dose treatment that day). The study coordinator will obtain a copy of the MRI scan to be  archived at 
DFCI.  Contact name for Massachusetts General Hosp ital Charlestown Navy Yard is Stephanie Salcedo ( ssalcedo@partners.org ).   
O  Bone scans should be performed in any pa tient with known bone metastases.    
P Adverse events information will be collected at study visits a nd may, in addition, be collected over the phone. For patients w ho come off 
cabozantinib for progressive disease, an end of Study Visit should be  completed within 30 days (+/- 7 days) of last dose of stu dy drug. 
Q  Follow-up every 6 months or until death 
R For patients that consent to optional biopsy only, preferentially  performed 1-2 weeks prior to receiving first dose of study d rug. 
S The participant will complete the pain diary and medication diar y each day for a 7-day interval w ithin 14 days of the first do se of cabozantinib 
and at 7-day intervals during Week 3 and the last week of the cycles that patients are scanned on ( ie end of cycle 2, 4, 6, 9,  12, etc). Pain 
Questionnaire and Analgesic Medication Diary will also be due  the last week of cycles that patients are scanned on (end of Cyc le 2, 4, 6, 9, 12, 
etc.)The first pain questionnaire completed can be used to repor t pain that the participant expe rienced the week prior to the d ate of the study 
consent signature.  Analgesic medications to  be recorded on the diary include narcoti cs and corticosteroids used to treat pain symptoms.  
T   Cabozantinib will be given orally once daily  
U    Trastuzumab will be given to HER2- positive patients (cohorts 1)
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
80 11 MEASUREMENT OF EFFECT 
Response in the CNS and non-CNS will use RECIST 1.1. Volumetric assessments of 
CNS response will also be conducted. Re sponse and progression in non-CNS sites 
will be evaluated in this study using the new international criteria proposed by the 
Response Evaluation Criteria in Solid Tumors (RECIST) Committee (Therasse, 
2000). Changes in only the largest diameter  (unidimensional measurement) of the 
tumor lesions are used in the RECIST 1.1 criteria. For the purposes of this study, 
participants should be re-evalu ated for response every 6 week s. Patients with stable or 
responsive disease after comple tion of 6 cycles may have the frequency of restaging 
scans reduced to once every 3 cycles. In addition to a baseline scan, confirmatory 
scans should also be obtained 3 weeks following initial documentation of objective 
response. 
Response in the CNS and in non-CNS sites wi ll be evaluated and r ecorded separately 
in this trial. 
11.1 Definitions Evaluable for toxicity. All participants who receive at least one dose of cabozantinib 
will be evaluable for to xicity from the time of  their first treatment. 
Evaluable for objective res ponse. Only those participan ts who have received at 
least one dose of therapy will be considered evaluable for response. These 
participants will have their response clas sified according to th e definitions stated 
below. (Note: Participants who exhibit objective disease progression or die prior to 
the end of cycle 1 will also be considered evaluable.) All participants who receive at least one dose of cabozantinib will be cons idered in the denominator for calculation 
of objective response rate.  
11.2 Disease Parameters 
Measurable disease.  
Measurable disease is the presence of at least one (1) lesion that can be 
accurately measured in at least one dimension with longest diameter  >20 millimeters 
(mm) using conventional techniques (CT, MRI, x-ray) or  >10 mm with spiral CT 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
81 scan. Measurable lesions must be at least 2 times the slice thickness in mm. All tumor 
measurements must be record ed in millimeters (or decima l fractions of centimeters). 
A lesion in a previously irradiated area is not eligible fo r measurable disease 
unless there is ob jective evidence of progression of the lesion prior to study 
enrollment. Lesions in previously irradiated areas must be clearly identified as 
such . 
Clinical lesions. Clinical lesions will only be considered measurable when they are 
superficial (e.g., skin nodules and palpable lymph nodes).  
Malignant lymph nodes.  
To be considered pathologically enlarged  and measurable, a ly mph node must be > 
15 mm in short axis when assessed by  CT scan (CT scan slice thickness 
recommended to be no great er than 5 mm). At baselin e and in follow-up, only the 
short axis will be m easured and followed. 
Non-measurable disease.  
All other lesions (or sites of disease), including small lesions (longest diameter <10 mm or pathological lymph nodes with > 10 to < 15mm short axis, are considered non-
measurable disease. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pul monis, inflammatory breast  disease, a bdominal masses 
identified by physical exam that  are not measurable by reproducible imaging techniques, 
and cystic lesions are all considered non-measurable. 
Target lesions.  
All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, 
representative of all involved organs, should be identified as target lesions and 
recorded and measured at baseline. Lesi ons must be accurately measured in 1 
dimension. Nodes must have a short axis > 15 mm. The short axis should be included 
in the sum of the lesions in the calculation of  response. Nodes that shrink to < 10 mm 
are considered normal. Target lesions should be selected on the basis of their size 
(lesions with the longest diameter) a nd their suitability for accurate repeated 
measurements (either by imag ing techniques or clinica lly).  For CNS and non-CNS 
sites, the sum of the longest diameter (LD)  for all target lesions will be calculated 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
82 and reported as the baseline sum LD.  The baseline sum LD will be  used as reference 
by which to characterize the objective tumo r response in CNS an d non-CNS sites.  
RECIST 1.1 criteria will be  used to assess overall response rates for CNS target 
lesions as the primary endpoint. In additi on, we will also report non-CNS response 
rates according to RECIST 1.1 criteria a nd CNS lesion responses according to 
volumetric and composite criteria.  
Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, 
that can be evaluated by cross sectional imag ing techniques such as CT or MRI can be 
considered target lesions if the soft tissue component  meets the definition of measurability 
as defined above. Cystic lesions thought to represent cystic metastases can be considered 
as target lesions. However, if non-cystic lesions are present, these are preferred for 
selection as target lesions. Lesions in previously irradiated areas or areas subject to other loco-regional therapy are usually not cons idered measurable unless there has been 
demonstrated progression of that lesion.  
Non-target lesions.  
All other lesions including small lesions  < 10 mm or pathol ogical lymph nodes 
measuring > 10 mm to < 15 mm  in short axis, as well as truly non-measurable 
lesions, which include bone lesions that do  not meet the requirements of the last 
paragraph, leptomeningeal disease, asc ites, pleural or pericardial effusion, 
inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal 
masses identified by physical exam that ar e not measurable by reproducible imaging 
techniques are considered non-target lesions. 
11.3 Methods for Evaluation of Measurable Disease All measurements should be taken and recorded in metric notation, using a ruler, calipers, 
or digital measurement tool. All baseline non-CNS evaluations should be performed as 
closely as possible to the begi nning of treatment and never more than 4 weeks before the 
beginning of the treatment.  Clinical brain MR I at screening will be performed within 28 
days of Cycle 1 Day 1 and re search MRI sequences will be performed within 7 days of 
Cycle 1 Day 1. The same method of assessment and the same  technique should be used to characterize 
each identified and reported lesion at baseline and duri ng follow-up. Imaging-based 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
83 evaluation is preferred to evaluation by clin ical examination when both methods have 
been used to assess the anti-tumor effect of a treatment. 
Methods of Evaluation for CNS Measurable Disease 
MRI Brain: Imaging with MRI brain is re quired for all participants on study to 
evaluate brain lesions. MRI images will  include T1-weighted images with and 
without gadolinium contrast, T2-weighted images, and FLAIR (fluid attenuated 
inversion recovery) images. 
 
Methods of Evaluation for Non-CNS Measurable Disease 
Clinical lesions. Measurable skin lesions  will be documented by color ph otography, 
including use of a ruler to es timate the size of the lesion. 
Chest x-ray. Lesions on chest x-ray are accep table as measurable lesions when they 
are clearly defined and surr ounded by aerated lung; howe ver, CT is preferable. 
Conventional CT and MRI. Th ese techniques should be perfo rmed with cuts of 10 mm 
or less in slice thickness contiguously. Sp iral CT should be performed using a 5 mm 
contiguous reconstruction algorith m. This applies to tumors of the chest, abdomen, and 
pelvis. Head and neck tumors and those of extremities usually require specific 
protocols. 
Ultrasound (US). When the primary endpoint of the study is objective response 
evaluation, US should not be used to measure tumor lesions. It is, however, a 
possible alternative to clini cal measurements of superficial palpable lymph nodes, 
subcutaneous lesions, and thyroid nodules. US might also be useful to confirm the 
complete disappearance of superficial lesion s usually assessed  by clinical 
examination. FDG PET and PET/CT. The acquisition of FDG PET and FDG PET/CT scans should 
follow the NCI Guidelines for using FDG PET as an indicator of therapeutic response 
(Shankar et al., 2006). Patients should avoi d strenuous exercise and be on a low 
carbohydrate diet for 24 hours prior to the s can. Patients should fast for 4 hours or 
longer prior to the FDG injection and shoul d have a serum glucose of less than 200 
mg/dL at the time of FDG injection. A 10-20 mCi dose of FDG should be injected for 
typical adult patients. For longitudinal studies with multiple scans, particular attention 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
84 should be paid to ensure consistent patie nt preparation and ac quisition parameters 
between the follow-up scan and the baseline scan.  
Endoscopy, Laparoscopy. The utilization of  these techniques for objective tumor 
evaluation has not yet been fully and widely validated. Their uses in this specific 
context require sophisticated e quipment and a high level of expertise that may only be 
available in some centers. Therefore, the utilization of such techniques for objective 
tumor response should be restricted to validation purposes in reference centers. 
However, such techniques may be useful to  confirm complete pathological response 
when biopsies are obtained . 
Tumor markers. Tumor markers alone cann ot be used to as sess response.  
11.4 Response Criteria 
11.4.1 Response Criteria for Target Lesions (RECIST 1.1) 
 
Complete Response (CR):  Disappearance of al l target lesions.  Any pathological lymph 
nodes (whether target or non-target) must have reduction in short axis to <10 mm. 
 
Partial Response (PR):  At least a 30% decreas e in the sum of the diameters of target 
lesions, taking as reference the baseline sum diameters. 
 
Progressive Disease (PD):  At least a 20% incr ease in the sum of the diameters of target 
lesions, taking as reference the smallest su m on study (this includes the baseline sum if 
that is the smallest on study).  In addition to  the relative increase of 20%, the sum must 
also demonstrate an absolute increase of at least 5 mm.  (Note:  the appearance of one or 
more new lesions is also considered progressions). 
 
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as refe rence the smallest sum diameters while on 
study. 
 
11.4.2 Response Criteria for Non-Target Lesions (RECIST 1.1) 
 
Complete Response (CR):  Disappearance of al l non-target lesions a nd normalization of 
tumor marker level.  All lymph nodes must be non-pathological in  size (<10 mm short 
axis). 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
85 Note:  If tumor markers are initially above the upper norma l limit, they must normalize 
for a patient to be considered in complete clinical response. 
 
Non-CR/Non-PD:  Persistence of one or more  non-target lesion(s) and/or maintenance 
of tumor marker level above the normal limits. Progressive Disease (PD):  Appearance of one or more new lesions and/or unequivocal 
progression of existing non-target lesions.  Unequivocal progression  should not 
normally trump target lesion stat us.  It must be representati ve of overall disease status 
change, not a single lesion increase.      Although a clear progressi on of “non-target” lesions only is exceptional, the opinion of 
the treating physician should pr evail in such circumstances, and the progression status 
should be confirmed at a later time by the review panel (or Prin cipal Investigator). 
 
11.4.3 Evaluation of New Lesions 
 
The finding of a new lesion should be unequivocal  (i.e. not due to difference in scanning 
technique, imaging modality, or findings thought to repr esent something other than 
tumor (for example, some ‘new’ bone lesions  may be simply healing or flare of pre-
existing lesions). However, a lesion identif ied on a follow-up scan in an anatomical 
location that was not scanned at baseline is considered new and will indicate PD. If a 
new lesion is equivocal (because of small size etc.), follow-up evalua tion will clarify if it 
truly represents new disease and if PD is  confirmed, progression should be declared 
using the date of the initial scan  on which the lesion was discovered. 
 
11.4.4 CNS Volumetric & Composite Response Criteria 
 
RECIST 1.1 criteria will be used to de termine response but volumetric/composite 
response will also be done as an exploratory study. 
CNS Complete Response (CR): All of the following must be satisfied: 
 Complete resolution of all measurable (≥  1 cm diameter) and non-measurable 
brain metastases 
 No new CNS lesions (n ew lesion defined as ≥  6 mm diameter) 
 Stable or decreasing steroid dose 
 No new/progressive tumor-related neurologic signs or symptoms 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
86  No progression of systemic (non-CNS)  disease as assessed by RECIST 
CNS Partial Response (PR): All of the following must be satisfied: 
 ≥ 50% reduction in the volumetric sum of all measurable ( ≥ 1 cm diameter) brain 
metastases compared to baseline 
 No progression of non-measurable lesions 
 No new lesions (new lesion defined as ≥ 6 mm) 
 Stable or decreasing steroid dose 
 No new/progressive tumor-related neurologic signs or symptoms 
 No progression of systemic (non-CNS)  disease as assessed by RECIST 
CNS Stable Disease (SD): All of the following must be satisfied: 
 < 50% reduction in the volumetric sum of all measurable ( ≥ 1 cm diameter) brain 
metastases compared to baseline, and not fulfilling the criteria for progressive 
disease 
 No progression of non-measurable lesions 
 No new lesions (new lesion defined as ≥ 6 mm) 
 Stable or decreasing steroid dose 
 No new/progressive tumor-related neurologic signs or symptoms 
 No progression of systemic (non-CNS)  disease as assessed by RECIST 
Note: CNS lesions were initially evaluable ( ≥ 1 cm diameter) at baseline and have 
decreased in size on trial therapy to < 1 cm  diameter will continue to be assessed 
volumetrically for response. 
CNS Progression (PD): Patients will be considered to have PD if ANY of the following 
are satisfied: 
 ≥40% increase in the volumetric sum of a ll measurable lesions as compared to 
the smallest volume since protocol -based therapy was initiated, OR 
 Progression of non-measur able lesions*, OR 
 New lesions (new lesion defined as ≥ 6 mm), OR 
 Increasing steroid requirement (As CNS progr ession is an eligibility requirement, 
increasing steroid dose within 4 weeks after study entry will not necessarily constitute disease progression), OR 
 New/progression tumor-related neurologic signs and symptoms (NSS) except for 
transient worsening lasting ≤ 14 days. (As CNS progres sion is an eligibility 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
87 requirement, worsening of NSS within 4 weeks after study entry will not 
necessarily constitute disease progression), OR 
 Progression of systemic (non-CNS)  disease as assessed by RECIST 
*Note: Progression of non-measurable ( non-target) CNS lesions is defined as 
follows: 
 A lesion initially at baseline ≤  5 mm in diameter that increases to ≥ 10 mm in 
diameter, or 
 A lesion initially at baseline 6-9 mm in  diameter that increases by at least 5 
mm in diameter. 
These criteria were chosen to minimize cl assifying subjects as  having progressive 
disease due to MRI sampling error, gi ven an MRI slice thickness of 3 mm. 
Table 15: Summary of Composit e Criteria for CNS Response 
 Complete 
Response Partial 
Response Stable 
Disease Progressive 
Disease 
Qualifying Criteria All All All Any 
Brain lesions (volumetric MRI) 
Target CR ≥ 50% volume 
decrease < 50% volume 
decrease ≥ 40% volume 
increase 
Non-target None/CR None/no progression Progression 
New None Yes 
Steroids Stable or decreasing Increasing dose 
Neurological signs/symptoms Stable or improving New or 
worsening 
Systemic disease (RECIST 1.1) No progression Progression 
 
11.4.5 Evaluation of Best Overall Response 
 
The best overall response is the best response recorded from the start of the treatment 
until disease progression/recurrence (taking as  reference for progressive disease the 
smallest measurements recorded since the treatment started). The participant's best response assignment will depend on the achievement of both measurement and confirmation criteria based on RECIST 1.1. 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
88 Table 16: Criteria for Patients with Measurable Disease (i.e., Target Disease)  
Target 
Lesions Non-Target 
Lesions New 
Lesions Overall 
Response Best Overall Response for 
when Confirmation is 
Required: 
CR CR No CR >4 wks confirmation 
CR Non-CR/Non-PD No PR >4 wks confirmation 
CR Not evaluated No PR 
PR Non-CR/Non-
PD/Not evaluated No PR 
SD Non-CR/Non-
PD/Not evaluated No SD Documented at least once 
>4 wks from baseline 
PD Any Yes or No PD No prior SD, PR or CR 
Any PD* Yes or No PD 
Any Any Yes PD 
* In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as 
disease progression. 
Note:   Participants with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
"symptomatic deterioration". Every effort should be made to document the objective progression 
even after discontinuation of treatment. 
 
11.4.6 Duration of Response 
 
Duration of overall re sponse: The duration of  overall response is measured from the 
time measurement criteria are met for CR or PR  (whichever is first recorded) until the 
first date that recurrence or  PD is objectively documented, taking as reference for PD 
the smallest measurements recorded since the treatment started. 
 Duration of overall complete response: The duration of overall CR is measured from 
the time measurement criteria are first met for CR until the first date that recurrent 
disease is objectively documented.  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
89 Duration of stable disease: Stable disease is  measured from the start of the treatment 
until the criteria for progression are met, taki ng as reference the smallest measurements 
recorded since the treatment started. 
 
11.4.7 Progression-Free Survival 
 
Progression-Free Survival (PFS) is defined as the duration of  time from start of treatment to 
time of objective disease progression or tim e of death from any cause, whichever comes 
first.  Included in the definition of progr ession for PFS are: objective progression of CNS 
lesions on MRI, neurologic deterioration leading to study discontinuation, global 
deterioration of health stat us requiring discontinuation of treatment, and death. For 
neurologic symptoms, the default will be to  assume that worsening of neurologic 
symptoms requiring discontinuation of treatment is related to progressive disease. However, it is anticipated that some patients may discontinue due to peripheral 
neuropathy or other neurologic symptoms that are more likely related to cumulative drug toxicity rather than CNS progression. For patients who are ta ken off of protocol treatment 
for a reason(s) other than progression, the date  of PFS will be censored at the date of last 
staging study (either while on or  off protocol therapy) on wh ich the patient is documented 
not to have progressed, or th e date of initiation of alternative anti-cancer therapy, 
whichever comes first. 
11.4.8 Response Review 
 
All CNS and non-CNS responses will be review ed by an independent radiologist as part 
of the DF/HCC Tumor Imaging Metrics Core (TIMC) facility. CNS response will be 
assessed centrally using the RECIST 1.1 and volumetric criteria outlined. Non-CNS 
scans will also be assessed centrally us ing RECIST 1.1 and recorded in the CRF by 
individual site personnel.  
 
11.5 Neurological Signs and Symptoms (NSS) 
Tumor-associated NSS will be recorded  on Appendix E at each study visit. 
Improvement or worsening of non-tumor associated NSS will not constitute a change in 
NSS. 
Improvement of NSS will be defined if all of the following are satisfied: 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
90  Decrease by 1 or more grades from baseline of any tumor-related NSS, with 
confirmation at least 3 weeks (1 cycle) later 
 No development or worsening in any tu mor related NSS during this interval 
 Stable or decreasing steroids during this interval 
In addition, Appendix E contains a global ques tion for the treating investigator, asking 
whether a patient’s neurological status is impr oved, stable or worse. The response to this 
question will be analyzed in relation to the itemized portion of the NSS worksheet, in 
order to further evaluate the utility of th e worksheet in evaluating NSS longitudinally 
over time. 
12 ADVERSE EVENT REPORTING REQUIREMENTS 
12.1 Definitions 
12.1.1  Adverse Event (AE) 
An adverse event (AE) is any undesirabl e sign, symptom or medical condition or 
experience that develops or worsens in sever ity after starting the first dose of cabozantinib 
or any procedure specified in the protocol, even if the event is not cons idered to be related 
to the study.  Abnormal laboratory values or diagnostic test results constitute adverse events only if they 
induce clinical signs or symptoms or requi re treatment or further diagnostic tests.  
12.1.2  Serious adverse event (SAE) 
A serious adverse event (SAE) is any adverse event, occurring at any dose and regardless 
of causality that:  
 Results in death 
 Is life-threatening. Life-threatening means that the person was at immediate risk 
of death from the reaction as it occurred, i.e., it does not include a reaction which 
hypothetically might have caused death had it occurred in a more severe form. 
 Requires or prolongs inpatient hospitaliza tion (i.e., the event required at least a 
24-hour hospitalization or prolonged a hospitalization beyond the expected 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
91 length of stay). Hospitalization admissions  and/or surgical operations scheduled 
to occur during the study  period, but planned prio r to study entry are not 
considered SAEs if the illness or disease existed before the person was enrolled 
in the trial, provided that it did not de teriorate in an unexpected manner during 
the trial (e.g., surgery perform ed earlier than planned). 
 Results in persistent or significant disability/incapacity. Disability is defined as a substantial disruption of a person’s ab ility to conduct normal life functions. 
 Is a congenital anomaly or birth defect; or 
 Is an important medical event when, based upon appropriate medical judgment, 
it may jeopardize the partic ipant and require medical  or surgical intervention to 
prevent one of the outcome s listed above. Examples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency 
room or at home; blood dyscrasias or convul sions that do not result in inpatient 
hospitalization, or the development of  drug dependency or drug abuse. 
Events not considered to be seri ous adverse events are hospitalizations for: 
 Routine treatment or monitoring of the studied indication, not  associated with 
any deterioration in condition, or for elective procedures 
 Elective or pre-planned treatment for a pr e-existing condition that did not worsen 
 Emergency outpatient treatment for an event not fulfilling the serious criteria outlined above and not resulting in inpatient admission 
 Respite care 
12.1.3  Expectedness 
Adverse events can be 'Exp ected' or 'Unexpected.'  
Expected Adverse Event 
Expected adverse events are those that have been previously identif ied as resulting from 
administration of the agent. For the purpos es of this study, an adverse event is 
considered expected when it appears in the cu rrent adverse event list , the Investigator’s 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
92 Brochure, the package insert or is include d in the informed consent document as a 
potential risk.    
Refer to Section 6.1 fo r a listing of expected adverse ev ents associated with the study 
agent(s). 
Unexpected Adverse Event 
For the purposes of this study, an adverse event is considered unexpected when it varies 
in nature, intensity or frequency from info rmation provided in the current adverse event 
list, the Investigator’s Brochur e, the package insert or when it is not included in the 
informed consent document as a potential risk.   
12.1.4  Attribution 
Assessment of the relationship of the AE to the cabozantinib by the i nvestigator is based 
on the following two definitions: 
 Not Related: A not-related AE is defined as an AE that is not associated with the 
cabozantinib and is attribut able to another cause. 
 Related: A related AE is defined as an  AE where a causal relationship between 
the event and the cabozantinib is a reas onable possibility. A reasonable causal 
relationship is meant to convey that there are facts (eg, evidence such as 
dechallenge/ rechallenge) or other clin ical arguments to suggest a causal 
relationship between the AE and cabozantinib. 
12.2 Procedures for AE and SAE Recording and Reporting Participating investigators will assess the o ccurrence of AEs and SAEs at all participant 
evaluation time points during the study.  All AEs and SAEs whether reported by the pa rticipant, discovered  during questioning, 
directly observed, or detected  by physical examination, laboratory test or other means, 
will be recorded in the participant’s medical  record and on the appropriate study-specific 
case report forms.  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
93 The descriptions and grading scales f ound in the revised NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for AE reporting. All 
appropriate treatment areas should have access to a copy of the CTCAE version 4.0. 
A copy of the CTCAE version 4.0 can be downloaded from the CTEP website at: 
http://ctep.cancer.gov/protocolDevelopment/electroni c_applications/ctc.htm .  
12.3 Expedited SAE Reporting Guidelines 
12.3.1 DF/HCC Expedited Reporting Guidelines 
 
Investigative sites within DF/HCC and DF/P CC will report SAEs directly to the DFCI 
Office for Human Research Studies (OHR S) per the DFCI IRB reporting policy.  
 
All serious adverse events that occur afte r the initial dose of cabozantinib, during 
treatment, or within 30 days of the last dose of treatment must be reported to the 
DF/HCC Overall Principal Investigator on the local institutional SAE form. 
 
Participating investigators must report each serious adverse event to the DF/HCC 
Overall Principal Investigator within 1 busine ss day of learning of the occurrence. In the 
event that the participating investigator does not become aware of the serious adverse 
event immediately (e.g., part icipant sought treatment else where), the participating 
investigator is to report the event within 1 business day after learning of it and document 
the time of his or her first awareness of the adverse event.  Report serious adverse events 
by telephone, email or facsimile to: 
  Sara Tolaney, MD, MPH   Phone: 617-632-2335     Email: stolaney@partners.org   Fax: 617-632-1930 
 
12.3.2 Serious Adverse Event Reporting to Exelixis 
 
All serious adverse events that occur afte r the initial dose of cabozantinib, during 
treatment, or within 30 days of the last dos e of treatment that meet the criteria per 
DF/HCC AE policy must be reported to Exe lixis on the local institutional SAE form.  
Forms should be sent to the following within two business days: 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
94 Exelixis Drug Safety: 
Email: drugsafety@exelixis.com  
Fax: 650-837-7392  
 This report must be submitted by the study site to Exelixis or designee within 
two business days, even if it is not felt to be drug related.   
 The investigator agrees to  provide supplementary information requested by the 
Exelixis Drug Safety personnel or designee. 
 Pregnancy, although not itself an SAE, should also be reported on an SAE 
form or pregnancy form and be followed up to determine outcome, including spontaneous or voluntary termination, de tails of birth, and the presence or 
absence of any birth defects or congenital abnormalities. 
12.3.3 Non-Serious Adverse Event Reporting 
 
Non-serious adverse events will be reported to the DF/HCC Overall Principal Investigator on the toxicity Case Report Forms.   
12.4 Reporting to the Institutional Review Board (IRB) 
Investigative sites within DF /HCC will report all serious adve rse events directly to the 
DFCI Office for Human Re search Studies (OHRS). 
12.5 Reporting to the Food and Drug Administration (FDA) The DF/HCC Overall Principal Investigator, as  holder of the IND, will be responsible 
for all communication with the FDA. The DF /HCC Overall Principal Investigator will 
report to the FDA, regardless of the site of occurrence, any a dverse event that is serious, 
unexpected and reasonably related (i.e., possibl e, probable, definite ) to the cabozantinib. 
Unexpected fatal or life-threatening expe riences associated with the use of the 
cabozantinib will be reported to FDA as s oon as possible but in no event later than 7 
calendar days after initial receipt of the information. 
All other serious unexpected experiences associ ated with the use of  the cabozantinib will 
be reported to FDA as soon as possible but in  no event later than 15 calendar days after 
initial receipt of the information. 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
95 Events will be reported to the FDA by telephone (1-800-FDA-1088) or by fax (1-800-
FDA-0178) using Form FDA 3500A (Mandatory  Reporting Form for investigational 
agents). Forms are available at http://www.fda.gov/medwatch/getforms.htm.  A hard 
copy of the form will also be submitted to the FDA. 
12.6 Reporting to the Hospital Risk Management 
Participating investigators will report to their local Risk Management office any subject 
safety reports or sentinel ev ents that require reporting acco rding to institutional policy. 
12.7 Monitoring of Adverse Events and Period of Observation 
All adverse events, both serious and non-seri ous, and deaths that are encountered from 
initiation of study interventi on, throughout the study, and within 30 days of the last 
study intervention should be followed to their resolution, or until the participating 
investigator assesses them as stable, or th e participating investigator determines the 
event to be irreversible, or  the participant is lost to follow-up. The presence and 
resolution of AEs and SAEs (with dates) s hould be documented on the appropriate case 
report form and recorded in the participant’ s medical record to facilitate source data 
verification.  
For some SAEs, the study sponsor or designee may follow-up by telephone, fax, and/or 
monitoring visit to obtain additional case details deemed necessary to appropriately evaluate the SAE report (e.g., hospital discharg e summary, consultant report, or autopsy 
report).  
Participants should be instru cted to report any serious pos t-study event(s) that might 
reasonably be related to participation in th is study. Participating investigators should 
notify the DF/HCC Overall Principal Investigator and their respective IRB of any 
unanticipated death or adverse event occurr ing after a participant has discontinued or 
terminated study participation that may reasonably be related to the study.   
13 DATA AND SAFETY MONITORING 
13.1 Data Reporting 
13.1.1 Method 
 
The QACT will collect, manage, and monitor data for this study. 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
96  13.1.2 Data Submission 
 
The schedule for completion and submission of case report forms (paper or electronic) to 
the QACT is as follows:  
 
          
 
  13.2 Safety Meetings The DF/HCC Data and Safety Monitoring Committee (DSMC) will review and monitor 
toxicity and accrual data from this trial.  The committee is composed of clinical 
specialists with experience in  oncology and who have no direct relationship with the 
study. Information that raises any questions about participant safety will be addressed with the Principal Investigator and study team. 
The DSMC will meet quarterly and/or more often if required to review toxicity and 
accrual data.  Information to be provided to the committee may include:  up-to-date 
participant accrual; cu rrent dose level information; DLT information; all grade 2 or 
higher unexpected adverse events that have  been reported; summary of all deaths 
occurring within 30 days for Phase I or II protocols; for gene transfer protocols, 
summary of all deaths while being treated  and during active follow-up; any response 
information; audit results, and a summary provided by the study team. Other information 
(e.g. scans, laboratory values) will be provided upon request. 
  Form Submission Timeline 
Eligibility Checklist Complete prior to registration with QACT 
On Study Form Within 14 days of registration 
Baseline Assessment Form Within 14 days of registration 
Treatment Form Within 10 days of the last day of the cycle 
Adverse Event Report Form Within 10 da ys of the last day of the cycle 
Response Assessment Form Within 10 days of  the completion of th e cycle required for 
response evaluation 
Off Treatment/Off Study Form Within 14 days of completing treatmen t or being taken off 
study for any reason 
Follow up/Survival Form Within  14 days of the protocol de fined follow up visit date 
or call 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
97 13.3 Monitoring 
Involvement in this study as a participating investigator implies acceptance of potential 
audits or inspections, including source data  verification, by repres entatives designated 
by the DF/HCC Overall Principal Investigat or (or Protocol Chair) or DF/HCC. The 
purpose of these audits or inspections is to examine study-related activities and 
documents to determine whether these act ivities were conducted and data were 
recorded, analyzed, and accurately reporte d in accordance with the protocol, 
institutional policy, and any appl icable regulato ry requirements.   
All data will be monitored for timeliness of submission, completeness, and adherence 
to protocol requirements. Monitoring will be gin at the time of participant registration 
and will continue during protocol performance and completion.  
14 REGULATORY CONSIDERATIONS 
14.1 Protocol Review and Amendments 
This protocol, the proposed informed consen t and all forms of pa rticipant information 
related to the study (e.g., advertisements used to recruit participants) and any other 
necessary documents must be submitted, reviewed an d approved by a properly 
constituted IRB governin g each study location.  
Any changes made to the protocol must be  submitted as amendm ents and must be 
approved by the IRB prior to implementati on. Any changes in st udy conduct must be 
reported to the IRB. The DF/HCC Overall Principal In vestigator (or Protocol Chair) 
will disseminate protocol amendment informa tion to all participat ing investigators.  
All decisions of the IRB concerning the conduct of the study must be made in 
writing. 
14.2 Informed Consent All participants must be provided a co nsent form describi ng this study and 
providing sufficient information for partic ipants to make an informed decision 
about their participation in this study. The form al consent of a pa rticipant, using 
the IRB approved consent form, must be  obtained before the participant is 
involved in any study-related procedure. The consent form must be signed and 
dated by the participant or the participant’s legally authorized representative, and 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
98 by the person obtaining the consent. The pa rticipant must be given a copy of the 
signed and dated consent document. The original signed copy of the consent 
document must be retained in the medical record or research file.  
14.3 Ethics 
This study is to be conducted accordin g to the following considerations, which 
represent good and sound  research practice: 
 US Code of Federal Regulations (CFR ) governing clinical study conduct 
and ethical principles that have their origin in the Declar ation of Helsinki 
o Title 21 Part 50 – Prot ection of Human Subjects 
www.access.gpo.gov/nara/cfr/wai sidx_02/21cfr50_02.html   
o Title 21 Part 54 – Financial Disc losure by Clinic al Investigators 
www.access.gpo.gov/nara/cfr/wai sidx_02/21cfr54_02.html   
o Title 21 Part 56 – Ins titutional Review Boards 
www.access.gpo.gov/nara/cfr/wai sidx_02/21cfr56_02.html   
o Title 21 Part 312 – Investig ational New Drug Application 
www.access.gpo.gov/nara/cfr/waisidx_02/21cfr312_02.html   
 State laws 
 DF/HCC research policies and procedures        
http://www.dfhcc.harvard.edu/clinical-research-support/clinical-research-
unit-cru/policies-and-procedures/  
It is understood that deviations from th e protocol should be avoided, except when 
necessary to eliminate an i mmediate hazard to a research participant. In such case, 
the deviation must be reported to the IRB according to the local  reporting policy.  
14.4 Study Documentation 
The investigator must prepare and mainta in adequate and accurate case histories 
designed to record all observations and other data pertinent to the study for each 
research participant. This information enab les the study to be fu lly documented and the 
study data to be subsequently verified. Original source documents supporting entries in the case report forms include but are 
not limited to hospital records, clinical charts, laboratory and pharmacy records, 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
99 recorded data from automated instrume nts, microfiches, photographic negatives, 
microfilm or magnetic media, and/or x-rays.  
14.5 Records Retention 
All study-related documents must be retained for the maximum period required by 
applicable federal regulations and guid elines or institu tional policies.  
15 STATISTICAL CONSIDERATIONS 
15.1 Study Design / Endpoints 
This is a two-stage phase 2 study of XL184 for HER2-positi ve metastatic breast cancer 
with known brain metastases, and a pilot study of XL184 for ER+ and TN breast cancer 
with known brain metastases. 
  The primary endpoint is response, defined as  a confirmed CR or confirmed PR per CNS 
objective response.  Patients who do not ach ieve a confirmed CR or confirmed PR will 
be considered non-responders. Assuming th e study does not terminate early and all 
patients enrolled begin protocol therapy, the 95% CI for the response rate will be determined accounting for the two-stage design. 
 All other analyses are exploratory with no pl ans for formal hypothesis testing given the 
limited sample size. Analyses will treat as cat egorical variables c-MET amplification in 
CTC’s, or marker levels that  can be categorized using esta blished cutpoints. Variables 
will be tabulated by RECIST response. For markers without an established cutpoint, 
analyses will involve summary statistics by RECIST response. PFS and OS, as defined 
in Section 11.4.5, will be described using the method of Kaplan-Meier.  The point 
estimate of median PFS and OS, as well as esti mates of PFS and OS at other time points, 
will be presented with 95% confidence intervals derived using log(-log(PFS)) methodology.  
15.2 Sample Size / Accrual Rate 
There are no data on the res ponse rate to XL184 in patients with metastatic breast cancer 
and brain metastases.  A true rate of 30% among predominantly pretreated patients with 
HER2-positive metastatic breast cancer would be considered worthy of further study. A 
true rate of 5% or less woul d not be of clinical interest . This is a one-arm two-stage 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
100  design to evaluate the efficacy of XL184 in patients with HER2-positive metastatic breast 
cancer and brain metastases.  The sample size was chosen to have high power (90%) with 
a Type I error no more than 10%.   In the first stage, 7 patients will be enrolle d. If there is at least 1 response, accrual will 
continue to the second stage where up to 14 a dditional patients will be enrolled. If at least 
3 of these 21 patients have a response rate, the regimen will be considered worthy of 
further study.  With this design, the probability  of stopping the trial early is 70% if the 
true response rate is 5%, and 8%  if the true response rate is 30%. If the true response rate 
is 5%, the chance the regimen is declared wort hy of further study is 10% and if the true 
response rate is 30% the chance that the regi men is declared wort hy of further study is 
90%.  Update: As of October 20, 2015, there have been  no confirmed CNS objective responses 
by RECIST 1.1 in the first seven patients enro lled in the HER2+ cohort.  There has been 
one volumetric partial response (PR) in the brain, along with a partial response (PR) in 
the body (Table 17). In addition, patients have  remained on trial for a significant amount 
of time, with two of seven patients on st udy for 9 cycles, and one on for 8 cycles, with 
continued stable disease. Given that there seems to be t meaningful clinical benefit 
received with the agent, we felt further study of  this agent is warrant ed in this population.  
Thus, an additional 14 patients will be enro lled to a maximum of 21 HER2+ patients in 
order to have more precise estimates of the efficacy of cabozantinib  in patients with 
metastatic breast cancer and brain metastases.  Table 17 : Data for the HER2+ Cohort as of October 20, 2015 
 RECIST Volume
‐/‐/+ Off 2 N SD  (‐13.1) SD (‐43.9) PD (75.2) Body  PD
+/+/+ Off 9 Y  (20mg) SD  (‐5.9) SD (6.3) SD  (‐8.9) Brain  and body PD
‐/‐/+ Off 5 N SD  (‐9.8) SD (‐39.5) SD  (0.0) Clinical  PD
+/+/+ Off 9 Y  (40mg) SD  (‐21.7) SD (‐46.3) NP  (0.0) Brain  PD
+/‐/+ Off 4 Y  (40mg) SD  (‐6.8) SD (‐41.3) PR  (‐42) Vol. PD and clinical PD
‐/‐/+ On 8 N SD  (‐0.3) SD (‐17.5) NP  (0.0) N /A
+/‐/+ On 5 Y  (40mg) SD  (‐8.7) PR (‐72.6) SD  (0.0) N/AHER2+ Cohort
BodyER/PR/HER2  status On/off Cycles Dose  red (Y/N)TIMC best response  (%)
Reason Off Brain
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
101  The primary analysis will declare that unde r the Simon two-stage design, we are unable 
to reject the null hypothesis fo r the true CNS objective respon se rate in HER2+ patients. 
Secondary analysis will be estimation-only, a nd report all endpoints of  clinical activity 
(best overall response by RECIST, best overa ll CNS volumetric response, best response 
in the body, progression-free survival) with 95%  confidence intervals. With 21 evaluable 
HER2+ patients, the maximum half-width of a confidence interval for response rates is 
0.22.     Eight patients with ER-positive metastatic breast cancer and brain metastases and 8 patients with triple-negative metastatic breast cancer and brain metastases will be enrolled in two pilot cohorts for studying th e efficacy of XL184 in patients with those 
two subtypes of metastatic brea st cancer. If the true respons e rate is 30% in ER+ and TN 
disease, the probability that no responses are se en in 8 patients is 5.7%. The table below 
gives exact 95% confidence intervals for seeing 1 to 3 responses in 8 patients. Even if the regimen is concluded as ineffective in inte rim analysis of the HER2-positive cohort, 
accrual in pilot cohorts will continue until reaching the goal accrual.     
Table 18: Estimated 95% Confidence Interval for Events 
Sample Size Number of Re sponse Response Rate 95% CI 
8 1 12.5% 0.3-52.7% 
8 2 25.0% 3.2-65.1% 
8 3 37.5% 8.5-75.5% 
 
Accrual is estimated to be 1-2 patients per month. Total accrual time is estimated to be 
approximately 18-24 months.  
15.2.1 Evaluation of toxicity 
 
All participants will be evaluable for toxicity from the time of their first treatment. 
 
  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
102  15.2.2 Evaluation of response 
 
All participants included in th e study must be assessed for re sponse to treatment, even if 
there are major protocol treatme nt deviations. Ineligible pa tients will be excluded. Each 
participant should be assigned one of the follo wing categories: 1) complete response, 2) 
partial response, 3) stable disease, 4) progre ssive disease, 5) early death from malignant 
disease, 6) early death from toxicity, 7) early  death because of other cause, or 9) unknown 
(not assessable, insufficient data). By arb itrary convention, category 9 usually designates 
the "unknown" status of any type of data in a clinical database.              
16 PUBLICATION PLAN 
The Principal Investigator (Proto col Chair) holds the primary res ponsibility for publication of the 
study results; provided that the Principal Inves tigator will provide any such publication to 
Exelixis, Inc. for review at least sixty (60) da ys prior to submission and also comply with any 
provisions regarding publication as  are agreed to between the Principal Investigator’s institution 
(e.g., Dana Farber/Partners Cancer Care, Inc.) and Exelixis, Inc. in  the Clinical Trial Agreement 
related to this study. The results will be made public within 24  months of the end of data 
collection. However, if a report is planned to be published in a peer-reviewed  journal, then that 
initial release may be an abstra ct that meets the requirements of the International Committee of 
Medical Journal Editors. In any event, a full re port of the outcomes should be made public no 
later than three (3) y ears after the end of data collec tion. Authorship for abstracts and 
manuscripts resulting from this study will be determined according to guidelines established by 
the International Committee of Medical Journal Editors.  
 
  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
103  REFERENCES 
Barnholtz-Sloan, J. S., Sloan, A. E., Davis, F. G., Vign eau, F. D., Lai, P., & Sawaya, R. E. (2004). Incidence 
proportions of brain metastases in patients diagnose d (1973 to 2001) in the Metropolitan Detroit Cancer 
Surveillance System. Journal of Clinical Oncology  : Official Journal of the American Society of Clinical 
Oncology , 22(14), 2865–72. doi:10.1200/JCO.2004.12.149 
Boix, L., Rosa, J. L., Ventura, F., Castells, a, Brui x, J., Rodés, J., & Bartrons, R. (1994). c-met mRNA 
overexpression in human hepatocellular carcinoma. Hepatology (Baltimore, Md.) , 19(1), 88–91. Retrieved 
from http://www.ncbi.nlm.nih.gov/pubmed/8276372 
Bottaro, D., Rubin, J., Faletto, D., Chan, A., Kmiecik, T., Vande Woude, G., & Aaronson, S. (1991). Identification 
of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science , 251 (4995), 802–4. 
Bullitt, E., Ewend, M., & Aylward, S. (2004). Abnormal vessel tortuosity as a marker of treatment response of 
malignant gliomas: preliminary report. Technol Cancer Res Treat , 3(6), 577–584. Retrieved from 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430601/ 
Bullitt, E., Zeng, D., Gerig, G., & Aylward, S. (2005). Ve ssel tortuosity and brain tumor malignancy: A blinded 
study. Academic Radiology , 3(10), 1232–1240. Retrieved from 
http://www.sciencedirect.com/science/article/pii/S1076633205005647 
Camp, R. L., Rimm, E., & Rimm, D. L. (1999). Met expressi on is associated with poor outcome in patients with 
axillary lymph node negative breast carcinoma. Cancer , 86(2259-65). 
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005). Drug resistance by evasion of antiangiogenic 
targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell , 8(4), 299–309. 
doi:10.1016/j.ccr.2005.09.005 
Christensen, J. G., Schreck, R., Burrows, J., Kuruganti, P., Chan, E., Le, P., … Mendel, D. B. (2003). A Selective 
Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes  in Vitro and Exhibits 
Cytoreductive Antitumor Activity in Vivo A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-
Met-Dependent Phenotypes in Vitro and E. Cancer Research , 63, 7345–7355. 
Di Tomaso, E., Snuderl, M., Kamoun, W. S., Duda, D. G., Auluck, P. K., Fazlollahi, L., … Jain, R. K. (2011). 
Glioblastoma recurrence afte r cediranib therapy in patients: lack of “rebound” revascularization as mode of 
escape. Cancer Research , 71(1), 19–28. doi:10.1158/0008-5472.CAN-10-2602 
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. a, Christensen,  J. G., & Kerbel, R. S. (2009). Accelerated 
metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell , 15(3), 232–9. 
doi:10.1016/j.ccr.2009.01.021 
Gherardi, E., & Stoker, M. (1990). Hepatocytes and scatter factor. Nature, 346, 228. 
Graveel, C., DeGroot, J., Su, Y., & Al, E. (2009). Me t induces diverse mammary carcinomas in mice and is 
associated with human basal breast cancer. Proc Natl Acad Sci USA , 106, 12909–14. 
Kang, J. Y., Dolled-filhart, M., Ocal, I. T., Singh, B., Lin, C., Dickson, R. B., … Camp, R. L. (2003). Tissue 
Microarray Analysis of Hepatocyte Growth Factor / Met Pathway Components Reveals a Role for Met , 
Matriptase , and Hepatocyte Growth Factor Activator Inhibitor 1  in th e Progression of Node-negative Breast 
Cancer Tissue Microarray Analysis of Hepato. Cancer Research, 63, 1101–1105. 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
104  Kitajima, Y., Ide, T., Ohtsuk a, T., & Miyazaki, K. (2008). Induction of hepatocyte gr owth factor activator gene 
expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 
in pancreatic cancer. Cancer Science , 99(7), 1341–7. doi:10.1111/j.1349-7006.2008.00828.x 
Kuniyasu, H., Yasui, W., Yokozaki, K., Kitadai, Y., & Tahara, E. (1993). Aberrant expression of c-met mRNA in 
human gastric carcinomas. International Journal of Cancer , 55(1), 72–75. 
Lengyel, E., Prechtel, D., Resau, J., Gauger, K., Welk, A., Lindemann, K., … Harbeck, N. (2005). C-Met 
overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. International Journal of Cancer , 113(4), 678–82. 
Lin, N. U., Bellon, J. R., & Winer, E. P. (2004). CNS metastases in breast cancer. Journal of Clinical Oncology  : 
Official Journal of the American Society of Clinical Oncology , 22(17), 3608–17. 
doi:10.1200/JCO.2004.01.175 
Lin, N. U., Claus, E., Sohl, J., Razzak, A. R., Arnaout, A., & Winer, E. P. (2008). Sites of di stant recurrence and 
clinical outcomes in patients with metastatic triple-n egative breast cancer: high incidence of central nervous 
system metastases. Cancer , 113(10), 2638–45. doi:10.1002/cncr.23930 
Ma, P. C., Maulik, G., Christensen, J., & Salgia, R. (2003 ). c-Met: structure, functions and potential for therapeutic 
inhibition. Cancer Metastasis Reviews , 22(4), 309–25. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/12884908 
Nakamura, T., Nishizawa, T., Hagiya, M., Seki, T., Shimoni shi, M., Sugimura, A., … Shimizu, S. (1989). Molecular 
cloning and expression and human hepatocyte growth. Nature, 342, 440–3. 
Norden, a D., Young, G. S., Setayesh, K., Muzikansky, a, Klufas, R., Ross, G. L., … Wen, P. Y. (2008). 
Bevacizumab for recurrent maligna nt gliomas: efficacy, toxicity , and patterns of recurrence. Neurology , 
70(10), 779–87. doi:10.1212/01.wnl.0000304121.57857.38 
Pàez-Ribes, M., Allen, E., Hudock,  J., Takeda, T., Okuyama, H., Viñals, F., … Casanovas, O. (2009). 
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell , 15(3), 220–31. doi:10.1016/j.ccr.2009.01.027 
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M. , Giordano, S., & Comoglio , P. M. (2003). Hypoxia 
promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell , 3(4), 347–61. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12726861 
Pestalozzi, B., & Brignoli, S. (2000). Trastuzumab in CSF. Journal of Clinical Oncology , 18(11), 2349–2352. 
Retrieved from http://jco.ascopubs.org/content/18/11/2349.3.short 
Plaza-Menacho, I., Morandi, A., Robertson, D., & Al, E. (2010). Targeting the receptor tyrosine kinase RET 
sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. 
Oncogene , 29, 4648–57. 
Ponzo, M., Lesurf, R., Petkiewicz, S., & Al, E. (2009). Met in duces mammary tu m
 ors with diverse histologies and is 
associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA , 106, 12903–8. 
Shankar, L. K., Hoffman, J. M., Bacharach, S., Graham, M. M., Karp, J., Lammertsma, A. a, … Sullivan, D. (2006). 
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. Journal of Nuclear Medicine  : Official Publication, Society of Nuclear 
Medicine, 47(6), 1059–66. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16741317 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
105  Shattuck, D., Miller, J., & Carraway, K. (2008). Met r eceptor contributes to trastuzumab resistance of Her2-
overexpressing breast cancer cells. Cancer Research, 68, 1471–7. 
Sheen-Chen, S., Liu, Y., Eng, H., & Al, E. (2005). Serum levels of hepatocyte growth factor in patients with breast 
cancer. Cancer Epidemiol Biomarkers Prev, 14, 715–7. 
Shojaei, F., Lee, J. H., Simmons, B. H., Wong, A., Esparza,  C. O., Plumlee, P. a, … Christensen, J. G. (2010). 
HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Research , 70(24), 
10090–100. doi:10.1158/0008-5472.CAN-10-0489 
Slamon, D., Eiermann, W., Robert, N., & Al., E. (2006). Ph ase III trial comparing AC-T with AC-TH and with TCH 
in the adjuvant treatment of HER2 positive early brea st cancer patients: second interim efficacy analysis. San 
Antonio Breast Ca Symp . 
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, a, & McGuire, W. L. (1987). Human breast cancer: 
correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York, N.Y.) , 
235(4785), 177–82. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/3798106 
Slamon, D. J., Godolphin, W., Jones, L. a, Holt, J. a, Wong , S. G., Keith, D. E., … Ullric h, a. (1989). Studies of the 
HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (New York, N.Y.) , 244 (4905), 707–
12. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2470152 
Slamon, D., & Leyland-Jones, B. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for 
metastatic breast cancer that overexpresses HER2. … England Journal of …, 344(11), 783–792. Retrieved 
from http://www.nejm.org/doi/f ull/10.1056/NEJM 200103153441101 
Stoker, M., Gherardi, E., Marion, P., & Gray, J. (1987). Scatter factor is a fibroblast-derived modulator of epithelial 
cell mobility. Nature, 327, 239–42. 
Therasse, P. (2000). New Guidelines to Evaluate the Response to Treatment in Solid Tumors. Journal of the 
National Cancer Institute, 92(3). Retrieved from http://jnci.oxford journals.org/content/92/3/205.short 
Toi, M., Taniguchi, T., Ueno, T., Asano, M., Funata, N. , Sekiguchi, K., … Tominaga, T. (1998). Significance of 
circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clinical Cancer 
Research : An Official Journal of the American Association for Cancer Research , 4(3), 659–64. Retrieved 
from http://www.ncbi.nlm.nih.gov/pubmed/9533534 
Trusolino, L., Bertotti, a, & Comoglio, P. M. (2001). A signaling adapter function for alpha6beta4 integrin in the 
control of HGF-dependent invasive growth. Cell, 107(5), 643–54. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/11733063 
Tsukada, Y., Fouad, A., Pickren, J., & Lane, W. (1983). Central nervous system metastasis from breast carcinoma: 
Autopsy study. Cancer, 52, 2349–2352. 
Tsukada, Y., Hurwitz, E., Kashi, R., & Al., E. (1983). E ffect of a conjugate of daunomycin and purified polyclonal 
or monoclonal antibodies to rat alpha-fetoprotein on the growth of alpha-fetoprotein-producing tumor cells. 
Ann N Y Acad  
Sci, 417, 262–9. 
Vogel, C. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-
overexpressing metastatic breast cancer. Journal of Clinical Oncology , 20(3), 719–726. Retrieved from 
http://jco.publicaciones. saludcastillayleon.es/content/20/3/719.short 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
106  Von Minckwitz, G., Vogel, P., Schmidt, M., & Al., E. (2007). Trastuzumab treatment beyond progression in patients 
with HER2-positive metastatic breast cancer - the TBP study (BDB26/GIB 3-05). Breast Cancer Res Treat , 
106(Suppl 1), 4056. 
Yamashita, J., Ogawa, M., Yamashita, S., Nomura, K., Kuramoto, M., & Saishoji, T. (1994). Immunoreactive 
Hepatocyte Growth Factor Is a Strong and Independent Predictor of Recurrence an d Survival in Human Breast 
Cancer Advances in Brief Immunoreactive Hepatocyte Gr owth Factor Is a Strong and Independent Predictor 
of Recurrence and Survival in H. Cancer Research , 54, 1630–1633. 
 
              
  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
107  APPENDIX A:  PERFORMANCE STATUS CRITERIA 
 
ECOG Performance Status Scale 
  
Karnofsky Performance Scale 
Grade Description Percent Description 
0 Normal activity. Fu lly active, able 
to carry on all pre-disease 
performance without restriction. 100 Normal, no complaints, no evidence of disease. 
90 Able to carry on normal activity; minor signs or symptoms of disease. 
1 Symptoms, but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work). 80 Normal activity with effort; some signs or symptoms of disease. 
70 Cares for self, unable to carry on normal activity or to do active work. 
2 In bed < 50% of the time. Ambulatory and capable of all self-care, but unable to carry out any work activities. Up  and about more 
than 50% of waking hours. 60 Requires occasional assistance, but is able to ca re for most of 
his/her needs. 
50 Requires considerable assistance and frequent medical care. 
3 In bed >50% of the time. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 40 Disabled, requires special care and assistance. 
30 Severely disabled, hospitalization indicated. Death not imminent. 
4 100% bedridden. Completely disabled. Cannot carry on any self-care. Totally conf ined to bed or 
chair. 20 Very sick, hospitalization indicated. Death not imminent. 
10 Moribund, fatal processes 
progressing rapidly.  
5 Dead. 0 Dead. 
 
    
  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
108  Pain Questionnaire and Analgesic Medication Di ary Due Dates for Appendix B and Appendix C 
The participant will complete the pain diary and anal gesic medication diary each day for a 7-day interval 
within 14 days of the first dose of cabozantinib and at 7-day intervals during Week 3 and the last week of 
the cycles that patients are scanned on ( ie end of cycle 2, 4, 6, 9, 12, etc) The pain questionnaire and analgesic medication diary will also be due  the last  week of cycles that patients are scanned on (end of 
Cycle 2, 4, 6, 9, 12, etc.) The first pain questionnaire completed can be used to report pain that the participant experienced the week prior to the date of  the study consent signature.  Analgesic medications 
to be recorded on the diary include narcotics and cortic osteroids used to treat pain symptoms.  As follows 
the pain questionnaire and analgesic medication diary should be completed by the participant and then 
brought with them to next appointment: 
 Questionnaire and diary completed during Cycle 1 Day 15-21 (Week 3); then they will be due on Cycle 2 Day 1 (Week 4). 
 Question and diary completed during Cycle 2 Day 15-21 (Week 6); then they will be due on 
Cycle 3 Day 1 (Week 7). 
 Questionnaire and diary completed during Cycle 4 Day 15-21 (Week 12); then they will be due on Cycle 5 Day 1 (Week 13). 
 Questionnaire and diary completed during Cycle 6 Day 15-21 (Week 18); then they will be due on Cycle 7 Day 1 (Week 19).  
 
  
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
109  APPENDIX B:  PAIN QUESTIONNAIRE 
Participant ID number: 
Date: ____________________    Participant Signature: ____________________________ 
 
1.   People with cancer frequently have symptoms  that are caused by their disease or by their 
treatment. We ask you to rate how severe the fo llowing symptoms have been in the last 24 hours. 
Please fill in the circle below from 0 (symptom ha s not been present) to 10 (the symptom was as 
bad as you can imagine it could be) for each item.   
 Not Present As Bad As You 
Can Imagine 
 0 1 2 3 4 5 6 7 8 9 10  
a. Your pain at its WORST? ○ ○  ○ ○ ○ ○ ○ ○ ○ ○ ○  
b. Your disturbed sleep at its   
WORST?  ○ ○  ○ ○ ○ ○ ○ ○ ○ ○ ○ 
 
2.   Symptoms frequently interfere with how  we feel and function. How much have your 
symptoms interfered with the follo wing items in the last 24 hours:  
 Did Not 
Interfere Interfered Completely 
 0 1 2 3 4 5 6 7 8 9 10  
a. General activity ? ○ ○  ○ ○ ○ ○ ○ ○ ○ ○ ○  
 
 
 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
110  Participant ID number:_________                                         Date: ________________ 
3. Compared to the last time I co mpleted this questionnaire, my pain in the last 24 hours was:  
 
  Very much worse 
  Moderately worse 
  A little worse 
  About the same 
  A little better 
  Moderately better 
  Very much better 
  Not Applicable (first time completing this form) 
  
            
Phase II study of cabozantinib in breast cancer with brain metastases   
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidential. Do not disclose or use except as authorized. 
111  APPENDIX C:  7-DAY ANAL GESIC MEDICATION DIARY  
 
                  
Patient Signature:___________: Date:_____________________ 
 

Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
112  APPENDIX D:  PARTICIPANT’S MEDICATION DIARY 
 
Participant’s Name ____________________ ( initials acceptable)  
Participant ID ________ 
Protocol #: ______  Cycle #:  _____ Study Drug:  CABOZANTINIB   Your Dose:     _____ 
 
 
 
 
 
Participant’s signature _____________________________________       Date: __________________INSTRUCTIONS FOR TAKING YOUR CABOZANTINIB: 1. Complete one form for each cycle of treatment (Cycle = 21 days). 2. You will take CABOZANTINIB tablets via mouth once a day.  You should take the tablets each morning after 
you have fasted for 2 hours (no food or drink with the exception of water). You should continue to fast for 1 hour after taking your CABOZANTINIB.  CABOZANTINIB should be taken with a full glass of water (8 oz 
minimum) and consumed over as short a time as possib le. Please swallow the tablets as a whole and do not 
crush, chew or dissolve in water.  Grapefruit and Seville oranges must be avoided while on study. 
3. If you forget to take your  daily CABOZANTINIB dose: 
 If it has been more than 12 hours since missing your scheduled dose, do NOT take your missed dose. 
 If it has been less than 12 hours since missing your  scheduled dose, take your dose immediately and 
continue taking your dose at y our regular time the next day. 
4.    If you vomit your dose, do NOT retake your dose.  Wait until the next day to take your next scheduled dose.  
Remember to tell your study doctor or nurse at  your next visit which dose(s) you missed. 
INSTRUCTIONS FOR COMPLETING THIS FORM: Record the date, the number of tablets of each size of tablet that you took, and when you took them.  If you have 
any comments or notice any side effects, pleas e record them in the Comments column.  Please bring this 
form and your bottles (even if they are empty) of CABOZANTINIB when you return for each 
appointment. 
 
Day  
Date  
Time of 
dose  # of tablets taken Comments
 mg  mg 
   
1      
2      
3      
4      
5      
6      
7      
8      
9      
10      
11      
12      
13      
14      
15      
16      
17      
18      
19      
20      
21      
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
113 APPENDIX E:  NEUROLOGICAL SIGNS AND SYMPTOMS 
Neurological Examination Worksheet 
(to be completed at baseline and at the end of each 3-week cycle) 
 
Please note if signs/symptoms are thought related or not-related to patient’s brain metastases 
 
Patient ____________________  Examiner __________________  Date________________ 
 
Level of consciousness (check one) 
___ Normal 
___ Somnolence or sedation not interfering with function ___ Somnolence or sedation interfering with  function, but not interfering with ADLs 
___ Obtundation or stupor, difficult to arouse; interfering with ADLs ___ Coma  
Neurological Symptoms (check if p resent, and specify CTCAE grade) 
** if asymptomatic, check here  ___ 
Headache        ___  present, specify grade _____ 
Dizziness/lightheadness   ___ present, specify grade _____ Vertigo         ___ present, specify grade _____ Nausea/vomiting      ___ present, specify grade _____ Visual problems      ___ present, specify grade _____ Seizure         ___ present, specify grade _____ Other          ___ absent,   ___ present, specify grade _____  
Cranial nerves II – XII
+ 
___ Normal 
___ Present, not inte rfering with ADLs 
___ Present, interfering with ADLs ___ Life-threatening, disabling 
+  If abnormal, please specify whic h cranial nerve(s) affected ________________________ 
 
Language 
___ Absence of dysphasia or aphasia 
___ Awareness of receptive or expressive apha sia, not impairing ability to communicate 
___ Receptive or expressive dysphasia,  impairing ability to communicate 
___ Inability to communicate  
Sensation** 
___ Normal 
___ Loss of deep tendon reflexes or paresthe sia, but not interf ering with function 
___ Objective sensory loss or paresthesia in terfering with functio n, but not with ADLs 
___ Sensory loss or paresthe sia interfering with ADLs 
___ Permanent sensory loss that interferes with function 
**  If abnormal, please specify location/distribution _________________________________ 
 
 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
114  Neurological Examination Worksheet 
(pg. 2 of 2) 
 
Patient ____________________  Examiner __________________  Date________________  
Strength* 
R upper extremity  ___ Normal   ___ Abnormal; please specify _________________ 
L upper extremity  ___ Normal   ___ Abnormal; please specify _________________ R lower extremity  ___ Normal   ___ Abnormal; please specify _________________ L lower extremity  ___ Normal   ___ Abnormal; please specify _________________  
*If abnormal, please specify muscle group and grade  according to the scale below: (e.g., biceps, 
grade 2) 
 Grade 1 = asymptomatic w ith weakness on physical exam  
 Grade 2 = symptomatic and interfering with  function, but not in terfering with ADLs 
 Grade 3 = symptomatic and interferi ng with activities of daily living  
 Grade 4 = bedridden or disabling  
 
Ataxia*** 
R upper extremity (finger-to-nose testing)  ___ Normal  ___ Abnormal; specify grade ___ 
L upper extremity (finger-to-nose testing)  ___ Normal  ___ Abnormal; specify grade ___ 
Gait              ___ Normal  ___ Abnormal; specify grade ___ 
Balance (Romber)         ___ No rmal  ___ Abnormal; specify grade ___ 
 
*** If any of above abnormal, please assign grade using the following criteria 
 Grade 1 = asymptomatic but abnormal on phys ical exam, and not interfering with 
function  
 Grade 2 = mild symptoms interfering with  function, but not interfering with ADLs  
 Grade 3 = moderate symptoms interfering with ADLs  
 Grade 4 = bedridden or disabling  
 
In the opinion of the treating physician, overall are the patients tumor-related  neurological 
signs and symptoms worsening, stable or improved (please check one)? 
___ Worsening 
___ Stable ___ Improved  
Is the patient currently taking corticosteroids? 
___ Yes 
___ No  If yes, please list name of medicati on and dose (e.g. decadron, 4 mg QD) ________________ 
 
 
 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
115  APPENDIX F:  RESEARCH SPECIMEN COLLECTION/SHIPPING GUIDELINES 
 Procedures for Collecting and Shipping Circulating Tumor Cells (CTCs): 
Automated CellSearch™ processing technique (Veridex). 8 mls of whole blood is collected in 10 ml CellSave tubes™. Samples must be kept at  room temperature and must be PROCESSED 
within 96 hours of draw.  SAMPLE COLLECTION 1. Ensure that peripheral blood collection occurs  prior to administration of i.v. therapy. 
2. The blood sample must be collected in a CellS ave preservative tube. La bel the tube with the 
sample identifier/number, protocol number, and submitting investigator. 3. Collect at least 8 ml of blood. Gently invert the tube 8 times to prevent clotting immediately 
after filling the tube. 4. Do not submit clotted samples.  SAMPLE SHIPPING 1. The blood sample must be transported a nd stored at room temperature (15-30C) until 
processing. Do NOT refrigerate or freeze the sample. 2. Samples must be processed within 96 hours of collection, but best results are obtained if the 
sample is processed as soon as possible. 3. Overnight ship the tube (along with the baseline CTC sample) AT ROOM TEMPERATURE 
to:  
For sample drawn at institution other than DFCI, ship to: Madeline Tenenbaum450 Brookline Ave., Mailstop DA157 Boston, MA 02215 
 
 Please email Madeline Tenenbaum(madelin e_tenenbaum@dfci.harvard.edu) the day 
before with sample information and tracking information. 
 CTC blood samples should not be drawn the day before a holiday weekend. 
 Email CTC core and cc Elena Ivanova and Ma sahiko Yanagita to co-ordinate (if sample 
coming from site other than DFCI, also cc DFCI CRCMadeline Tenenbaum), BWHPathologyCTCLab@partners.org ; evivanova@partners.org ; 
myanagita@partners.org ; madeline_tenenbaum@dfci.harvard.edu 
 Please include the following info in the email:  Protocol: 14-359 Patient: ____________ MRN: _____________ Time point: BL / C1D1 Date of draw: __________ 
Time of draw: __________  
Enumeration, profile, or both: Profile kit (tube) 
 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
116   DFCI CRC will take tubes and requisition to CTC core for same day or next day early 
morning processing. (For Friday patients tube s may be processed at CTC core on Monday 
depending on whether Elena prefers that)  
 CTC core should email Elena when tubes are ready for pick up.  Samples will be processed 
in Dr. Cloud Paweletz’s laboratory at the Dana-Farber Cancer Institute. 
 
Procedures for Collecting and Shipping Plasma Biomarkers 
Exploratory analyses of pot ential biomarkers of ca bozantinib activity will be 
performed by measuring proteins in the plasma and circulating cells at the following timepoints: 
 Baseline 
 Cycle 1 Day 8 
 Day 1 of each cycle of therapy (Cycles 1-6) 
 When scans are reviewed after restaging afte r Cycle 6 (Day 1 every 3 cycles after 18 
weeks have passed) 
 At the end of treatment (if available) 
 8cc of blood will be collected in purple top (plasma EDTA) v acutainers, with a 
minimum of 5cc required. Each sample will be de -identified and shipped on wet ice to the Steele 
Laboratory at MGH (via c ourier from DFCI).   
 CRC to Email Anna Khachatryan ( akhachatryan@partners.org ) and Julia Kahn 
(jakahn@partners.org ) a list of expected samples for next week. For example: 
 
12-431 00011 R-W C3D1 2 purple tops 11/11/2013 10:20 AM 
 
Procedures for Collecting and Shipping cfDNA: 
One 10 ml Streck tube will be collected and processed at baseline and at the end of treatment for 
evaluation of cfDNA.  Fill the St reck tube completely and immedi ately mix by gentle inversion 8 
to 10 times.  Inadequate or delayed mixing may re sult in accurate results.  Ship within 24 hours 
of collection at ambient temperature overnight to:  Madeline Tenenbaum 450 Brookline Avenue, DA157 Boston, MA 02215  Ph:  617-632-2342 Fax:  617-632-3550  madeline_tenenbaum@dfci.harvard.edu  Email Madeline Tenenbaum with the sample information and tracking information the day before shipping specimens: madeline_tenenbaum@dfci.harvard.edu 
 
Tube precautions: 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
117   If samples cannot be shipped within 24 hours of collection, c ontact DFCI.  DO NOT 
FREEZE OR REFRIDGERATE TUBES as this c ould result in cfDNA breakage.  Blood 
collected in the Streck tube can be stored  for 14 days between 6-37 degrees Celsius.  
 Do not use tubes af ter expiration date. 
 Fill the tube completely; overfilling or underf illing of tubes will re sult in an incorrect 
blood-to-additive ratio and may lead to incorrect analytical results. 
 
Shipping Note:  Streck tube samples are sent am bient.  Frozen and ambient specimens obtained 
and shipped on the same day to Madeline Te nenbaum(e.g., Progression or Off Study Biopsy 
Specimens, Streck Tubes, and Circulating Tu mor Cells) may be placed in a combination 
shipping box which contains separate compartmen ts for frozen and ambient samples.  If a 
combination shipping box is not availabl e, two shipping boxes should be used.   
 
Please refer to Appendix H  for additional processing details specific to the laboratories at 
Dana-Farber Cancer Institute. 
 
Procedures for Collecting and Shippin g Optional Research Biopsy Tissue 
Tissue specimens will be collected from recurrent or metastatic lesions using standard 
institutional procedures. The am ount of tissue collected  will follow the guidelines listed below:  
 Breast: A goal of 3-6 core biopsy specimens will be obtained using standard institutional 
guidelines for a diagnostic core biopsy of a breast mass. 
 
Skin/chest wall: A goal of 1-2 5-mm punch biops ies will be obtained.  
 Lymph node: A goal of 3-6 core biopsy specimens will be obtained using an 18-gauge needle.  
 Liver:  A goal of 3-6 core biopsy specimens will be obtained using an 18-gauge needle. 
 Lung: Because of the risk of pneumothorax associated with core needle biopsies of lung nodules, 
no core biopsies of lung nodules wi ll be performed on this protocol; unless if they are clinically 
indicated.   
Bone:  Because the yield of malignant  tissue from bone biopsies tends to be relatively low, if a 
patient has another accessible site  of disease (i.e. skin, lymph node, liver), that site should be 
biopsied preferentially. If bone is the only biopsy-acce ssible site, then a goal of 3-6 core biopsy 
specimens will be obtained using an 11-13 gauge needle. 
 Pleural Fluid:  A goal of 500 cc of pleural fluid will be obtained with a standard thoracentesis 
procedure, with or without image guidance, acco rding to the clinical judgment of the treating 
physician and clinician performing the procedure.  Less than the goal amount is acceptable, and 
should be based upon the clinical judgment of the Investigator and the clinician performing the 
procedure. If more than the goal amount of fluid is obtained, then the enti re specimen (with the 
exception of what is needed for c linical purposes, if app licable) will be stored  in the tissue bank. 
 
Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
118  Ascites fluid:  A goal of 500 cc of ascites fluid will be obtained with a standard paracentesis 
procedure, with or without image guidance, acco rding to the clinical judgment of the treating 
physician and clinician performing the procedure.  Less than the goal amount is acceptable, and 
should be based upon the clinical judgment of the Investigator and the clinician performing the 
procedure. If more than the goal amount of fluid is obtained, then the enti re specimen (with the 
exception of what is needed for c linical purposes, if app licable) will be stored  in the tissue bank. 
 
Please note that the above are guidelines for the amount of tissue to be obtained, and are 
not meant to replace clinical judgment at  the time the procedure is performed . Less than the 
goal quantity of tissue is accepted for each type  of biopsy, and will be left to the clinical 
judgment of the physician performing the  procedure. If ascites or pleural fluid is to be used as the 
investigational biopsy specimen,  consideration should be given to confirming the malignant 
nature of the ascites or pleural  fluid prior to study entry.  
 If a patient is undergoing resection of a lesion for clinical reasons (i.e. wedge resection of a 
new lung lesion for confirmation of diagnosis or re-testing of hormone receptor or HER2 status; 
or, resection of a chest wall lesi on; or, resection of a lymph node ), then the patient may opt to 
have a portion of that tissue (roughly equivalent to the goal amount of tissue listed in the 
guidelines above, i.e. the equiva lent of two 5-mm punch biopsies of the skin, or 3-6 18-gauge 
core biopsies) stored for research at the time of the procedure (provided that the tissue is 
processed as specified), in whic h case, the patient would not be  required to undergo a separate 
research biopsy for entry into this protocol. 
 
Half of the cores should be frozen in OCT and the other half should be placed in formalin 
and made into paraffin blocks.  
Specimens will be shipped to the Clinical Resear ch Coordinator, the frozen sample in OCT will 
be shipped on dry ice and the ones in formalin or paraffin will be shipped ambient, who will then 
deliver tissues to pathology lab:  Madeline Tenenbaum 450 Brookline Avenue, DA157 Boston, MA 02215  Ph:  617-632-2342 Fax:  617-632-3550  Madeline_tenenbaum@dfci.harvard.edu  
Guidelines for Archival Tissue  
Archival tissue from the most recent pr ocedure is preferred, if available. 
 15 unstained slides and 1 H&E OR 1 block and 1 H&E 
 Thickness of slides should be 4-5 µm 
  
Phase II study of cabozantinib in breast cancer with brain metastases   
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidential. Do not disclose or use except as authorized. 
119  APPENDIX G:  STUDY D RUG ORDER FORM   
 

Phase II study of cabozantinib in breast cancer with brain metastases    
Version 7/ October 18, 2016 
 
CONFIDENTIAL 
This document is confidentia l. Do not disclose or use except as authorized. 
120  APPENDIX H:  STRECK COLLECTION AND PROCESSING INSTRUCTIONS – FOR 
OUTSIDE OF DFCI LAB USE ONLY   
 

Protocol #13-359 D: 8/5/2014 KAJ; F: 9/22/2014 LK;  
 DANA-FARBER CANCER INSTITUTE 
Nursing Protocol Education Sheet 
Protocol Number: 14-359 
Protocol Name: A Phase II Study of cabozantinib alone or in combination with trastuzumab in breast 
cancer patients with brain metastases 
DFCI Site PI: Sara Tolaney, MD, MPH 
DFCI Research Nurse: Peg Haldoupis, RN; Liz Kasparian, RN; Mary O’Dr iscoll, RN; Kathy Roche, RN; Myra St. Amand, 
RN 
Page the DFCI research nurse or DFCI site PI if there are any questions/concerns about the protocol.   
Please also refer to ONC 15 : Oncology Nursing Protocol Education Policy 
*** Remember to check the ALERT PAGE*** 
              SPECIAL NURSING CONSIDERATIONS UNIQUE TO THIS PROTOCOL Study Design 
 It is estimated that approximately 10-15% of women with metastatic breast cancer will eventually develop brain 
metastases. Recent data suggests that anti-angiogenic therapy can be safely given to patients with brain 
metastases and clinical activity has been not ed.  Evidence from studies suggests that cabozantinib  has anti-
angiogenic activity, CNS penetration, activity in breast canc er and could be efficacious in the treatment of brain 
metastases from breast cancer.  In this study, par ticipants with HER2-positive will also be treated with 
trastuzumab  (humanized anti-HER2 antibody). Study Design – Section 1.1; Study Rationale – Section 2.6; A 
cycle is 21 days  – Section 1.1 Dose 
Calc.  Cabozantinib  is fixed dosing in mg; no calculation is required – Section 5.4.1 
 Trastuzumab  is dosed in mg/kg – Section 5.4.2 
 Study Drug  
Administration Cabozantinib  – Sections 5.1 and 5.4.1  
 Pre-treatment criteria  – Section 5.2 
 Oral, taken once per day each morning with a full glass of water (minimum 8oz/240mL) – Section 5.4.1 
 Must fast 2 hours before and 1 hour after dose; Tablets must be swallowed whole & not chewed – Section 5.4.1
 Missed doses may taken up to 12 hours after scheduled dosing time – Section 5.4.1 
 Vomited doses are not re-taken – Section 5.4.1 
 Grapefruit and Seville oranges must be avoided while on study – Section 5.6.1 
Trastuzumab  – Section 5.1 and 5.4.2   
 IV, administered on Day 1 of each cycle – Section 5.4.2 
 A loading may be required for some participants.  Pl ease see Section 5.4.2 for guidelines on loading doses and 
rate(s) of infusion. 
 Infusion reaction s – see Section 7.2 for management and requi red observation periods post-reaction. 
 Dose 
Modifications 
& Toxicity Dose Modifications/Dosing Delay for Toxicity  are in Sections 6  (cabozantinib) and Section 7  (trastuzumab) 
 This protocol uses NCI CTCAE criteria, version 4.0 – Section 6 
 The definition of a DLT (for the cabozantin ib + trastuzumab cohort) is in Section 5.3 
 Clinical experience of cabozantinib is in Section 2.3 
 Safety profile of trastuzumab is in Section 2.4.2 Con 
Meds Concomitant Therapy  Guidelines are in Sections 5.5 and 5.6 
 Please review the cited sections for permitted, prohibited, and “use with caution” medications/therapies/foods Required  
Data  Study Calendar and Assessment Required data  are outlined in Sections 9 and 10  
 Please review the study calendar in Section 10 Charting Tips All study drugs require documentat ion of exact administration time. 
Please be sure to DOCUMENT study medication actual  UP/DOWN times in medical record (e.g. LMR, eMAR, 
nursing notes). Edit eMAR as needed to match the exact time given . 
 If there is a discrepancy in the infusion time, delay in administration, or infusion takes longer than is permitted 
by the guidelines of the protocol, please document the reason for the discrepancy in the medical record.  
Please also DOCUMENT any required observation periods (i.e . if an infusion reaction occurs), any additional vital 
signs, routes of administration. 
 
 
1 
 HIGHLIGHTS OF PRESCRIBING INFORMATION 
These highlights do not include all the information needed to use 
Herceptin safely and effectively.  See full prescribing information for 
Herceptin.  
 
HERCEPTIN® (trastuzumab) for injection, for intravenous use  
Initial U.S. Approval:  1998  
 
WARNING: CARDIOMYOPATHY, INFUSION REACTIONS,  
EMBRYO- FETAL TOXICITY, and PULMONARY TOXICITY  
 
See full prescribing information for complete boxed warning  
Cardiom yopathy: Herceptin can resul t in subclinical and clinical cardiac 
failure manif esting as CHF, and decreased LVEF, with greatest risk 
when administered concurrently with anthracyclines. Evaluate cardiac 
function prior to and during treatment. Discontinue Herceptin for 
cardiomyopathy.  (2.3, 5.1) 
 Infusion Reactions , Pulmonary Toxicity: Discontinue Herceptin for 
anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory 
distress syndrome . (5.2, 5.4)  
 
Embryo -Fetal Toxicity: Exposure to Herceptin during pregnancy can 
result in oligohydramnios, in some cases complicated by pulmonary 
hypoplasia and neonatal death.  Advise patients of these risks and the 
need for effective contraception.
  (5.3, 8.1 , 8.3) 
-----------------------------RECENT MAJOR CHANGES ------------------------- 
  
Dosage and Administration  (2.1) 04/2017 
Warnings and Precautions  (5.3) 03/2016  
---------------------------INDICATIONS AND USAGE ---------------------------- 
Herceptin is a HER2/ neu receptor  antagonist indicated for : 
• The treatment of HER2 -overexpressing breast cancer . (1.1, 1.2)  
• The treatment of HER2- overexpressing metastatic  gastric  or 
gastroesophageal junction adenocarcinoma . (1.3)  
Select patients for therapy based on an FDA -approved companion diagnostic 
for Herceptin (1, 2.1).  
------------------------DOSAGE AND ADMINISTRATION---------------------- 
For intravenous (IV) infusion only.  Do not administer as an IV push or 
bolus . (2.2)  
Do not substitute Herceptin (trastuzumab) for or with ado -trastuzumab 
emtansine. (2. 2) 
Perform HER2 testing using FDA -approved tests by laboratories with 
demonstrated proficiency . (1, 2.1) 
 Adjuvant Treatment of HER2- Overexpressing Breast Cancer (2. 2) 
Administer at either : 
• Initial dose of 4 mg/kg over 90 minute IV infusion, then 2  mg/kg over 
30 minute IV infusion weekly for 12 weeks (with paclitaxel or docetaxel) 
or 18 weeks (with docetaxel/carboplatin) .  One week after the last weekly 
dose of Herceptin, administer 6 mg/kg as an IV infusion over 30 −90 
minutes every three weeks to complete a total of 52 weeks of therapy , or 
• Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 
30−90 minutes IV infusion every three weeks for 52 weeks.  
Metastatic HER2 -Overexpressing Breast Cancer (2. 2) 
• Initial dose of 4  mg/kg as a 90 minute IV infusion followed by subsequent 
weekly doses of 2  mg/kg as 30 minute IV infusions. 
Metastatic HER2 -Overexpressing Gastric Cancer (2.2) 
• Initial dose of 8  mg/kg over 90  minutes IV infusion, followed by 6  mg/kg 
over 30 to 90  minutes IV infusion every 3  weeks.   
---------------------DOSAGE FORMS AND STRENGTHS ---------------------- 
• For Injection: 150 mg lyophilized powder in a single -dose vial for 
reconstitution  
• For Injection: 420 mg lyophilized powder in a multiple- dose vial for 
reconstitution  
------------------------------CONTRAINDICATIONS ------------------------------ 
• None. (4 ) 
-----------------------WARNINGS AND PRECAUTIONS------------------------ 
• Exacerbation of Chemotherapy -Induced Neutropenia . (5.5 , 6.1)  
------------------------------ADVERSE REACTIONS ------------------------------ 
Adjuvant Breast Cancer  
• Most common adverse reactions  (≥ 5%) are headache, diarrhea, nausea, and 
chills. (6.1)  
Metastatic Breast  Cancer  
• Most common a dverse reactions (≥ 10%) are fever, chills, headache, 
infection, congestive heart failure, insomnia, cough, and rash. (6.1)  
Metastatic Gastric Cancer  
• Most common adverse reactions  (≥ 10%) are neutropenia, diarrhea, fatigue, 
anemia, stomatitis, weig ht loss, upper respiratory tract infections , fever, 
thrombocytopenia, mucosal inflammation, nasopharyngitis, and dysgeusia.  
(6.1) 
To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 
1-888- 835-2555 or FDA at 1 -800-FDA -1088 or www.fda.gov/medwatch . 
----------------------USE IN SPECIFIC POPULATIONS---------------------- 
Females and Males of Reproductive Potential: Verify the pregnancy status of 
females prior to initiation of Herceptin  (8.3).  
 See 17 for PATIENT COUNSELING INFORMATION.  
Revised: 04/ 2017 
 
 
 
FULL PRESCRIBING INFORMATION:  CONTENTS * 
WARNING −
 CARDIOMYOPATHY, INFUSION REACTIONS , 
EMBRYO- FETAL TOXICITY , and PULMONARY TOXICITY  
1 INDICATIONS AND USAGE  
1.1 Adjuvant Breast Cancer  
1.2 Metastatic  Breast Cancer  
1.3 Metastatic Gastric Cancer  
2 DOSAGE AND ADMINISTRATION 
2.1 Patient Selection  
2.2 Recommended Doses and Schedules  
2.3 Important Dosing Considerations  
2.4 Preparation for Administration  
3 DOSAGE FORMS AND STRENGTHS  
4 CONTRAINDICA TIONS  
5 WARNINGS AND PRECAUTIONS  
5.1 Cardiomyopathy  
5.2 Infusion Reactions  
5.3 Embryo-Fetal Toxicity  
5.4 Pulmonary Toxicity  
5.5 Exacerbation of Chemotherapy -Induced Neutropenia   
6 ADVERSE REACTIONS  
6.1 Clinical  Trials  Experience  
6.2 Immunogenicity 
6.3 Post- Marketing Experience  
7 DRUG INTERACTIONS  8 USE IN SPECIFIC POPULATIONS 
8.1 Pregnancy  
8.2 Lactation  
8.3 Females and Males of Reproductive Potential  
8.4 Pediatric Use  
8.5 Geriatric Use  
10 OVERDOSAGE  
11 DESCRIPTION 
12 CLINICAL PHARMACOLOGY 12.1 Mechanism  of Action  
12.2 Pharmacodynamics 
12.3 Pharmacokinetics 
13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility  
14 CLINICAL STUDIES  
14.1 Adjuvant Breast Cancer  
14.2 Metastatic Breast Cancer  
14.3 Metastatic Gastric Cancer  
16 HOW SUPPLIED/STORAGE AND HANDLING  
16.1 How Supplied  
16.2 Stability and Storage  
17 PATIENT COUNSELING INFORMATION  
 
* Sections or subsections omitted from the full prescribing information are not 
listed.  
 
2 FULL PRESCRIBING INFORMATION 1 
WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL 2 
TOXICITY, and PULMONARY TOXICITY  3 
Cardiomyopathy 4 
 Herceptin administration can result in sub-clinical and clinical cardiac failure.  The 5 
incidence and severity was highest in patients receiving Herceptin with 6 
anthracycline-containing chemotherapy regimens. 7 
 Evaluate left ventricular function in all patients prior to and during treatment with 8 
Herceptin.  Discontinue Herceptin treatment in patients receiving adjuvant therapy and 9 
withhold Herceptin in patients with metastatic disease for clinically significant decrease in left 10 
ventricular function [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)]. 11 
Infusion Reactions; Pulmonary Toxicity 12 
 Herceptin administration can result in serious and fatal infusion reactions and pulmonary 13 
toxicity.  Symptoms usually occur during or within 24 hours of Herceptin administration.  14 
Interrupt Herceptin infusion for dyspnea or clinically significant hypotension.  Monitor 15 
patients until symptoms completely resolve.  Discontinue Herceptin for anaphylaxis, 16 
angioedema, interstitial pneumonitis, or acute respiratory distress syndrome [see Warnings 17 
and Precautions (5.2, 5.4)]. 18 
Embryo-Fetal Toxicity  19 
 Exposure to Herceptin during pregnancy can result in oligohydramnios and 20 
oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and 21 
neonatal death. Advise patients of these risks and the need for effective contraception [see 22 
Warnings and Precautions (5.3) and Use in Specific Populations (8.1, 8.3)]. 23 
 24 
1 INDICATIONS AND USAGE 25 
1.1 Adjuvant Breast Cancer 26 
 Herceptin is indicated for adjuvant treatment of HER2 overexpressing node positive or node 27 
negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1)] ) breast cancer  28 
• as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either 29 
paclitaxel or docetaxel 30 
• as part of a treatment regimen with docetaxel and carboplatin  31 
• as a single agent following multi-modality anthracycline based therapy.   32 
 Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin [see 33 
Dosage and Administration (2.1)] . 34 
1.2 Metastatic Breast Cancer 35 
 Herceptin is indicated: 36 
• In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic 37 
breast cancer 38 
• As a single agent for treatment of HER2-overexpressing breast cancer in patients who have 39 
received one or more chemotherapy regimens for metastatic diseas e. 40 
 Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin [see 41 
Dosage and Administration (2.1)] . 42 
1.3 Metastatic Gastric Cancer  43 
 Herceptin is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the 44 
treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction 45 
adenocarcinoma who have not received prior treatment for metastatic disease. 46 
 
3  Select patients for therapy based on an FDA-approved companion diagnostic for Herceptin [see 47 
Dosage and Administration (2.1)] . 48 
 49 
2 DOSAGE AND ADMINISTRATION 50 
2.1 Patient Selection 51 
Select patients based on HER2 protein overexpression or HER2 gene amplification in tumor 52 
specimens [see Indications and Usage (1) and Clinical Studies (14)] .  Assessment of HER2 protein 53 
overexpression and HER2 gene amplification should be performed using FDA-approved tests 54 
specific for breast or gastric cancers  by laboratories with demonstrated proficiency.  Information on 55 
the FDA-approved tests for the detection of HER2 protein overexpression and HER2 gene 56 
amplification is available at:  http://www.fda.gov/CompanionDiagnostics. 57 
 Assessment of HER2 protein overexpression and HER2 gene amplification in metastatic gastric 58 
cancer should be performed using FDA-approved tests specifically for gastric cancers due to 59 
differences in gastric vs. breast histopathology, including incomplete membrane staining and more 60 
frequent heterogeneous expression of HER2 seen in gastric cancers.  61 
Improper assay performance, including use of suboptimally fixed tissue, failure to utilize 62 
specified reagents, deviation from specific assay instructions, and failure to include appropriate 63 
controls for assay validation, can lead to unreliable results.  64 
2.2 Recommended Doses and Schedules 65 
• Do not administer as an intravenous push or bolus. Do not mix Herceptin with other 66 
drugs. 67 
• Do not substitute Herceptin (trastuzumab) for or with ado-trastuzumab emtansine. 68 
Adjuvant Treatment, Breast Cancer 69 
Administer according to one of the following doses and schedules for a total of 52 weeks of 70 
Herceptin therapy: 71 
 During and following paclitaxel, docetaxel, or docetaxel/carboplatin: 72 
• Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an 73 
intravenous infusion over 30 minutes weekly during chemotherapy for the first 12 weeks 74 
(paclitaxel or docetaxel) or 18 weeks (docetaxel/carboplatin). 75 
• One week following the last weekly dose of Herceptin, administer Herceptin at 6 mg/kg as an 76 
intravenous infusion over 30−90 minutes every three weeks. 77 
As a single agent within three weeks following completion of multi-modality, 78 
anthracycline-based chemotherapy regimens :  79 
• Initial dose at 8 mg/kg as an intravenous infusion over 90 minutes  80 
• Subsequent doses at 6 mg/kg as an intravenous infusion over 30−90 minutes every 81 
three weeks [see Dosage and Administration (2.3)]. 82 
• Extending adjuvant treatment beyond one year is not recommended  [see Adverse Reactions 83 
(6.1)] . 84 
Metastatic Treatment, Breast Cancer 85 
• Administer Herceptin, alone or in combination with paclitaxel, at an initial dose of 4 mg/kg as 86 
a 90-minute intravenous infusion followed by subsequent once weekly doses of 2 mg/kg as 87 
30-minute intravenous infusions until disease progression. 88 
Metastatic Gastric Cancer  89 
• Administer Herceptin at an initial dose of 8 mg/kg as a 90-minute intravenous infusion 90 
followed by subsequent doses of 6 mg/kg as an intravenous infusion over 30–90 minutes every 91 
three weeks until disease progression [see Dosage and Administration (2.3)]. 92 
 
4 2.3 Important Dosing Considerations 93 
If the patient has missed a dose of Herceptin by one week or less, then the usual maintenance dose 94 
(weekly schedule: 2 mg/kg; three-weekly schedule: 6 mg/kg) should be administered as soon as 95 
possible.  Do not wait until the next planned cycle.  Subsequent Herceptin maintenance doses should 96 
be administered 7 days or 21 days later according to the weekly or three-weekly schedules, 97 
respectively. 98 
If the patient has missed a dose of Herceptin by more than one week, a re-loading dose of 99 
Herceptin should be administered over approximately 90 minutes (weekly schedule: 4 mg/kg; three- 100 
weekly schedule: 8 mg/kg) as soon as possible.  Subsequent Herceptin maintenance doses (weekly 101 
schedule: 2 mg/kg; three-weekly schedule 6 mg/kg) should be administered 7 days or 21 days later 102 
according to the weekly or three-weekly schedules, respectively. 103 
Infusion Reactions 104 
[See Boxed Warning, Warnings and Precautions (5.2)]  105 
• Decrease the rate of infusion for mild or moderate infusion reactions 106 
• Interrupt the infusion in patients with dyspnea or clinically significant hypotension 107 
• Discontinue Herceptin for severe or life-threatening infusion reactions. 108 
Cardiomyopathy 109 
[See Boxed Warning, Warnings and Precautions (5.1)]  110 
 Assess left ventricular ejection fraction (LVEF) prior to initiation of Herceptin and at regular 111 
intervals during treatment.  Withhold Herceptin dosing for at least 4 weeks for either of the 112 
following: 113 
•  ≥ 16% absolute decrease in LVEF from pre-treatment values 114 
• LVEF below institutional limits of normal and ≥ 10% absolute decrease in LVEF from 115 
pretreatment values. 116 
 Herceptin may be resumed if, within 4−8 weeks, the LVEF returns to normal limits and the 117 
absolute decrease from baseline is ≤ 15%. 118 
 Permanently discontinue Herceptin for a persistent (> 8 weeks) LVEF decline or for suspension of 119 
Herceptin dosing on more than 3 occasions for cardiomyopathy. 120 
2.4 Preparation for Administration 121 
 To prevent medication errors, it is important to check the vial labels to ensure that the drug being 122 
prepared and administered is Herceptin (trastuzumab) and not ado-trastuzumab emtansine. 123 
420 mg Multiple-dose vial 124 
Reconstitution 125 
 Reconstitute each 420 mg vial of Herceptin with 20 mL of Bacteriostatic Water for Injection 126 
(BWFI), USP, containing 1.1% benzyl alcohol as a preservative to yield a multiple-dose solution 127 
containing 21 mg/mL trastuzumab that delivers 20 mL (420 mg trastuzumab).  In patients with 128 
known hypersensitivity to benzyl alcohol, reconstitute with 20 mL of Sterile Water for Injection 129 
(SWFI) without preservative to yield a single use solution. 130 
 Use appropriate aseptic technique when performing the following reconstitution steps: 131 
• Using a sterile syringe, slowly inject the 20 mL of diluent into the vial containing the 132 
lyophilized cake of Herceptin.  The stream of diluent should be directed into the lyophilized 133 
cake. The reconstituted vial yields a solution for multiple-dose use, containing 21 mg/mL 134 
trastuzumab. 135 
• Swirl the vial gently to aid reconstitution.  DO NOT SHAKE. 136 
• Slight foaming of the product may be present upon reconstitution.  Allow the vial to stand 137 
undisturbed for approximately 5 minutes. 138 
 
5 • Parenteral drug products should be inspected visually for particulate matter and discoloration 139 
prior to administration, whenever solution and container permit.  Inspect visually for 140 
particulates and discoloration.  The solution should be free of visible particulates, clear to 141 
slightly opalescent and colorless to pale yellow. 142 
• Store reconstituted Herceptin in the refrigerator at 2○C to 8○C (36°F to 46°F); discard unused 143 
Herceptin after 28 days.  If Herceptin is reconstituted with SWFI without preservative, use 144 
immediately and discard any unused portion.  Do not freeze. 145 
Dilution 146 
• Determine the dose (mg) of Herceptin [see  Dosage and Administration (2.2)] .  Calculate the 147 
volume of the 21 mg/mL reconstituted Herceptin solution needed, withdraw this amount from 148 
the vial and add it to an infusion bag containing 250 mL of 0.9% Sodium Chloride Injection, 149 
USP.  DO NOT USE DEXTROSE (5%) SOLUTION. 150 
• Gently invert the bag to mix the solution. 151 
• The solution of Herceptin for infusion diluted in polyvinylchloride or polyethylene bags 152 
containing 0.9% Sodium Chloride Injection, USP, should be stored at 2°C to 8°C (36°F to 153 
46°F) for no more than 24 hours prior to use. Do not freeze. 154 
 155 
150 mg Single-dose vial 156 
Reconstitution 157 
 Reconstitute each 150 mg vial of Herceptin with 7.4 mL of Sterile Water for Injection (SWFI) 158 
(not supplied) to yield a single-dose solution containing 21 mg/mL trastuzumab that delivers 7.15 159 
mL (150 mg trastuzumab). 160 
 Use appropriate aseptic technique when performing the following reconstitution steps: 161 
• Using a sterile syringe, slowly inject 7.4 mL of SWFI (not supplied) into the vial containing 162 
the lyophilized 150 mg Herceptin, directing the diluent stream into the lyophilized cake. The 163 
reconstituted vial yields a solution for single-dose use, containing 21 mg/mL trastuzumab. 164 
• Swirl the vial gently to aid reconstitution.  DO NOT SHAKE.  165 
• Slight foaming of the product may be present upon reconstitution.  Allow the vial to stand 166 
undisturbed for approximately 5 minutes.  167 
• Parenteral drug products should be inspected visually for particulate matter and discoloration 168 
prior to administration, whenever solution and container permit.  Inspect visually for 169 
particulates and discoloration.  The solution should be free of visible particulates, clear to 170 
slightly opalescent and colorless to pale yellow. 171 
• Use the Herceptin solution immediately following reconstitution with SWFI, as it contains no 172 
preservative and is intended for single-dose only. If not used immediately, store the 173 
reconstituted Herceptin solution for up to 24 hours at 2○C to 8○C (36○F to 46○F); discard any 174 
unused Herceptin after 24 hours.  Do not freeze.  175 
Dilution 176 
• Determine the dose (mg) of Herceptin [see Dosage and Administration (2.1)] .   177 
• Calculate the volume of the 21 mg/mL reconstituted Herceptin solution needed. 178 
• Withdraw this amount from the vial and add it to an infusion bag containing 250 mL of 179 
0.9% Sodium Chloride Injection, USP.  DO NOT USE DEXTROSE (5%) SOLUTION. 180 
• Gently invert the bag to mix the solution. 181 
• The solution of Herceptin for infusion diluted in polyvinylchloride or polyethylene bags 182 
containing 0.9% Sodium Chloride Injection, USP, should be stored at 2°C to 8°C (36°F to 183 
46°F) for no more than 24 hours prior to use.  Discard after 24 hours.  This storage time is 184 
additional to the time allowed for the reconstituted vials.  Do not freeze. 185 
 186 
 
6 3 DOSAGE FORMS AND STRENGTHS 187 
• For injection: 150 mg lyophilized powder in a single-dose vial 188 
• For injection: 420 mg lyophilized powder in a multiple-dose vial. 189 
 190 
4 CONTRAINDICATIONS 191 
 None. 192 
 193 
5 WARNINGS AND PRECAUTIONS 194 
5.1 Cardiomyopathy 195 
 Herceptin can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling 196 
cardiac failure, cardiomyopathy, and cardiac death [see Boxed Warning: Cardiomyopathy] .  197 
Herceptin can also cause asymptomatic decline in left ventricular ejection fraction (LVEF). 198 
 There is a 4−6 fold increase in the incidence of symptomatic myocardial dysfunction among 199 
patients receiving Herceptin as a single agent or in combination therapy compared with those not 200 
receiving Herceptin.  The highest absolute incidence occurs when Herceptin is administered with an 201 
anthracycline. 202 
 Withhold Herceptin for ≥ 16% absolute decrease in LVEF from pre-treatment values or an LVEF 203 
value below institutional limits of normal and ≥ 10% absolute decrease in LVEF from pretreatment 204 
values [see  Dosage and Administration (2.3)] .  The safety of continuation or resumption of 205 
Herceptin in patients with Herceptin-induced left ventricular cardiac dysfunction has not been 206 
studied. 207 
 Patients who receive anthracycline after stopping Herceptin may also be at increased risk of 208 
cardiac dysfunction [see Drug Interactions (7) and Clinical Pharmacology (12.3)] .   209 
Cardiac Monitoring 210 
 Conduct thorough cardiac assessment, including history, physical examination, and determination 211 
of LVEF by echocardiogram or MUGA scan.  The following schedule is recommended: 212 
• Baseline LVEF measurement immediately prior to initiation of Herceptin 213 
• LVEF measurements every 3 months during and upon completion of Herceptin 214 
• Repeat LVEF measurement at 4 week intervals if Herceptin is withheld for significant left 215 
ventricular cardiac dysfunction [see Dosage and Administration (2.3)]  216 
• LVEF measurements every 6 months for at least 2 years following completion of Herceptin as 217 
a component of adjuvant therapy. 218 
 In Study 1, 15% (158/1031) of patients discontinued Herceptin due to clinical evidence of 219 
myocardial dysfunction or significant decline in LVEF after a median follow-up duration of 220 
8.7 years in the AC-TH arm.  In Study 3 (one-year Herceptin treatment), the number of patients who 221 
discontinued Herceptin due to cardiac toxicity at 12.6 months median duration of follow-up was 222 
2.6% (44/1678).  In Study 4, a total of 2.9% (31/1056) of patients in the TCH arm (1.5% during the 223 
chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) of patients in the 224 
AC-TH arm (1.5% during the chemotherapy phase and 4.2% during the monotherapy phase) 225 
discontinued Herceptin due to cardiac toxicity. 226 
 Among 64 patients receiving adjuvant chemotherapy (Studies 1 and 2) who developed congestive 227 
heart failure, one patient died of cardiomyopathy, one patient died suddenly without documented 228 
etiology, and 33 patients were receiving cardiac medication at last follow-up.  Approximately 24% 229 
of the surviving patients had recovery to a normal LVEF (defined as ≥ 50%) and no symptoms on 230 
continuing medical management at the time of last follow-up.  Incidence of congestive heart failure 231 
(CHF) is presented in Table 1.  The safety of continuation or resumption of Herceptin in patients 232 
with Herceptin-induced left ventricular cardiac dysfunction has not been studied. 233 
 234 
 
7 Table 1  
Incidence of Congestive Heart Failure in Adjuvant Breast Cancer Studies 
 Incidence of C HF 
Study  Regimen  Herceptin  Control  
1 & 2a ACb→Paclitaxel +Herceptin 3.2% (64/2000)c 1.3% ( 21/1655) 
3d Chemo → Herceptin  2% (30/1678)  0.3% (5/1708)  
4  ACb→Docetaxel +Herceptin 2% (20/1068)  0.3% (3/1050)  
4  Docetaxel+Carbo+H erceptin  0.4% (4/1056)  0.3% (3/1050)  
  a Median follow -up duration for studies 1 and 2 combined was 8.3 years in the AC →TH arm.    
   b Anthracycline  (doxorubicin) and cyclophosphamide.  
   c Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented 
etiology.  
   d Includes NYHA II- IV and cardiac death at 12.6 months median duration of follow -up in the one -year 
Herceptin arm.  
 235 
 In Study 3 (one-year Herceptin treatment), at a median follow-up duration of 8 years, the incidence 236 
of severe CHF (NYHA III & IV) was 0.8%, and the rate of mild symptomatic and asymptomatic left 237 
ventricular dysfunction was 4.6%. 238 
 239 
Table 2  
Incidence of Cardiac Dysfunctiona in Metastatic Breast Cancer Studies 
Study  Event  Incidence 
NYHA I −IV  NYHA III −IV  
Herceptin  Control  Herceptin  Control  
5 
(AC)b Cardiac Dysfunction 28% 7% 19% 3% 
5 
(paclitaxel)  Cardiac Dysfunction 11% 1% 4% 1% 
6 Cardiac Dysfunctionc 7%  N/A 5% N/A 
 a Congestive heart failure or significant asymptomatic decrease in LVEF.  
 b Anthracycline (doxorubicin or epirubicin) and cyclophosphamide. 
 c Includes 1 patient with fatal cardiomyopathy.  
 240 
 In Study 4, the incidence of NCI-CTC Grade 3/4 cardiac ischemia/infarction was higher in the 241 
Herceptin containing regimens (AC-TH: 0.3% (3/1068) and TCH: 0.2% (2/1056)) as compared to 242 
none in AC-T. 243 
5.2 Infusion Reactions 244 
 Infusion reactions consist of a symptom complex characterized by fever and chills, and on 245 
occasion included nausea, vomiting, pain (in some cases at tumor sites), headache, dizziness, 246 
dyspnea, hypotension, rash, and asthenia [see  Adverse Reactions (6.1)]. 247 
 In post-marketing reports, serious and fatal infusion reactions have been reported.  Severe 248 
reactions, which include bronchospasm, anaphylaxis, angioedema, hypoxia, and severe hypotension, 249 
were usually reported during or immediately following the initial infusion.  However, the onset and 250 
clinical course were variable, including progressive worsening, initial improvement followed by 251 
clinical deterioration, or delayed post-infusion events with rapid clinical deterioration.  For fatal 252 
events, death occurred within hours to days following a serious infusion reaction. 253 
 
8  Interrupt Herceptin infusion in all patients experiencing dyspnea, clinically significant 254 
hypotension, and intervention of medical therapy administered (which may include epinephrine, 255 
corticosteroids, diphenhydramine, bronchodilators, and oxygen).  Patients should be evaluated and 256 
carefully monitored until complete resolution of signs and symptoms.  Permanent discontinuation 257 
should be strongly considered in all patients with severe infusion reactions. 258 
 There are no data regarding the most appropriate method of identification of patients who may 259 
safely be retreated with Herceptin after experiencing a severe infusion reaction.  Prior to resumption 260 
of Herceptin infusion, the majority of patients who experienced a severe infusion reaction were 261 
pre-medicated with antihistamines and/or corticosteroids.  While some patients tolerated Herceptin 262 
infusions, others had recurrent severe infusion reactions despite pre-medications. 263 
5.3 Embryo-Fetal Toxicity  264 
 Herceptin can cause fetal harm when administered to a pregnant woman. In post-marketing 265 
reports, use of Herceptin during pregnancy resulted in cases of oligohydramnios and 266 
oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and 267 
neonatal death.  268 
 Verify the pregnancy status of females of reproductive potential prior to the initiation of 269 
Herceptin. Advise pregnant women and females of reproductive potential that exposure to 270 
Herceptin during pregnancy or within 7 months prior to conception can result in fetal harm.  Advise 271 
females of reproductive potential to use effective contraception during treatment and for 7 months 272 
following the last dose of Herceptin [see Use in Specific Populations (8.1, 8.3) and Clinical 273 
Pharmacology (12.3)]. 274 
5.4 Pulmonary Toxicity 275 
 Herceptin use can result in serious and fatal pulmonary toxicity.  Pulmonary toxicity includes 276 
dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, non-cardiogenic 277 
pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and 278 
pulmonary fibrosis.  Such events can occur as sequelae of infusion reactions  [see Warnings and 279 
Precautions (5.2)] .  Patients with symptomatic intrinsic lung disease or with extensive tumor 280 
involvement of the lungs, resulting in dyspnea at rest, appear to have more severe toxicity. 281 
5.5 Exacerbation of Chemotherapy-Induced Neutropenia 282 
 In randomized, controlled clinical trials, the per-patient incidences of NCI-CTC Grade 3−4 283 
neutropenia and of febrile neutropenia were higher in patients receiving Herceptin in combination 284 
with myelosuppressive chemotherapy as compared to those who received chemotherapy alone.  The 285 
incidence of septic death was similar among patients who received Herceptin and those who did not 286 
[see Adverse Reactions (6.1)]. 287 
 288 
6 ADVERSE REACTIONS 289 
 The following adverse reactions are discussed in greater detail in other sections of the label: 290 
• Cardiomyopathy [see Warnings and Precautions (5.1)]  291 
• Infusion Reactions [see Warnings and Precautions (5.2)]  292 
• Embryo-Fetal Toxicity [see Warnings and Precautions (5.3)]  293 
• Pulmonary Toxicity [see Warnings and Precautions (5.4)]  294 
• Exacerbation of Chemotherapy-Induced Neutropenia [see Warnings and Precautions (5.5)]  295 
 296 
 The most common adverse reactions in patients receiving Herceptin in the adjuvant and metastatic 297 
breast cancer setting are fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased 298 
cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia.  Adverse reactions 299 
requiring interruption or discontinuation of Herceptin treatment include CHF, significant decline in 300 
 
9 left ventricular cardiac function, severe infusion reactions, and pulmonary toxicity [see Dosage and 301 
Administration (2.3)] . 302 
 In the metastatic gastric cancer setting, the most common adverse reactions (≥  10%) that were 303 
increased (≥  5% difference) in the Herceptin arm as compared to the chemotherapy alone arm were 304 
neutropenia, diarrhea, fatigue, anemia, stomatitis, weight loss, upper respiratory tract infections, 305 
fever, thrombocytopenia, mucosal inflammation, nasopharyngitis, and dysgeusia.  The most 306 
common adverse reactions which resulted in discontinuation of treatment on the Herceptin- 307 
containing arm in the absence of disease progression were infection, diarrhea, and febrile 308 
neutropenia. 309 
6.1 Clinical Trials Experience 310 
 Because clinical trials are conducted under widely varying conditions, adverse reaction rates 311 
observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of 312 
another drug and may not reflect the rates observed in practice. 313 
Adjuvant Breast Cancer Studies 314 
 The data below reflect exposure to one-year Herceptin therapy across three randomized, 315 
open-label studies, Studies 1, 2, and 3, with (n  = 3678) or without (n  = 3363) trastuzumab in the 316 
adjuvant treatment of breast cancer. 317 
 The data summarized in Table 3 below, from Study 3, reflect exposure to Herceptin in 318 
1678 patients; the median treatment duration was 51 weeks and median number of infusions was 18.  319 
Among the 3386 patients enrolled in the observation and one-year Herceptin arms of Study 3 at a 320 
median duration of follow-up of 12.6 months in the Herceptin arm, the median age was 49 years 321 
(range: 21 to 80 years), 83% of patients were Caucasian, and 13% were Asian. 322 
 323 
 
10 Table 3  
Adverse Reactions for Study 3a, All Gradesb 
   
Adverse Reaction One Year Herceptin  
(n = 1678)  Observation  
(n = 1708)  
Cardiac  
Hypertension  64 (4%) 35 (2%) 
Dizziness  60 (4%) 29 (2%) 
Ejection Fraction Decreased  58 (3.5%) 11 (0.6%) 
Palpitations  48 (3%) 12 (0.7%) 
Cardiac Arrhythmiasc 40 (3%) 17 (1%) 
Cardiac Failure Congestive  30 (2%) 5 (0.3%) 
Cardiac Failure 9 (0.5%) 4 (0.2%) 
Cardiac Disorder  5 (0.3%) 0 (0%) 
Ventricular Dysfunction  4 (0.2%) 0 (0%) 
Respiratory Thoracic Mediastinal Disorders 
Cough  81 (5%)  34 (2%)  
Influenza 70 (4%)  9 (0.5%)  
Dyspnea  57 (3%)  26 (2%)  
URI 46 (3%)  20 (1%)  
Rhinitis  36 (2%)  6 (0.4%)  
Pharyngolaryngeal Pain  32 (2%)  8 (0.5%)  
Sinusitis  26 (2%)  5 (0.3%)  
Epistaxis  25 (2%)  1 (0.06%)  
Pulmonary Hypertension  4 (0.2%)  0 (0%)  
Interstitial Pneumonitis  4 (0.2%)  0 (0%)  
Gastrointestinal Disorders  
Diarrhea  123 (7%)  16 (1%)  
Nausea  108 (6%)  19 (1%)  
Vomiting  58 (3.5%)  10 (0.6%)  
Constipation 33 (2%)  17 (1%) 
Dyspepsia  30 (2%)  9 (0.5%)  
Upper Abdominal Pain  29 (2%)  15 (1%)  
Musculoskeletal & Connective Tissue Disorders  
Arthralgia  137 (8%) 98 (6%) 
Back Pain 91 (5%)  58 (3%)  
Myalgia  63 (4%) 17 (1%) 
Bone Pain 49 (3%) 26 (2%) 
Muscle Spasm 46 (3%) 3 (0.2%) 
Nervous System Disorders  
Headache  162 (10%) 49 (3%) 
Paraesthesia  29 (2%) 11 (0.6%) 
Skin & Subcutaneous Tissue Disorders  
Rash  70 (4%) 10 (0.6%)  
Nail Disorders  43 (2%) 0 (0%) 
Prurit us 40 (2%) 10 (0.6%) 
 324 
 
11 Table 3 (cont’d) 
Adverse Reactions for Study 3a, All Gradesb 
Adverse Reaction One Year Herceptin  
(n = 1678)  Observation  
(n = 1708)  
General Disorders  
Pyrexia  100 (6%) 6 (0.4%) 
Edema Peripheral  79 (5%)  37 (2%)  
Chills  85 (5%)  0 (0%)  
Asthenia  75 (4.5%)  30 (2%)  
Influenza- like Illness  40 (2%) 3 (0.2%) 
Sudden Death  1 (0.06%) 0 (0%) 
Infections  
Nasopharyngitis  135 (8%)  43 (3%) 
UTI 39 (3%) 13 (0.8%) 
Immune System Disorders  
Hypersensitivity  10 (0.6%)  1 (0.06%)  
Autoimmune Thyroiditis  4 (0.3%) 0 (0%) 
 a Median follow- up duration of 12.6 months in the one -year Herceptin 
treatment arm.  
 b The incidence of Grade 3 or higher adverse reactions was <1% in both 
arms for each listed term. 
 c Higher level grouping term.  
 325 
 In Study 3, a comparison of 3-weekly Herceptin treatment for two years versus one year was also 326 
performed.  The rate of asymptomatic cardiac dysfunction was increased in the 2-year Herceptin 327 
treatment arm (8.1% versus 4.6% in the one-year Herceptin treatment arm).  More patients 328 
experienced at least one adverse reaction of Grade 3 or higher in the 2-year Herceptin treatment arm 329 
(20.4%) compared with the one-year Herceptin treatment arm (16.3%). 330 
 The safety data from Studies 1 and 2 were obtained from 3655 patients, of whom 2000 received 331 
Herceptin; the median treatment duration was 51 weeks.  The median age was 49 years (range: 332 
24−80); 84% of patients were White, 7% Black, 4% Hispanic, and 3% Asian.   333 
 In Study 1, only Grade 3−5 adverse events, treatment-related Grade 2 events, and Grade 2−5 334 
dyspnea were collected during and for up to 3 months following protocol-specified treatment.  The 335 
following non-cardiac adverse reactions of Grade 2 −5 occurred at an incidence of at least 2% greater 336 
among patients receiving Herceptin plus chemotherapy as compared to chemotherapy alone:  fatigue 337 
(29.5% vs. 22.4%), infection (24.0% vs. 12.8%), hot flashes (17.1% vs. 15.0%), anemia (12.3% vs. 338 
6.7%), dyspnea (11.8% vs. 4.6%), rash/desquamation (10.9% vs. 7.6%), leukopenia (10.5% vs. 339 
8.4%), neutropenia (6.4% vs. 4.3%), headache (6.2% vs. 3.8%), pain (5.5% vs. 3.0%), edema (4.7% 340 
vs. 2.7%), and insomnia (4.3% vs. 1.5%).  The majority of these events were Grade 2 in severity.  341 
 In Study 2, data collection was limited to the following investigator-attributed treatment-related 342 
adverse reactions: NCI-CTC Grade 4 and 5 hematologic toxicities, Grade 3−5 non-hematologic 343 
toxicities, selected Grade 2−5 toxicities associated with taxanes (myalgia, arthralgias, nail changes, 344 
motor neuropathy, and sensory neuropathy) and Grade 1−5 cardiac toxicities occurring during 345 
chemotherapy and/or Herceptin treatment.  The following non-cardiac adverse reactions of 346 
Grade 2−5 occurred at an incidence of at least 2% greater among patients receiving Herceptin plus 347 
chemotherapy as compared to chemotherapy alone:  arthralgia (12.2% vs. 9.1%), nail changes 348 
(11.5% vs. 6.8%), dyspnea (2.4% vs. 0.2%), and diarrhea (2.2% vs. 0%).  The majority of these 349 
events were Grade 2 in severity. 350 
 Safety data from Study 4 reflect exposure to Herceptin as part of an adjuvant treatment regimen 351 
from 2124 patients receiving at least one dose of study treatment [AC-TH: n  = 1068; TCH: n  = 1056].  352 
 
12 The overall median treatment duration was 54 weeks in both the AC-TH and TCH arms.  353 
The median number of infusions was 26 in the AC-TH arm and 30 in the TCH arm, including 354 
weekly infusions during the chemotherapy phase and every three week dosing in the monotherapy 355 
period.  Among these patients, the median age was 49 years (range 22 to 74 years).  In Study 4, the 356 
toxicity profile was similar to that reported in Studies 1, 2, and 3 with the exception of a low 357 
incidence of CHF in the TCH arm. 358 
Metastatic Breast Cancer Studies 359 
 The data below reflect exposure to Herceptin in one randomized, open-label study, Study 5, of 360 
chemotherapy with (n  = 235) or without (n  = 234) trastuzumab in patients with metastatic breast 361 
cancer, and one single-arm study (Study 6; n  = 222) in patients with metastatic breast cancer.  Data 362 
in Table 4 are based on Studies 5 and 6. 363 
 Among the 464 patients treated in Study 5, the median age was 52 years (range: 25−77 years).  364 
Eighty-nine percent were White, 5% Black, 1% Asian, and 5% other racial/ethnic groups.  365 
All patients received 4 mg/kg initial dose of Herceptin followed by 2 mg/kg weekly.  The 366 
percentages of patients who received Herceptin treatment for ≥ 6 months and ≥ 12 months were 58% 367 
and 9%, respectively. 368 
 Among the 352 patients treated in single agent studies (213 patients from Study 6), the median 369 
age was 50 years (range 28−86 years), 86% were White, 3% were Black, 3% were Asian, and 8% in 370 
other racial/ethnic groups.  Most of the patients received 4 mg/kg initial dose of Herceptin followed 371 
by 2 mg/kg weekly.  The percentages of patients who received Herceptin treatment for ≥ 6 months 372 
and ≥ 12 months were 31% and 16%, respectively. 373 
 374 
Table 4 
Per-Patient Incidence of Adverse Reactions Occurring in ≥ 5% of Patients in 
Uncontrolled Studies or at Increased Incidence in the Herceptin Arm (Studies 5 and 6)  
 Single Agenta 
n = 352 Herceptin + 
Paclitaxel  
n = 91 Paclitaxel 
Alone  
n = 95 Herceptin + 
ACb 
n = 143 ACb Alone  
n = 135 
Body as a Whole       
Pain 47% 61% 62% 57% 42% 
Asthenia  42% 62% 57% 54% 55% 
Fever  36% 49% 23% 56% 34% 
Chills  32% 41% 4% 35% 11% 
Headache  26% 36% 28% 44% 31% 
Abdominal pain  22% 34% 22% 23% 18% 
Back pain 22% 34% 30% 27% 15% 
Infection  20% 47% 27% 47% 31% 
Flu syndrome  10% 12% 5% 12% 6% 
Accidental injury 6% 13% 3% 9% 4% 
Allergic reaction  3% 8% 2% 4% 2% 
Cardiovascular       
Tachycardia  5% 12% 4% 10% 5% 
Congestive heart failure 7% 11% 1% 28% 7% 
 375 
 
13 Table 4 (cont’d) 
Per-Patient Incidence of Adverse Reactions Occurring in ≥ 5% of Patients in 
Uncontrolled Studies or at Increased Incidence in the Herceptin Arm (Studies 5 and 6)  
 Single Agenta 
n = 352 Herceptin + 
Paclitaxel  
n = 91 Paclitaxel 
Alone  
n = 95 Herceptin + 
ACb 
n = 143 ACb Alone  
n = 135 
Digestive       
Nausea  33% 51% 9% 76% 77% 
Diarrhea  25% 45% 29% 45% 26% 
Vomiting  23% 37% 28% 53% 49% 
Nausea and vomiting  8% 14% 11% 18% 9% 
Anorexia  14% 24% 16% 31% 26% 
Heme & Lymphatic       
Anemia  4% 14% 9% 36% 26% 
Leukopenia 3% 24% 17% 52% 34% 
Metabolic       
Peripheral edema  10% 22% 20% 20% 17% 
Edema  8% 10% 8% 11% 5% 
Musculoskeletal       
Bone pain 7% 24% 18% 7% 7% 
Arthralgia  6% 37% 21% 8% 9% 
Nervous       
Insomnia  14% 25% 13% 29% 15% 
Dizziness  13% 22% 24% 24% 18% 
Paresthesia  9% 48% 39% 17% 11% 
Depression  6% 12% 13% 20% 12% 
Peripheral neuritis  2% 23% 16% 2% 2% 
Neuropathy  1% 13% 5% 4% 4% 
Respiratory       
Cough increased 26% 41% 22% 43% 29% 
Dyspnea  22% 27% 26% 42% 25% 
Rhinitis  14% 22% 5% 22% 16% 
Pharyngitis  12% 22% 14% 30% 18% 
Sinusitis  9% 21% 7% 13% 6% 
Skin      
Rash  18% 38% 18% 27% 17% 
Herpes simplex  2% 12% 3% 7% 9% 
Acne  2% 11% 3% 3% < 1% 
Urogenital       
Urinary tract infection  5% 18% 14% 13% 7% 
 a Data for Herceptin single agent were from 4  studies, including 213  patients from Study  6. 
 b Anthracycline (doxorubicin or epirubicin) and cyclophosphamide. 
 376 
 Metastatic Gastric Cancer 377 
 The data below are based on the exposure of 294 patients to Herceptin in combination with a 378 
fluoropyrimidine (capecitabine or 5-FU) and cisplatin (Study 7).  In the Herceptin plus 379 
chemotherapy arm, the initial dose of Herceptin 8 mg/kg was administered on Day 1 (prior to 380 
 
14 chemotherapy) followed by 6 mg/kg every 21 days until disease progression.  Cisplatin was 381 
administered at 80 mg/m2 on Day 1 and the fluoropyrimidine was administered as either 382 
capecitabine 1000 mg/m2 orally twice a day on Days 1–14 or 5-fluorouracil 800 mg/m2/day as a 383 
continuous intravenous infusion Days 1 through 5.  Chemotherapy was administered for six 21-day 384 
cycles.  Median duration of Herceptin treatment was 21 weeks; median number of Herceptin 385 
infusions administered was eight. 386 
 387 
Table 5 
Study 7:  Per Patient Incidence of Adverse Reactions of All Grades  
(Incidence  ≥ 5% between Arms) or Grade 3/4 (Incidence >  1% between Arms)  
and Higher Incidence in Herceptin Arm 
Body System/Adverse Event  Herceptin  + FC   
(N = 294) 
N (%)  FC  
(N = 290)  
N (%)  
All Grades  Grades 3/4  All Grades  Grades 3/4  
Investigations  
Neutropenia  230 (78)  101 (34)  212 (73)  83 (29)  
Hypokalemia  83 (28)  28 (10)  69 (24)  16 (6)  
Anemia  81 (28)  36 (12)  61 (21)  30 (10)  
Thrombocytopenia  47 (16)  14 (5)  33 (11)  8 (3)  
Blood and Lymphatic System Disorders  
Febrile Neutropenia  ⎯ 15 (5)  ⎯ 8 (3)  
Gastrointestinal Disorders  
Diarrhea  109 (37)  27 (9)  80 (28)  11 (4)  
Stomatitis  72 (24)  2 (1)  43 (15)  6 (2)  
Dysphagia  19 (6)  7 (2)  10 (3)  1 (≤ 1) 
Body as a Whole  
Fatigue  102 (35)  12 (4) 82 (28)  7 (2)  
Fever  54 (18)  3 (1)  36 (12)  0 (0)  
Mucosal Inflammation  37 (13)  6 (2)  18 (6)  2 (1)  
Chills  23 (8)  1 (≤ 1) 0 (0)  0 (0)  
Metabolism and Nutrition Disorders  
Weight Decrease  69 (23)  6 (2)  40 (14)  7 (2)  
Infections and Infestations 
Upper Respiratory Tract Infections  56 (19)  0 (0)  29 (10)  0 (0)  
Nasopharyngitis  37 (13)  0 (0)  17 (6)  0 (0)  
Renal and Urinary Disorders 
Renal Failure and Impairment  53 (18)  8 (3)  42 (15)  5 (2)  
Nervous System Disorders  
Dysgeusia  28 (10)  0 (0)  14 (5)  0 (0)  
 388 
 
15  The following subsections provide additional detail regarding adverse reactions observed in 389 
clinical trials of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, or 390 
post-marketing experience. 391 
Cardiomyopathy 392 
 Serial measurement of cardiac function (LVEF) was obtained in clinical trials in the adjuvant 393 
treatment of breast cancer.  In Study 3, the median duration of follow-up was 12.6 months 394 
(12.4 months in the observation arm; 12.6 months in the 1-year Herceptin arm); and in Studies 1 and 395 
2, 7.9 years in the AC-T arm, 8.3 years in the AC-TH arm.  In Studies 1 and 2, 6% of all randomized 396 
patients with post-AC LVEF evaluation were not permitted to initiate Herceptin following 397 
completion of AC chemotherapy due to cardiac dysfunction (LVEF < LLN or ≥ 16 point decline in 398 
LVEF from baseline to end of AC).  Following initiation of Herceptin therapy, the incidence of 399 
new-onset dose-limiting myocardial dysfunction was higher among patients receiving Herceptin and 400 
paclitaxel as compared to those receiving paclitaxel alone in Studies 1 and 2, and in patients 401 
receiving one-year Herceptin monotherapy compared to observation in Study 3 (see Table 6, 402 
Figures 1 and 2).  The per-patient incidence of new-onset cardiac dysfunction, as measured by 403 
LVEF, remained similar  when compared to the analysis performed at a median follow-up of 2.0 404 
years in the AC-TH arm.  This analysis also showed evidence of reversibility of left ventricular 405 
dysfunction, with 64.5% of patients who experienced symptomatic CHF in the AC-TH group being 406 
asymptomatic at latest follow-up, and 90.3% having full or partial LVEF recovery. 407 
 408 
 
16 Table 6a  
Per-patient Incidence of New Onset  
Myocardial Dysfunction (by LVEF) Studies 1, 2, 3 and 4 
 LVEF < 50%  
and Absolute Decrease from Baseline   Absolute LVEF Decrease  
 LVEF 
< 50% ≥ 10% 
decrease ≥ 16% 
decrease < 20% and ≥ 10% ≥ 20% 
Studies 1 & 2b,c  
AC→TH 
(n = 1856) 23.1% 
(428) 18.5% 
(344) 11.2% 
(208) 37.9% 
(703) 8.9% 
(166) 
AC→T 
(n = 1170) 11.7% 
(137) 7.0% 
(82) 3.0% 
(35) 22.1% 
(259) 3.4% 
(40) 
Study 3d 
Herceptin  
(n = 1678)  8.6%  
(144)  7.0%  
(118)  3.8%  
(64) 22.4%  
(376)  3.5%  
(59) 
Observation  
(n = 1708)  2.7%  
(46) 2.0%  
(35) 1.2%  
(20) 11.9%  
(204)  1.2%  
(21) 
Study 4e 
TCH  
(n = 1056)  8.5%  
(90) 5.9%  
(62) 3.3%  
(35) 34.5%  
(364)  6.3%  
(67) 
AC→TH 
(n = 1068)  17% 
(182) 13.3%  
(142) 9.8% 
(105) 44.3% 
(473) 13.2% 
(141) 
AC→T 
(n = 1050)  9.5% 
(100) 6.6% 
(69) 3.3% 
(35) 34% 
(357) 5.5% 
(58) 
 a For Studies 1, 2 and 3, events are counted from the beginning of Herceptin treatment.  For 
Study 4, events are counted from the date of randomization.  
 b Studies 1 and 2 regimens: doxorubicin and cyclophosphamide followed by paclitaxel 
(AC→T) or paclitaxel plus Herceptin (AC →TH). 
   c Median duration of follow -up for Studies 1 and 2 combined was 8.3 years in the AC→ TH 
arm. 
  d  Median follow- up duration of 12.6 months in the one -year Herceptin treatment arm.  
  e Study 4 regimens: doxorubici n and cyclophosphamide followed by docetaxel (AC →T) or 
docetaxel plus Herceptin (AC →TH); docetaxel and carboplatin plus Herceptin (TCH) . 
 
 409 
 
17 Figure 1  410 
Studies 1 and 2:  Cumulative Incidence of Time to First LVEF  411 
Decline of ≥ 10 Percentage Points from Baseline and to  412 
Below 50% with Death as a Competing Risk Event 413 
 414 
 415 
Time 0 is initiation of paclitaxel or Herceptin + paclitaxel therapy.  416 
 417 

 
18 Figure 2  418 
Study 3:  Cumulative Incidence of Time to First LVEF  419 
Decline of ≥ 10 Percentage Points from Baseline and to  420 
Below 50% with Death as a Competing Risk Event 421 
 422 
Time 0 is the date of randomization. 423 
 424 
Figure 3 425 
Study 4:  Cumulative Incidence of Time to First LVEF  426 
Decline of ≥ 10 Percentage Points from Baseline and to  427 
Below 50% with Death as a Competing Risk Event 428 
 429 
Time 0 is the date of randomization. 430 
 431 

 
19  The incidence of treatment emergent congestive heart failure among patients in the metastatic  432 
breast cancer trials was classified for severity using the New York Heart Association classification 433 
system (I−IV, where IV is the most severe level of cardiac failure) (see Table 2).  In the metastatic 434 
breast cancer trials, the probability of cardiac dysfunction was highest in patients who received 435 
Herceptin concurrently with anthracyclines. 436 
 In Study 7, 5.0% of patients in the Herceptin plus chemotherapy arm compared to 1.1% of 437 
patients in the chemotherapy alone arm had LVEF value below 50% with a  ≥ 10% absolute decrease 438 
in LVEF from pretreatment values. 439 
Infusion Reactions 440 
 During the first infusion with Herceptin, the symptoms most commonly reported were chills and 441 
fever, occurring in approximately 40% of patients in clinical trials.  Symptoms were treated with 442 
acetaminophen, diphenhydramine, and meperidine (with or without reduction in the rate of 443 
Herceptin infusion); permanent discontinuation of Herceptin for infusion reactions was required in 444 
< 1% of patients.  Other signs and/or symptoms may include nausea, vomiting, pain (in some cases 445 
at tumor sites), rigors, headache, dizziness, dyspnea, hypotension, elevated blood pressure, rash, and 446 
asthenia.  Infusion reactions occurred in 21% and 35% of patients, and were severe in 1.4% and 9% 447 
of patients, on second or subsequent Herceptin infusions administered as monotherapy or in 448 
combination with chemotherapy, respectively.  In the post-marketing setting, severe infusion 449 
reactions, including hypersensitivity, anaphylaxis, and angioedema have been reported.   450 
Anemia 451 
 In randomized controlled clinical trials, the overall incidence of anemia (30% vs. 21% [Study 5]), 452 
of selected NCI-CTC Grade 2–5 anemia (12.3% vs. 6.7% [Study 1]), and of anemia requiring 453 
transfusions (0.1% vs. 0 patients [Study 2]) were increased in patients receiving Herceptin and 454 
chemotherapy compared with those receiving chemotherapy alone.  Following the administration of 455 
Herceptin as a single agent (Study 6), the incidence of NCI-CTC Grade 3 anemia was < 1%.  In 456 
Study 7 (metastatic gastric cancer), on the Herceptin containing arm as compared to the 457 
chemotherapy alone arm, the overall incidence of anemia was 28% compared to 21% and of NCI- 458 
CTC Grade 3/4 anemia was 12.2% compared to 10.3%. 459 
Neutropenia 460 
 In randomized controlled clinical trials in the adjuvant setting, the incidence of selected 461 
NCI-CTC Grade 4−5 neutropenia (1.7% vs. 0.8% [Study 2]) and of selected Grade 2−5 neutropenia 462 
(6.4% vs. 4.3% [Study 1]) were increased in patients receiving Herceptin and chemotherapy 463 
compared with those receiving chemotherapy alone.  In a randomized, controlled trial in patients 464 
with metastatic breast cancer, the incidences of NCI-CTC Grade 3/4 neutropenia (32% vs. 22%) and 465 
of febrile neutropenia (23% vs. 17%) were also increased in patients randomized to Herceptin in 466 
combination with myelosuppressive chemotherapy as compared to chemotherapy alone.  In Study 7 467 
(metastatic gastric cancer) on the Herceptin containing arm as compared to the chemotherapy alone 468 
arm, the incidence of NCI-CTC Grade 3/4 neutropenia was 36.8% compared to 28.9%; febrile 469 
neutropenia 5.1% compared to 2.8%. 470 
Infection 471 
 The overall incidences of infection (46% vs. 30% [Study 5]), of selected NCI-CTC Grade 2−5 472 
infection/febrile neutropenia (24.3% vs. 13.4% [Study 1]) and of selected Grade 3−5 473 
infection/febrile neutropenia (2.9% vs. 1.4%) [Study 2]) were higher in patients receiving Herceptin 474 
and chemotherapy compared with those receiving chemotherapy alone.  The most common site of 475 
infections in the adjuvant setting involved the upper respiratory tract, skin, and urinary tract. 476 
 In Study 4, the overall incidence of infection was higher with the addition of Herceptin to AC-T 477 
but not to TCH [44% (AC-TH), 37% (TCH), 38% (AC-T)].  The incidences of NCI-CTC Grade 3−4 478 
infection were similar [25% (AC-TH), 21% (TCH), 23% (AC-T)] across the three arms. 479 
 
20  In a randomized, controlled trial in treatment of metastatic breast cancer, the reported incidence of 480 
febrile neutropenia was higher (23% vs. 17%) in patients receiving Herceptin in combination with 481 
myelosuppressive chemotherapy as compared to chemotherapy alone. 482 
Pulmonary Toxicity 483 
Adjuvant Breast Cancer 484 
 Among women receiving adjuvant therapy for breast cancer, the incidence of selected NCI-CTC 485 
Grade 2−5 pulmonary toxicity (14.3% vs. 5.4% [Study 1]) and of selected NCI-CTC Grade 3−5 486 
pulmonary toxicity and spontaneous reported Grade 2 dyspnea (3.4% vs. 0.9% [Study 2]) was higher 487 
in patients receiving Herceptin and chemotherapy compared with chemotherapy alone.  The most 488 
common pulmonary toxicity was dyspnea (NCI-CTC Grade 2−5:  11.8% vs. 4.6% [Study 1]; 489 
NCI-CTC Grade 2−5:  2.4% vs. 0.2% [Study 2]). 490 
 Pneumonitis/pulmonary infiltrates occurred in 0.7% of patients receiving Herceptin compared 491 
with 0.3% of those receiving chemotherapy alone.  Fatal respiratory failure occurred in 3 patients 492 
receiving Herceptin, one as a component of multi-organ system failure, as compared to 1 patient 493 
receiving chemotherapy alone. 494 
 In Study 3, there were 4 cases of interstitial pneumonitis in the one-year Herceptin treatment arm 495 
compared to none in the observation arm at a median follow-up duration of 12.6 months. 496 
Metastatic  Breast Cancer 497 
 Among women receiving Herceptin for treatment of metastatic breast cancer, the incidence of 498 
pulmonary toxicity was also increased.  Pulmonary adverse events have been reported in the 499 
post-marketing experience as part of the symptom complex of infusion reactions.  Pulmonary events 500 
include bronchospasm, hypoxia, dyspnea, pulmonary infiltrates, pleural effusions, non-cardiogenic 501 
pulmonary edema, and acute respiratory distress syndrome.  For a detailed description, see Warnings 502 
and Precautions (5.4). 503 
Thrombosis/Embolism 504 
 In 4 randomized, controlled clinical trials, the incidence of thrombotic adverse events was higher 505 
in patients receiving Herceptin and chemotherapy compared to chemotherapy alone in three studies 506 
(2.6% vs. 1.5% [Study 1], 2.5% and 3.7% vs. 2.2% [Study 4] and 2.1% vs. 0% [Study 5]). 507 
Diarrhea 508 
 Among women receiving adjuvant therapy for breast cancer, the incidence of NCI-CTC 509 
Grade 2−5 diarrhea (6.7% vs. 5.4% [Study 1]) and of NCI-CTC Grade 3−5 diarrhea (2.2% vs. 0% 510 
[Study 2]), and of Grade 1−4 diarrhea (7% vs. 1% [Study 3; one-year Herceptin treatment at 511 
12.6  months median duration of follow-up]) were higher in patients receiving Herceptin as compared 512 
to controls.  In Study 4, the incidence of Grade 3−4 diarrhea was higher [5.7% AC-TH, 5.5% TCH 513 
vs. 3.0% AC-T] and of Grade 1−4 was higher [51% AC-TH, 63% TCH vs. 43% AC-T] among 514 
women receiving Herceptin.  Of patients receiving Herceptin as a single agent for the treatment of 515 
metastatic breast cancer, 25% experienced diarrhea.  An increased incidence of diarrhea was 516 
observed in patients receiving Herceptin in combination with chemotherapy for treatment of 517 
metastatic breast cancer. 518 
Renal Toxicity 519 
 In Study 7 (metastatic gastric cancer) on the Herceptin-containing arm as compared to the 520 
chemotherapy alone arm the incidence of renal impairment was 18% compared to 14.5%.  Severe 521 
(Grade 3/4) renal failure was 2.7% on the Herceptin-containing arm compared to 1.7% on the 522 
chemotherapy only arm.  Treatment discontinuation for renal insufficiency/failure was 2% on the 523 
Herceptin-containing arm and 0.3% on the chemotherapy only arm.  524 
 In the post-marketing setting, rare cases of nephrotic syndrome with pathologic evidence of 525 
glomerulopathy have been reported.  The time to onset ranged from 4 months to approximately 526 
18 months from initiation of Herceptin therapy.  Pathologic findings included membranous 527 
 
21 glomerulonephritis, focal glomerulosclerosis, and fibrillary glomerulonephritis.  Complications 528 
included volume overload and congestive heart failure. 529 
6.2 Immunogenicity 530 
 As with all therapeutic proteins, there is a potential for immunogenicity.  Among 903 women with 531 
metastatic breast cancer, human anti-human antibody (HAHA) to Herceptin was detected in one 532 
patient using an enzyme-linked immunosorbent assay (ELISA).  This patient did not experience an 533 
allergic reaction.  Samples for assessment of HAHA were not collected in studies of adjuvant breast 534 
cancer. 535 
 The incidence of antibody formation is highly dependent on the sensitivity and the specificity of 536 
the assay.  Additionally, the observed incidence of antibody (including neutralizing antibody) 537 
positivity in an assay may be influenced by several factors including assay methodology, sample 538 
handling, timing of sample collection, concomitant medications, and underlying disease.  For these 539 
reasons, comparison of the incidence of antibodies to Herceptin with the incidence of antibodies to 540 
other products may be misleading. 541 
6.3 Post-Marketing Experience 542 
 The following adverse reactions have been identified during post-approval use of Herceptin.  543 
Because these reactions are reported voluntarily from a population of uncertain size, it is not always 544 
possible to reliably estimate their frequency or establish a causal relationship to drug exposure. 545 
• Infusion reaction [see Warnings and Precautions (5.2)]  546 
• Oligohydramnios or oligohydramnios sequence, including pulmonary hypoplasia, skeletal 547 
abnormalities, and neonatal death [see Warnings and Precautions (5.3)]  548 
• Glomerulopathy [see Adverse Reactions (6.1)]  549 
• Immune thrombocytopenia 550 
 551 
7 DRUG INTERACTIONS 552 
  Patients who receive anthracycline after stopping Herceptin may be at increased risk of cardiac 553 
dysfunction because of trastuzumab’s long washout period based on population PK analysis [see 554 
Clinical Pharmacology (12.3)] .  If possible, physicians should avoid anthracycline-based therapy for 555 
up to 7 months after stopping Herceptin.  If anthracyclines are used, the patient’s cardiac function 556 
should be monitored carefully. 557 
 558 
8 USE IN SPECIFIC POPULATIONS 559 
8.1  Pregnancy  560 
Pregnancy Exposure Registry and Pharmacovigilance Program 561 
 There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to 562 
Herceptin during pregnancy.  Encourage women who receive Herceptin during pregnancy or within 563 
7 months prior to conception to enroll in the MotHER Pregnancy Registry by contacting 1-800-690- 564 
6720 or visiting http://www.motherpregnancyregistry.com/.   565 
In addition, there is a pregnancy pharmacovigilance program for Herceptin.  If Herceptin is 566 
administered during pregnancy, or if a patient becomes pregnant while receiving Herceptin or within 567 
7 months following the last dose of Herceptin, health care providers and patients should immediately 568 
report Herceptin exposure to Genentech at 1-888-835-2555. 569 
Risk Summary 570 
  Herceptin can cause fetal harm when administered to a pregnant woman.  In post-marketing 571 
reports, use of Herceptin during pregnancy resulted in cases of oligohydramnios and of 572 
oligohydramnios sequence, manifesting as pulmonary hypoplasia, skeletal abnormalities, and 573 
neonatal death [see Data].  Apprise the patient of the potential risks to a fetus.  There are clinical 574 
 
22 considerations if Herceptin is used in a pregnant woman or if a patient becomes pregnant within 7 575 
months following the last dose of Herceptin [see Clinical Considerations]. 576 
  The estimated background risk of major birth defects and miscarriage for the indicated population 577 
is unknown.  In the U.S. general population, the estimated background risk of major birth defects 578 
and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.   579 
Clinical Considerations 580 
Fetal/Neonatal Adverse Reactions 581 
 Monitor women who received Herceptin during pregnancy or within 7 months prior to conception 582 
for oligohydramnios.  If oligohydramnios occurs, perform fetal testing that is appropriate for 583 
gestational age and consistent with community standards of care.   584 
Data  585 
Human Data 586 
 In post-marketing reports, use of Herceptin during pregnancy resulted in cases of oligohydramnios 587 
and of oligohydramnios sequence, manifesting in the fetus as pulmonary hypoplasia, skeletal 588 
abnormalities, and neonatal death.  These case reports described oligohydramnios in pregnant 589 
women who received Herceptin either alone or in combination with chemotherapy.  In some case 590 
reports, amniotic fluid index increased after Herceptin was stopped.  In one case, Herceptin therapy 591 
resumed after amniotic index improved and oligohydramnios recurred. 592 
Animal Data 593 
 In studies where trastuzumab was administered to pregnant Cynomolgus monkeys during the 594 
period of organogenesis at doses up to 25 mg/kg given twice weekly (up to 25 times the 595 
recommended weekly human dose of 2 mg/kg), trastuzumab crossed the placental barrier during the 596 
early (Gestat ion Days 20 to 50) and late (Gestation Days 120 to 150) phases of gestation.  The 597 
resulting concentrations of trastuzumab in fetal serum and amniotic fluid were approximately 33% 598 
and 25%, respectively, of those present in the maternal serum but were not associated with adverse 599 
developmental effects.  600 
8.2 Lactation 601 
Risk Summary    602 
 There is no information regarding the presence of trastuzumab in human milk, the effects on the 603 
breastfed infant, or the effects on milk production.  Published data suggest human IgG is present in 604 
human milk but does not enter the neonatal and infant circulation in substantial amounts.  605 
Trastuzumab was present in the milk of lactating Cynomolgus monkeys but not associated with 606 
neonatal toxicity [see Data] .  Consider the developmental and health benefits of breastfeeding along 607 
with the mother’s clinical need for Herceptin treatment and any potential adverse effects on the 608 
breastfed child from Herceptin or from the underlying maternal condition. This consideration should 609 
also take into account the trastuzumab wash out period of 7 months [see Clinical Pharmacology 610 
(12.3)].  611 
Data  612 
 In lactating Cynomolgus monkeys, trastuzumab was present in breast milk at about 0.3% of 613 
maternal serum concentrations after pre- (beginning Gestation Day 120) and post-partum (through 614 
Post-partum Day 28) doses of 25 mg/kg administered twice weekly (25 times the recommended 615 
weekly human dose of 2 mg/kg of Herceptin).  Infant monkeys with detectable serum levels of 616 
trastuzumab did not exhibit any adverse effects on growth or development from birth to 1 month of 617 
age.  618 
  619 
 
23 8.3  Females and Males of Reproductive Potential  620 
Pregnancy Testing 621 
 Verify the pregnancy status of females of reproductive potential prior to the initiation of 622 
Herceptin.   623 
Contraception 624 
Females 625 
 Herceptin can cause embryo-fetal harm when administered during pregnancy. Advise females of 626 
reproductive potential to use effective contraception during treatment with Herceptin and for 7 627 
months following the last dose of Herceptin [see Use in Specific Populations (8.1) and Clinical 628 
Pharmacology (12.3)].   629 
8.4 Pediatric Use 630 
 The safety  and effectiveness of Herceptin in pediatric patients have not been established. 631 
8.5 Geriatric Use 632 
 Herceptin has been administered to 386 patients who were 65 years of age or over (253 in the 633 
adjuvant treatment and 133 in metastatic breast cancer treatment settings).  The risk of cardiac 634 
dysfunction was increased in geriatric patients as compared to younger patients in both those 635 
receiving treatment for metastatic disease in Studies 5 and 6, or adjuvant therapy in Studies 1 and 2.  636 
Limitations in data collection and differences in study design of the 4 studies of Herceptin in 637 
adjuvant treatment of breast cancer preclude a determination of whether the toxicity profile of 638 
Herceptin in older patients is different from younger patients.  The reported clinical experience is not 639 
adequate to determine whether the efficacy improvements (ORR, TTP, OS, DFS) of Herceptin 640 
treatment in older patients is different from that observed in patients < 65 years of age for metastatic 641 
disease and adjuvant treatment. 642 
 In Study 7 (metastatic gastric cancer), of the 294 patients treated with Herceptin, 108 (37%) were 643 
65 years of age or older, while 13 (4.4%) were 75 and over.  No overall differences in safety or 644 
effectiveness were observed. 645 
 646 
10 OVERDOSAGE 647 
 There is no experience with overdosage in human clinical trials.  Single doses higher than 8 mg/kg 648 
have not been tested. 649 
 650 
11 DESCRIPTION 651 
 Herceptin (trastuzumab) is a humanized IgG1 kappa monoclonal antibody that selectively binds 652 
with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 653 
protein, HER2.  Trastuzumab is produced by recombinant DNA technology in a mammalian cell 654 
(Chinese Hamster Ovary) culture containing the antibiotic gentamicin.  Gentamicin is not detectable 655 
in the final product. 656 
 Herceptin (trastuzumab) is a sterile, white to pale yellow, preservative-free lyophilized powder for 657 
Injection, for intravenous administration.   658 
 Each multiple-dose vial of Herceptin delivers 420 mg trastuzumab, 381.8 mg α,α-trehalose 659 
dihydrate, 9.5 mg L-histidine HCl monohydrate, 6.1 mg L-histidine, and 1.7 mg polysorbate 20.  660 
Reconstitution with 20 mL of the appropriate diluent (BWFI or SWFI) yields a solution containing 661 
21 mg/mL trastuzumab at a pH of approximately 6.   If Herceptin is reconstituted with SWFI without 662 
preservative, the reconstituted solution is considered single-dose. 663 
 Each single-dose vial of Herceptin delivers 150 mg trastuzumab, 136.2 mg α,α-trehalose 664 
dihydrate, 3.4 mg L-histidine HCl monohydrate, 2.2 mg L-histidine, and 0.6 mg polysorbate 20. 665 
Reconstitution with 7.4 mL of sterile water for injection (SWFI) yields a solution containing 21 666 
mg/mL trastuzumab that delivers 7.15 mL (150 mg trastuzumab), at a pH of approximately 6. 667 
 
24  668 
12 CLINICAL PHARMACOLOGY 669 
12.1 Mechanism of Action 670 
 The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, 671 
which is structurally related to the epidermal growth factor receptor.  Herceptin has been shown, in 672 
both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress 673 
HER2. 674 
 Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC).  In vitro , 675 
Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing 676 
cancer cells compared with cancer cells that do not overexpress HER2. 677 
12.2 Pharmacodynamics 678 
Cardiac Electrophysiology 679 
 The effects of trastuzumab on electrocardiographic (ECG) endpoints, including QTc interval 680 
duration, were evaluated in patients with HER2 positive solid tumors. Trastuzumab had no clinically 681 
relevant effect on the QTc interval duration and there was no apparent relationship between serum 682 
trastuzumab concentrations and change in QTcF interval duration in patients with HER2 positive 683 
solid tumors.  684 
12.3 Pharmacokinetics 685 
 The pharmacokinetics of trastuzumab was evaluated in a pooled population pharmacokinetic (PK) 686 
model analysis of 1,582 subjects with primarily breast cancer and metastatic gastric cancer (MGC) 687 
receiving intravenous Herceptin.  Total trastuzumab clearance increases with decreasing 688 
concentrations due to parallel linear and non-linear elimination pathways.  689 
 Although the average trastuzumab exposure was higher following the first cycle in breast cancer 690 
patients receiving the three-weekly schedule compared to the weekly schedule of Herceptin, the 691 
average steady-state exposure was essentially the same at both dosages. The average trastuzumab 692 
exposure following the first cycle and at steady state as well as the time to steady state was higher in 693 
breast cancer patients compared to MGC patients at the same dosage; however, the reason for this 694 
exposure difference is unknown. Additional predicted trastuzumab exposure and PK parameters 695 
following the first Herceptin cycle and at steady state exposure are described in Tables 7 and 8, 696 
respectively. 697 
 Population PK based simulations indicate that following discontinuation of Herceptin, 698 
concentrations in at least 95% of breast cancer and MGC patients will decrease to approximately 3% 699 
of the population predicted steady-state trough serum concentration (approximately 97% washout) 700 
by 7 months [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1, 8.3)] . 701 
 702 
Table 7 703 
Population Predicted Cycle 1 PK Exposures (Median with  5th – 95th Percentiles) in Breast Cancer 704 
and MGC Patients  705 
Schedule  Primary tumor 
type N Cmin 
(µg/mL) Cmax 
(µg/mL) AUC 0-21days 
(µg.day/mL)  
8 mg/kg +  
6 mg/kg q3w  Breast cancer  1195 
 29.4 
(5.8 - 59.5) 178 
(117 - 291) 1373 
(736 - 2245)  
MGC 274 
 23.1 
(6.1 - 50.3) 132 
(84.2 - 225) 1109 
(588 - 1938)  
4 mg/kg +  
2 mg/kg qw  Breast cancer  1195 
 37.7 
(12.3 - 70.9) 88.3 
(58 - 144) 1066 
(586 - 1754)  
 706 
 
25 Table 8 707 
Population Predicted Steady State PK Exposures (Median with 5th - 95th Percentiles) in Breast 708 
Cancer and MGC Patients  709 
Schedule  Primary 
tumor type N Cmin,ssa
 
(µg/mL) Cmax,ssb
 
(µg/mL) AUC ss, 0-21 days  
(µg.day/mL)  Time to  
steady-
state 
(week) Total CL 
range at 
steady- state   
(L/day) 
8 mg/kg +  
6 mg/kg 
q3w 
 Breast 
cancer  1195 
 47.4 
(5 - 115) 179 
(107 - 309) 1794 
(673 - 3618)  12 
 0.173 - 0.283 
 
MGC 274 
 32.9 
(6.1 - 88.9)  131 
(72.5 - 251) 1338 
(557 - 2875)  9 
 0.189 - 0.337 
 
4 mg/kg +  
2 mg/kg qw  Breast 
cancer  1195 
 66.1 
(14.9 - 142) 109 
(51.0 - 209) 1765 
(647 - 3578)  12 
 0.201 - 0.244 
 
   a Steady -state trough serum concentration of trastuzumab  710 
   b Maximum steady -state serum concentration of trastuzumab  711 
 712 
Specific Populations 713 
Based on a population pharmacokinetic analysis, no clinically significant differences were observed 714 
in the pharmacokinetics of trastuzumab based on age (< 65 (n = 1294); ≥ 65 (n = 288)), race (Asian 715 
(n = 264); non-Asian (n = 1324)) and renal impairment (mild (creatinine clearance [CLcr] 60 to 716 
90 mL/min) (n = 636) or moderate (CLcr 30 to 60 mL/min) (n = 133)).  The pharmacokinetics of 717 
trastuzumab in patients with severe renal impairment, end-stage renal disease with or without 718 
hemodialysis, or hepatic impairment is unknown. 719 
Drug Interaction Studies  720 
There have been no formal drug interaction studies performed with Herceptin in humans. Clinically 721 
significant interactions between Herceptin and concomitant medications used in clinical trials have 722 
not been observed. 723 
Paclitaxel and doxorubicin: Concentrations of paclitaxel and doxorubicin and their major 724 
metabolites (i.e., 6-α hydroxyl-paclitaxel [POH], and doxorubicinol [DOL], respectively) were not 725 
altered in the presence of trastuzumab when used as combination therapy in clinical trials. 726 
Trastuzumab concentrations were not altered as part of this combination therapy. 727 
Docetaxel and carboplatin: When Herceptin was administered in combination with docetaxel or 728 
carboplatin, neither the plasma concentrations of docetaxel or carboplatin nor the plasma 729 
concentrations of trastuzumab were altered.   730 
Cisplatin and capecitabine: In a drug interaction substudy conducted in patients in Study 7, the 731 
pharmacokinetics of cisplatin, capecitabine and their metabolites were not altered when administered 732 
in combination with Herceptin. 733 
 734 
13 NONCLINICAL TOXICOLOGY 735 
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 736 
 Herceptin has not been tested for carcinogenic potential. 737 
 No evidence of mutagenic activity was observed when trastuzumab was tested in the standard 738 
Ames bacterial and human peripheral blood lymphocyte mutagenicity assays at concentrations of up 739 
to 5000 mcg/mL.  In an in vivo micronucleus assay, no evidence of chromosomal damage to mouse 740 
bone marrow cells was observed following bolus intravenous doses of up to 118 mg/kg of 741 
trastuzumab. 742 
 
26  A fertility study was conducted in female Cynomolgus monkeys at doses up to 25 times the 743 
weekly recommended human dose of 2 mg/kg of trastuzumab and has revealed no evidence of 744 
impaired fertility, as measured by menstrual cycle duration and female sex hormone levels. 745 
 746 
14 CLINICAL STUDIES 747 
14.1 Adjuvant Breast Cancer 748 
 The safety and efficacy of Herceptin in women receiving adjuvant chemotherapy for HER2 749 
overexpressing breast cancer were evaluated in an integrated analysis of two randomized, 750 
open-label, clinical trials (Studies 1 and 2) with a total of 4063 women at the protocol-specified final 751 
overall survival analysis, a third randomized, open-label, clinical trial (Study 3) with a total of 752 
3386 women at definitive Disease-Free Survival analysis for one-year Herceptin treatment versus 753 
observation, and a fourth randomized, open-label clinical trial with a total of 3222 patients (Study 4). 754 
Studies 1 and 2 755 
 In Studies 1 and 2, breast tumor specimens were required to show HER2 overexpression (3+ by 756 
IHC) or gene amplification (by FISH).  HER2 testing was verified by a central laboratory prior to 757 
randomization (Study 2) or was required to be performed at a reference laboratory (Study 1).  758 
Patients with a history of active cardiac disease based on symptoms, abnormal electrocardiographic, 759 
radiologic, or left ventricular ejection fraction findings or uncontrolled hypertension 760 
(diastolic > 100 mm Hg or systolic > 200 mm Hg) were not eligible. 761 
 Patients were randomized (1:1) to receive doxorubicin and cyclophosphamide followed by 762 
paclitaxel (AC→paclitaxel) alone or paclitaxel plus Herceptin (AC →paclitaxel + Herceptin).  763 
In both trials, patients received four 21-day cycles of doxorubicin 60 mg/m2 and cyclophosphamide 764 
600 mg/m2.  Paclitaxel was administered either weekly (80 mg/m2) or every 3 weeks (175 mg/m2) 765 
for a total of 12 weeks in Study 1; paclitaxel was administered only by the weekly schedule in 766 
Study 2.  Herceptin was administered at 4 mg/kg on the day of initiation of paclitaxel and then at a 767 
dose of 2 mg/kg weekly for a total of 52 weeks.  Herceptin treatment was permanently discontinued 768 
in patients who developed congestive heart failure, or persistent/recurrent LVEF decline [see 769 
Dosage and Administration (2.3)] .  Radiation therapy, if administered, was initiated after the 770 
completion of chemotherapy.  Patients with ER+ and/or PR+ tumors received hormonal therapy.  771 
The primary endpoint of the combined efficacy analysis was Disease -Free Survival (DFS), defined 772 
as the time from randomization to recurrence, occurrence of contralateral breast cancer, other second 773 
primary cancer, or death.  The secondary endpoint was overall survival (OS). 774 
 A total of 3752 patients were included in the joint efficacy analysis of the primary endpoint of 775 
DFS following a median follow-up of 2.0 years in the AC→paclitaxel + Herceptin arm.  The 776 
pre-planned final OS analysis from the joint analysis included 4063 patients and was performed 777 
when 707 deaths had occurred after a median follow-up of 8.3 years in the AC→paclitaxel + 778 
Herceptin arm.  The data from both arms in Study 1 and two of the three study arms in Study 2 were 779 
pooled for efficacy analyses.  The patients included in the primary DFS analysis had a median age of 780 
49 years (range, 22−80 years; 6% > 65 years), 84% were white, 7% black, 4% Hispanic, and 4% 781 
Asian/Pacific Islander.  Disease characteristics included 90% infiltrating ductal histology, 38% T1, 782 
91% nodal involvement, 27% intermediate and 66% high grade pathology, and 53% ER+ and/or 783 
PR+ tumors.  Similar demographic and baseline characteristics were reported for the efficacy 784 
evaluable population, after 8.3 years of median follow-up in the AC→paclitaxel + Herceptin arm.  785 
Study 3 786 
 In Study 3, breast tumor specimens were required to show HER2 overexpression (3+ by IHC) or 787 
gene amplification (by FISH) as determined at a central laboratory.  Patients with node-negative 788 
disease were required to have ≥ T1c primary tumor.  Patients with a history of congestive heart 789 
failure or LVEF <  55%, uncontrolled arrhythmias, angina requiring medication, clinically significant 790 
 
27 valvular heart disease, evidence of transmural infarction on ECG, poorly controlled hypertension 791 
(systolic > 180 mm Hg or diastolic > 100 mm Hg) were not eligible. 792 
 Study 3 was designed to compare one and two years of three-weekly Herceptin treatment versus 793 
observation in patients with HER2 positive EBC following surgery, established chemotherapy and 794 
radiotherapy (if applicable).  Patients were randomized (1:1:1) upon completion of definitive 795 
surgery, and at least four cycles of chemotherapy to receive no additional treatment, or one year of 796 
Herceptin treatment or two years of Herceptin treatment.  Patients undergoing a lumpectomy had 797 
also completed standard radiotherapy.  Patients with ER+ and/or PgR+ disease received systemic 798 
adjuvant hormonal therapy at investigator discretion.  Herceptin was administered with an initial 799 
dose of 8 mg/kg followed by subsequent doses of 6 mg/kg once every three weeks.  The main 800 
outcome measure was Disease -Free Survival (DFS), defined as in Studies 1 and 2. 801 
 A protocol specified interim efficacy analysis comparing one-year Herceptin treatment to 802 
observation was performed at a median follow-up duration of 12.6 months in the Herceptin arm and 803 
formed the basis for the definitive DFS results from this study.  Among the 3386 patients 804 
randomized to the observation (n  = 1693) and Herceptin one-year (n  = 1693) treatment arms, the 805 
median age was 49 years (range 21−80), 83% were Caucasian, and 13% were Asian.  Disease 806 
characteristics:  94% infiltrating ductal carcinoma, 50% ER+ and/or PgR+, 57% node positive, 32% 807 
node negative, and in 11% of patients, nodal status was not assessable due to prior neo-adjuvant 808 
chemotherapy.  Ninety-six  percent (1055/1098) of patients with node-negative disease had high-risk 809 
features: among the 1098 patients with node-negative disease, 49% (543) were ER− and PgR−, and 810 
47% (512) were ER and/or PgR+ and had at least one of the following high-risk features:  811 
pathological tumor size greater than 2 cm, Grade 2−3, or age < 35 years.  Prior to randomization, 812 
94% of patients had received anthracycline-based chemotherapy regimens. 813 
 After the definitive DFS results comparing observation to one-year Herceptin treatment were 814 
disclosed, a prospectively planned analysis that included comparison of one year versus two years of 815 
Herceptin treatment at a median follow-up duration of 8 years was performed. Based on this 816 
analysis, extending Herceptin treatment for a duration of two years did not show additional benefit 817 
over treatment for one  year [Hazard Ratios of two -years Herceptin versus one-year Herceptin 818 
treatment in the intent to treat (ITT) population for Disease-Free Survival (DFS) = 0.99 (95% CI: 819 
0.87, 1.13), p-value  = 0.90 and Overall Survival (OS)   = 0.98 (0.83, 1.15); p-value  = 0.78].   820 
Study 4 821 
 In Study 4, breast tumor specimens were required to show HER2 gene amplification (FISH+ only) 822 
as determined at a central laboratory.  Patients were required to have either node-positive disease, or 823 
node-negative disease with at least one of the following high-risk features:  ER/PR-negative, tumor 824 
size >  2 cm, age < 35 years, or histologic and/or nuclear Grade 2 or 3.  Patients with a history of 825 
CHF, myocardial infarction, Grade 3 or 4 cardiac arrhythmia, angina requiring medication, clinically 826 
significant valvular heart disease, poorly controlled hypertension (diastolic >  100 mm Hg), any T4 or 827 
N2, or known N3 or M1 breast cancer were not eligible. 828 
 Patients were randomized (1:1:1) to receive doxorubicin and cyclophosphamide followed by 829 
docetaxel (AC-T), doxorubicin and cyclophosphamide followed by docetaxel plus Herceptin 830 
(AC-TH), or docetaxel and carboplatin plus Herceptin (TCH).  In both the AC-T and AC-TH arms, 831 
doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 were administered every 3 weeks for 832 
four cycles; docetaxel 100 mg/m2 was administered every 3 weeks for four cycles.  In the TCH arm, 833 
docetaxel 75 mg/m2 and carboplatin (at a target AUC of 6 mg/mL/min as a 30- to 60-minute 834 
infusion) were administered every 3 weeks for six cycles.  Herceptin was administered weekly 835 
(initial dose of 4 mg/kg followed by weekly dose of 2 mg/kg) concurrently with either T or TC, and 836 
then every 3 weeks (6 mg/kg) as monotherapy for a total of 52 weeks.  Radiation therapy, if 837 
administered, was initiated after completion of chemotherapy.  Patients with ER+ and/or PR+ tumors 838 
received hormonal therapy.  Disease-Free Survival (DFS) was the main outcome measure. 839 
 
28  Among the 3222 patients randomized, the median age was 49 (range 22 to 74 years; 6% 840 
≥ 65 years).  Disease characteristics included 54% ER+ and/or PR+ and 71% node positive.  Prior to 841 
randomization, all patients underwent primary surgery for breast cancer. 842 
 The results for DFS for the integrated analysis of Studies 1 and 2, Study 3, and Study 4 and OS 843 
results for the integrated analysis of Studies 1 and 2, and Study 3 are presented in Table 9.  For 844 
Studies 1 and 2, the duration of DFS following a median follow-up of 2.0 years in the AC→TH arm 845 
is presented in Figure 4, and the duration of OS after a median follow-up of 8.3 years in the 846 
AC→TH arm is presented in Figure 5.  The duration of DFS for Study 4 is presented in Figure 6.  847 
Across all four studies, at the time of definitive DFS analysis, there were insufficient numbers of 848 
patients within each of the following subgroups to determine if the treatment effect was different 849 
from that of the overall patient population: patients with low tumor grade, patients within specific 850 
ethnic/racial subgroups (Black, Hispanic, Asian/Pacific Islander patients), and patients  > 65 years of 851 
age.  For Studies 1 and 2, the OS hazard ratio was 0.64 (95% CI: 0.55, 0.74).  At 8.3 years of median 852 
follow-up [AC→TH], the survival rate was estimated to be 86.9% in the AC →TH arm and 79.4% in 853 
the AC→T arm.  The final OS analysis results from Studies 1 and 2 indicate that OS benefit by age, 854 
hormone receptor status, number of positive lymph nodes, tumor size and grade, and 855 
surgery/radiation therapy was consistent with the treatment effect in the overall population. In 856 
patients ≤ 50 years of age (n  = 2197), the OS hazard ratio was 0.65 (95% CI: 0.52, 0.81) and in 857 
patients > 50 years of age (n  = 1866), the OS hazard ratio was 0.63 (95% CI: 0.51, 0.78). In the 858 
subgroup of patients with hormone receptor-positive disease (ER-positive and/or PR-positive) 859 
(n = 2223), the hazard ratio for OS was 0.63 (95% CI: 0.51, 0.78). In the subgroup of patients with 860 
hormone receptor-negative disease (ER-negative and PR-negative) (n  = 1830), the hazard ratio for 861 
OS was 0.64 (95% CI: 0.52, 0.80). In the subgroup of patients with tumor size ≤  2 cm (n  = 1604), the 862 
hazard ratio for OS was 0.52 (95% CI: 0.39, 0.71). In the subgroup of patients with tumor size >  2 863 
cm (n  = 2448), the hazard ratio for OS was 0.67 (95% CI: 0.56, 0.80).  864 
 
29 Table 9 
Efficacy Results from Adjuvant Treatment of  
Breast Cancer (Studies 1 + 2, Study 3, and Study 4) 
 DFS 
events  DFS Hazard 
ratio  
(95% CI) 
p-value  Deaths  
(OS events)  OS Hazard ratio  
p-value  
Studies 1 + 2a 
AC→TH 
(n = 1872)b  
(n = 2031)c 133b 0.48b,d 
(0.39, 0.59)  
p< 0.0001e 289c 
 0.64c,d 
(0.55, 0.74)  
p< 0.0001e 
AC→T  
(n = 1880)b 
(n = 2032)c 261b  418c 
  
Study 3f 
Chemo→  
Herceptin  
(n = 1693 ) 127 0.54 
(0.44, 0.67)  
p< 0.0001g 31 0.75 
p = NSh 
Chemo→  
Observation  
(n = 1693)  219  40  
Study 4i 
TCH  
(n = 1075)  134 0.67 
 (0.54 – 0.84)  
p=0.0006e,j 56  
AC→TH 
(n = 1074)  121 0.60 
(0.48 – 0.76)  
p< 0.0001e,i 49  
AC→T 
(n = 1073)  180   80  
CI = confidence interval.  
 a Studies 1 and 2 regimens: doxorubicin and cyclophosphamide followed by paclitaxel 
(AC→T) or paclitaxel plus Herceptin (AC →TH). 
b Efficacy evaluable population, for the primary DFS analysis, following a median follow -up 
of 2.0 years in the AC →TH arm.  
c Efficacy evaluable population,  for the final OS analysis, following 707 deaths (8.3 years of 
median follow -up in the AC →TH arm).  
d Hazard ratio estimated by Cox regression stratified by clinical trial, intended paclitaxel 
schedule, number of positive nodes, and hormone receptor status.  
 e stratified log -rank test.  
 f  At definitive DFS analysis with median duration of follow -up of 12.6 months in the one-
year Herceptin treatment arm.  
 g log-rank test.  
 h NS =  non-significant.  
 i Study 4 regimens: doxorubicin and cyclophosphamide followed by docetaxel (AC →T) or 
docetaxel plus Herceptin (AC →TH); docetaxel and carboplatin plus Herceptin (TCH).  
 j A two -sided alpha level of 0.025 for each comparison.  
   
 865 
 
30 Figure 4  866 
Duration of Disease-Free Survival in  867 
Patients with Adjuvant Treatment of Breast Cancer (Studies 1 and 2) 868 
 869 
 870 

 
31 Figure 5 871 
Duration of Overall Survival in Patients with  872 
Adjuvant Treatment of Breast Cancer (Stud ies 1 and 2) 873 
 874 
Figure 6 875 
Duration of Disease-Free Survival in Patients with  876 
Adjuvant Treatment of Breast Cancer (Study 4) 877 
 878 
 Exploratory analyses of DFS as a function of HER2 overexpression or gene amplification were 879 
conducted for patients in Studies 2 and 3, where central laboratory testing data were available.  880 
The results are shown in Table 10.  The number of events in Study 2 was small with the exception of 881 

 
32 the IHC 3+/FISH+ subgroup, which constituted 81% of those with data.  Definitive conclusions 882 
cannot be drawn regarding efficacy within other subgroups due to the small number of events.  883 
The number of events in Study 3 was adequate to demonstrate significant effects on DFS in the 884 
IHC 3+/FISH unknown and the FISH +/IHC unknown subgroups. 885 
 886 
Table 10 
Treatment Outcomes in Studies 2 and 3 as a Function of  
HER2 Overexpression or Amplification 
 Study 2  Study 3c 
HER2 Assay 
Resulta Number of 
Patients  Hazard Ratio DFS  
(95% CI) Number of 
Patients  Hazard Ratio DFS  
(95% CI) 
IHC 3+  
 FISH (+)  1170 0.42 
(0.27, 0.64)  91 0.56 
(0.13, 2.50)  
 FISH ( −) 51 0.71 
(0.04, 11.79)  8 ⎯ 
 FISH Unknown  51 0.69 
(0.09, 5.14)  2258 0.53 
(0.41, 0.69)  
IHC < 3+ /  
FISH (+)  174 1.01 
(0.18, 5.65)  299b 0.53 
(0.20, 1.42)  
IHC unknown / 
FISH (+)  ⎯ ⎯ 724 0.59 
(0.38, 0.93)  
 a IHC by HercepTest, FISH by PathVysion (HER2/CEP17 ratio ≥ 2.0) as per formed  
at a central laboratory.  
 b All cases in this category in Study 3 were IHC 2+ . 
 c Median follow- up duration of 12.6 months in the one -year Herceptin treatment 
arm. 
 887 
14.2 Metastatic Breast Cancer 888 
 The safety and efficacy of Herceptin in treatment of women with metastatic breast cancer were 889 
studied in a randomized, controlled clinical trial in combination with chemotherapy (Study 5, 890 
n = 469 patients) and an open-label single agent clinical trial (Study 6, n  = 222 patients).  Both trials 891 
studied patients with metastatic breast cancer whose tumors overexpress the HER2 protein.  Patients 892 
were eligible if they had 2 or 3 levels of overexpression (based on a 0 to 3 scale) by 893 
immunohistochemical assessment of tumor tissue performed by a central testing lab. 894 
Previously Untreated Metastatic Breast Cancer (Study 5) 895 
 Study 5 was a multicenter, randomized, open-label clinical trial conducted in 469 women with 896 
metastatic breast cancer who had not been previously treated with chemotherapy for metastatic 897 
disease.  Tumor specimens were tested by IHC (Clinical Trial Assay, CTA) and scored as 0, 1+, 2+, 898 
or 3+, with 3+ indicating the strongest positivity.  Only patients with 2+ or 3+ positive tumors were 899 
eligible (about 33% of those screened).  Patients were randomized to receive chemotherapy alone or 900 
in combination with Herceptin given intravenously as a 4 mg/kg loading dose followed by weekly 901 
doses of Herceptin at 2 mg/kg.  For those who had received prior anthracycline therapy in the 902 
adjuvant setting, chemotherapy consisted of paclitaxel (175 mg/m2 over 3 hours every 21 days for at 903 
least six cycles); for all other patients, chemotherapy consisted of anthracycline plus 904 
cyclophosphamide (AC:  doxorubicin 60 mg/m2 or epirubicin 75 mg/m2 plus 600 mg/m2 905 
cyclophosphamide every 21 days for six cycles).  Sixty-five percent of patients randomized to 906 
 
33 receive chemotherapy alone in this study received Herceptin at the time of disease progression as 907 
part of a separate extension study. 908 
 Based upon the determination by an independent response evaluation committee, the patients 909 
randomized to Herceptin and chemotherapy experienced a significantly longer median time to 910 
disease progression, a higher overall response rate (ORR), and a longer median duration of response 911 
as compared with patients randomized to chemotherapy alone.  Patients randomized to Herceptin 912 
and chemotherapy also had a longer median survival (see Table 11).  These treatment effects were 913 
observed both in patients who received Herceptin plus paclitaxel and in those who received 914 
Herceptin plus AC; however the magnitude of the effects was greater in the paclitaxel subgroup. 915 
 916 
Table 11 
Study 5:  Efficacy Results in  
First-Line Treatment for Metastatic Breast Cancer 
 Combined Results  Paclitaxel Subgroup  AC Subgroup  
Herceptin + 
All Chemo -
therapy  
(n = 235) All Chemo -
therapy  
(n = 234) Herceptin + 
Paclitaxel  
(n = 92) Paclitaxel  
(n = 96) Herceptin + 
ACa 
(n = 143) AC 
(n = 138) 
Primary Endpoint  
Median 
TTP(mos)b,c 7.2 4.5 6.7 2.5 7.6 5.7 
95% CI  7, 8 4, 5 5, 10 2, 4 7, 9 5, 7 
p-valued  < 0.0001 < 0.0001 0.002 
Secondary Endpoints  
Overall 
Response 
Rateb 45 29 38 15 50 38 
95% CI  39, 51 23, 35 28, 48 8, 22 42, 58 30, 46 
p-valuee  < 0.001  < 0.001 0.10 
Median Resp 
Duration 
(mos)b,c 8.3 5.8 8.3 4.3 8.4 6.4 
25%, 75%  
Quartile 6, 15 4, 8 5, 11 4, 7 6, 15 4, 8 
Med Survival 
(mos)c 25.1 20.3 22.1 18.4 26.8 21.4 
95% CI  22, 30 17, 24 17, 29 13, 24 23, 33 18, 27 
p-valued  0.05 0.17 0.16 
 a AC = Anthracycline (doxorubicin or epirubicin) and cyclophosphamide.  
 b Assessed by an independent Response Evaluation Committee.  
 c Kaplan -Meier Estimate.  
 d log-rank test.  
 e χ2-test. 
 917 
 Data from Study 5 suggest that the beneficial treatment effects were largely limited to patients 918 
with the highest level of HER2 protein overexpression (3+) (see Table 12). 919 
 
34 Table 12 
Treatment Effects in Study 5 as a  
Function of HER2 Overexpression or Amplification 
HER2 Assay 
Result  Number of 
Patients  
(N) Relative Riskb for Time to 
Disease Progression  
(95% CI) Relative Riskb for Mortality  
(95% CI) 
CTA 2+ or 3+ 469 0.49 (0.40, 0.61)  0.80 (0.64, 1.00)  
FISH (+)a 325 0.44 (0.34, 0.57)  0.70 (0.53, 0.91)  
FISH ( −)a 126 0.62 (0.42, 0.94)  1.06 (0.70, 1.63)  
CTA 2+  120 0.76 (0.50, 1.15)  1.26 (0.82, 1.94)  
FISH (+)  32 0.54 (0.21, 1.35)  1.31 (0.53, 3.27)  
FISH ( −) 83 0.77 (0.48, 1.25)  1.11 (0.68, 1.82)  
CTA 3+  349 0.42 (0.33, 0.54)  0.70 (0.51, 0.90)  
FISH (+)  293 0.42 (0.32, 0.55)  0.67 (0.51, 0.89)  
FISH ( −) 43 0.43 (0.20, 0.94)  0.88 (0.39, 1.98)  
 a FISH testing results were available for 451 of the 469 patients enrolled on study.  
 b The relative risk represents the risk of progression or death in the Herceptin plus 
chemotherapy arm versus the chemotherapy arm.  
 920 
Previously Treated Metastatic Breast Cancer (Study 6) 921 
 Herceptin was studied as a single agent in a multicenter, open-label, single-arm clinical trial 922 
(Study 6) in patients with HER2 overexpressing metastatic breast cancer who had relapsed following 923 
one or two prior chemotherapy regimens for metastatic disease.  Of 222 patients enrolled, 66% had 924 
received prior adjuvant chemotherapy, 68% had received two prior chemotherapy regimens for 925 
metastatic disease, and 25% had received prior myeloablative treatment with hematopoietic rescue.  926 
Patients were treated with a loading dose of 4 mg/kg IV followed by weekly doses of Herceptin at 927 
2 mg/kg IV. 928 
 The ORR (complete response + partial response), as determined by an independent Response 929 
Evaluation Committee, was 14%, with a 2% complete response rate and a 12% partial response rate.  930 
Complete responses were observed only in patients with disease limited to skin and lymph nodes.  931 
The overall response rate in patients whose tumors tested as CTA 3+ was 18% while in those that 932 
tested as CTA 2+, it was 6%. 933 
14.3  Metastatic Gastric Cancer 934 
 The safety and efficacy of Herceptin in combination with cisplatin and a fluoropyrimidine 935 
(capecitabine or 5-fluorouracil) were studied in patients previously untreated for metastatic  gastric or 936 
gastroesophageal junction adenocarcinoma (Study 7).  In this open-label, multi-center trial, 937 
594 patients were randomized 1:1 to Herceptin in combination with cisplatin and a fluoropyrimidine 938 
(FC+H) or chemotherapy alone (FC).  Randomization was stratified by extent of disease (metastatic 939 
vs. locally advanced), primary site (gastric vs. gastroesophageal junction), tumor measurability (yes 940 
vs. no), ECOG performance status (0,1 vs. 2), and fluoropyrimidine (capecitabine vs. 5-fluorouracil).  941 
All patients were either HER2 gene amplified (FISH+) or HER2 overexpressing (IHC 3+).  Patients 942 
were also required to have adequate cardiac function (e.g., LVEF > 50%). 943 
 On the Herceptin-containing arm, Herceptin was administered as an IV infusion at an initial dose 944 
of 8 mg/kg followed by 6 mg/kg every 3 weeks until disease progression.  On both study arms 945 
cisplatin was administered at a dose of 80 mg/m2 Day 1 every 3 weeks for 6 cycles as a 2 hour IV 946 
 
35 infusion.  On both study arms, capecitabine was administered at 1000 mg/m2 dose orally twice daily 947 
(total daily dose 2000 mg/m2) for 14 days of each 21 day cycle for 6 cycles. Alternatively, 948 
continuous intravenous infusion (CIV) 5-fluorouracil was administered at a dose of 800 mg/m2/day 949 
from Day 1 through Day 5 every three weeks for 6 cycles.   950 
 The median age of the study population was 60 years (range: 21−83); 76% were male; 53% were 951 
Asian , 38% Caucasian, 5% Hispanic, 5% other racial/ethnic groups; 91% had ECOG PS of 0 or 1; 952 
82% had primary gastric cancer and 18% had primary gastroesophageal adenocarcinoma.  Of these 953 
patients, 23% had undergone prior gastrectomy, 7% had received prior neoadjuvant and/or adjuvant 954 
therapy, and 2% had received prior radiotherapy. 955 
 The main outcome measure of Study 7 was overall survival (OS), analyzed by the unstratified log- 956 
rank test. The final OS analysis based on 351 deaths was statistically significant (nominal 957 
significance level of 0.0193).  An updated OS analysis was conducted at one year after the final 958 
analysis. The efficacy results of both the final and the updated analyses are summarized in Table 13 959 
and Figure 7.   960 
 961 
Table 13 
Study 7: Overall Survival in ITT Population 
 FC Arm  
N = 296 FC + H Arm  
N = 298 
Definitive (Second Interim) Overall Survival    
     No. Deaths (%)  
     Median  
     95% CI (mos.)  184 (62.2%)  
11.0 
(9.4, 12.5)  167 (56.0%)  
13.5 
(11.7, 15.7)  
     Hazard Ratio  
     95% CI  
     p- value*, two- sided 0.73 
(0.60, 0.91)  
0.0038 
Updated Overall Survival    
     No. Deaths (%)  
     Median  
     95% CI (mos.)  227 (76.7%)  
11.7 
(10.3, 13.0)  221 (74.2%)  
13.1 
(11.9, 15.1)  
     Hazard Ratio  
     95% CI  0.80 
(0.67, 0.97)  
 * Comparing with the nominal significance level of 0.0193.  
 962 
 
36 Figure 7 963 
Updated Overall Survival in Patients with Metastatic Gastric Cancer (Study 7) 964 
 965 
 966 
An exploratory analysis of OS in patients based on HER2 gene amplification (FISH) and protein 967 
overexpression (IHC) testing is summarized in Table 14.  968 
 969 

 
37 Table 14  
Exploratory Analyses by HER2 Status  Using Updated Overall Survival Results 
 FC 
(N = 296)a FC+H  
(N = 298)b 
FISH+ / IHC 0, 1+ subgroup (N=133)    
   No. Deaths / n (%)  
   Median OS Duration (mos.)  
   95% CI (mos.)  57/71 (80%)  
8.8 
(6.4, 11.7)  56/62 (90%)  
8.3 
(6.2, 10.7)  
   Hazard ratio (95% CI)  1.33 (0.92, 1.92)  
FISH+ / IHC2+ subgroup (N=160)    
   No. Deaths / n (%)  
   Median OS Duration (mos.)  
   95% CI (mos.)  65/80 (81%)  
10.8 
(6.8, 12.8)  64/80 (80%)  
12.3 
(9.5, 15.7)  
   Hazard ratio (95% CI)  0.78 (0.55, 1.10)  
FISH+ or FISH - / IHC3+c subgroup (N=294)    
   No. Deaths / n (%)  
   Median OS Duration (mos.)  
   95% CI (mos.)  104/143 (73%)  
13.2 
(11.5 , 15.2)  96/151 (64%)  
18.0 
(15.5, 21.2)  
   Hazard ratio (95% CI)  0.66 (0.50, 0.87)  
 a Two patients on the FC arm who were  FISH+ but IHC status unknown were excluded from the exploratory 
subgroup analyses.  
 b Five patients on the Herceptin -containing arm  who were FISH+,  but IHC status unknown were excluded from the 
exploratory subgroup analyses. 
 c Includes 6 patients  on chemotherapy arm,  10 patients on Herceptin arm with  FISH –, IHC3+ and 8 patients on 
chemotherapy arm , 8 patients on Herceptin arm with FISH status unknown, IHC 3+ . 
 970 
16 HOW SUPPLIED/STORAGE AND HANDLING 971 
16.1 How Supplied 972 
420 mg Multiple-dose vial  973 
 Herceptin (trastuzumab) for Injection 420 mg/vial is supplied in a multiple-dose vial as a 974 
lyophilized sterile powder, under vacuum.  Each carton contains one multiple-dose vial of Herceptin 975 
and one vial (20 mL) of Bacteriostatic Water for Injection (BWFI), USP, containing 1.1% benzyl 976 
alcohol as a preservative.   977 
NDC 50242-333-01. 978 
150 mg Single-dose vial  979 
 Herceptin (trastuzumab) for Injection 150 mg/vial is supplied in a single-dose vial as a lyophilized 980 
sterile powder, under vacuum.  Each carton contains one single-dose vial of Herceptin.  981 
NDC 50242-132-01. 982 
16.2 Storage 983 
 Store Herceptin vials in the refrigerator at 2°C to 8°C (36°F to 46°F) until time of reconstitution.   984 
 985 
17 PATIENT COUNSELING INFORMATION 986 
Cardiomyopathy  987 
• Advise patients to contact a health care profession al immediately for any of the following: new 988 
onset or worsening shortness of breath, cough, swelling of the ankles/legs, swelling of the face, 989 
 
38 palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness 990 
[see Boxed Warning: Cardiomyopathy] . 991 
 992 
Embryo-Fetal Toxicity 993 
• Advise pregnant women and females of reproductive potential that Herceptin exposure during 994 
pregnancy or within 7 months prior to conception can result in fetal harm.  Advise female 995 
patients to contact their healthcare provider with a known or suspected pregnancy [see Use in 996 
Specific Populations (8.1)]. 997 
• Advise women who are exposed to Herceptin during pregnancy or who become pregnant within 998 
7 months following the last dose of Herceptin that there is a pregnancy exposure registry and a 999 
pregnancy pharmacovigilance program that monitor pregnancy outcomes.  Encourage these 1000  
patients to enroll in the MotHER Pregnancy Registry and report their pregnancy to Genentech 1001  
[see Use in Specific Populations (8.1)] . 1002  
• Advise females of reproductive potential to use effective contraception during treatment and for 1003  
7 months following the last dose of Herceptin [see Use in Specific Populations (8.3)] . 1004  
 1005  
HERCEPTIN® [trastuzumab] 
Manufactured by: 
Genentech, Inc. 
A Member of the Roche Group 
1 DNA Way 
South San Francisco, CA  94080-4990 
US License No.1048 Herceptin® is a registered trademark of Genentech, Inc. 
©2017 Genentech, Inc. 
 
 
      
 
 
  
May 2017  
ANNOUNCEMENT – HERCEPTIN
® VIAL CHANGE   
 Dear Pharmacist:  
 We want to make you aware of an u pcoming change to Herceptin
 (trastuzumab) .  Recently, the  FDA 
approved a revised USPI for Herceptin (dated 04 /2017) that lists a new 150mg singe- dose configuration 
along with additional label changes to meet current FDA guidance.  The  new 150mg single -dose vial 
configuration for Herceptin will be introduced on May 30, 2017 .   
 Important information for you to know:  
 
● All customers will be asked to transition to the 150mg single -dose vial once available for order on 
May 30
th.  After  July 7, 2017,  Genentech will only ship 150mg vials to distributors and will 
discontinue shipping the 440mg multiple -dose vial to distributors .  
● The National Drug Code (NDC) for the Herceptin 150mg vial is: 50242 -132-01. 
● After July 7th, you may continue using any 440mg vials in your inventory until the expiration date 
noted on the vial when stored in conditions recommended in the USPI.  
● All payers, pharmacies and distributors should  confirm that the current NDC for the 440mg 
multiple -use vial [NDC 50242 -134-68] remains active within all  systems, through product 
expiration date, in order to ensure this medicine remains available to providers and patients.  
● The Herceptin Wholesale Acquisition Cost (WAC) per milligram does not change with the new 150mg vial introduction.  
● Authorized Herceptin distributors do not change.  A complete listing of distributors can be found 
on https://www.genentech- access.com/hcp/brands/herceptin/learn- about -our-services/product -
distribution.html  
Decisions on how we manufacture and package our medicines are taken very seriously and all of our medicines, including all configurations of Herceptin, are packaged to meet FDA regulations and 
specifications.  If you have any questions, please contact your  Genentec h Clinical Oncology Specialist or 
call the Genentech Customer Service Department at 1 -800-551-2231, Monday through Friday, 6:00AM to 
5:00PM PST. 
  
Sincerely,  
 
 
Cindy Perettie Vice President, HER2 Franchise  
Genentech  USA, Inc . 
 
HPK/102416/0066  

	
  
	
   2	
  Indications  
 
Adjuvant Breast Cancer  
Herceptin is indicated for adjuvant treatment of HER2 -overexpressing  node- positive or node- negative 
(ER/PR -negative or with one high- risk feature*) breast cancer:  
• As part of a treatment regimen containing doxorubicin, cyc lophosphamide, and either paclitaxel or 
docetaxel  
• With docetaxel and carboplatin  
• As a single agent following multi -modality anthracycline -based therapy 
• Select patients for therapy based on an FDA -approved companion diagnostic for Herceptin 
*High -risk is defined as ER/PR positive with one of the following features: tumor size >2 cm, age <35 years, or tumor 
grade 2 or 3.  
 
Metastatic Breast Cancer  
Herceptin is indicated:  
• In combination with paclitaxel for the first line treatment of HER2 -overexpressing metastatic breast 
cancer  
• As a single agent for treatment of HER2 -overexpressing breast cancer in patients who have received 
one or more chemotherapy regimens for metastatic disease  
• Select patients for therapy based on an FDA -approved companion diagnostic for Herceptin  
 
Metastatic Gastric Cancer  
Herceptin is indicated, in combination with cisplatin and capecitabine or 5 -fluorouracil, for the treatment of 
patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, 
who have not  received prior treatment for metastatic disease.   
Select patients for therapy based on an FDA -approved companion diagnostic for Herceptin 
 
Boxed WARNINGS and Additional Important Safety Information  
 
• Herceptin administration can result in sub -clinical and clinical cardiac failure. The incidence and 
severity was highest in patients receiving Herceptin with anthracycline -containing 
chemotherapy regimens. In a pivotal adjuvant trial, one patient who developed CHF died of 
cardiomyopathy  
• Evaluate left ventricula r function in all patients prior to and during treatment with Herceptin. 
Discontinue Herceptin treatment in patients receiving adjuvant therapy and withhold Herceptin in patients with metastatic disease for clinically significant decrease in left ventricul ar function 
• Herceptin administration can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of Herceptin administration.  Interrupt Herceptin infusion for dyspnea or clinically significan t hypotension. Monitor patients 
until symptoms completely resolve. Discontinue Herceptin for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome 
• Exposure to Herceptin during pregnancy can result in oligohydramnios and oligohydramnios 
sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. 
Advise patients of these risks and the need for effective contraception  
• Exacerbation of chemotherapy -induced neutropenia has also occurred  
• The most common adverse reactions associated with Herceptin in breast cancer were fever, nausea, 
vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, 
neutropenia, anemia, and myalgia 
• The most common adverse reaction s associated with Herceptin in metastatic gastric cancer were 
neutropenia, diarrhea, fatigue, anemia, stomatitis, weight loss, upper respiratory tract infections, fever, thrombocytopenia, mucosal inflammation, nasopharyngitis, and dysgeusia  
 
You may report  side effects to the FDA at (800) FDA -1088 or www.fda.gov/medwatch . You may also 
report side effects to Genentech at (888) 835 -2555.  
 Please see the accompanying full Prescribing Information, including Boxed WARNINGS . 
XL184-IST Pharmacy Manual Version 3.0  CONFIDENTIAL            Page 1 of 10  
 
 
 
STUDY PHARMACY MANUAL 
 
PROTOCOL NUMBER: IST-____ __ 
 
XL184
-Investigator Sponsored Trial (IST) 
     
 
    
 
Investigational Product Main 
Distributor:  Exelixis , Inc. 
210 East Grand Avenue  
South San Francisco, CA 9408 0 
 
Study Drug:    
Cabozantinib (XL184) Tablets  
 
 
IND Number:                     72,596 
 
Date:                                                               21-Nov- 2017 
 
Version Number:                                           3.0 
   
                   
        
                 
 
 
 
 
 
 
All queries regarding investigational product (IP) shipments should be directed to 
Exelixis Clinical Supplies at Clinical_Supplies@Exelixis.com   

XL184-IST Pharmacy Manual Version 3.0  CONFIDENTIAL            Page 2 of 10  
 
This Pharmacy Manual provides instructions to help you understand the management of 
the investigational product (IP), Cabozantinib. This manual should be stored in the 
Pharmacy Binder at the same location where IP is stored. 
Detailed instructions on the management of IP are also included in the protocol. You are 
encouraged to read both this manual and the protocol closely before the study 
commences at your site and refer to them whenever a new study subject is enrolled.  
An initial 
supply of IP will be shipped to your site upon request following regulatory 
approval and site activation by Exelixis.  
 
 
 
 
 
 
 
 
 
 
 
 
  

XL184-IST Pharmacy Manual Version 3.0  CONFIDENTIAL            Page 3 of 10 XL184-IST  PHARMACY MANUAL 
Table  of Contents 
1 SITE PERSONNEL RESPONSIBILITIES ..................................................... 4 
2 STUDY DESCRIPTION ................................................................................. 4 
3 INVESTIGATIONAL PRODUCT DESCRIPTION AND PACKAGING ........... 4 
3.1 Cabozantinib (XL184) Description ......................................................... 4 
     3.2       Cabozantinib (XL184) Packaging .......................................................... 5 
4 STORAGE AND HANDLING .......................................................................... 5 
5 DRUG SHIPMENTS ...................................................................................... 5 
5.1 Initial and Resupply Shipments ............................................................. 5 
5.2 Shipment Requests and Timelines ........................................................ 5 
5.3 Drug Expiry Date and Notification ......................................................... 6 
5.4 Drug Receipt and Confirmation ............................................................. 6 
6 INVESTIGATIONAL PRODUCT ADMINISTRATION ....................................7  
6.1 Dispensation and Administration ........................................................... 7 
6.1.1  Cabozantinib Dispensation ......................................................... 7 
6.1.2  Cabozantinib Administration ....................................................... 7 
6.2 Instructions on Dose Reduction and/or Hold .........................................7  
6.3 Subject Dosing Instructions ...................................................................7  
7 RECORD KEEPING………………………………………………………………7 
8       INVESTIGATIONAL PRODUCT ACCOUNTABILITY PROCEDURES ........8  
9 INVESTIGATIONAL PRODUCT DISPOSITION ..........................................  .8 
10 PHARMACY MANUAL HISTORY ................................................... ……......8 
ATTACHMENT 1.0 SAMPLE OF DRUG REQUEST FORM………….…………...10 
ATTACH
MENT 2.0 INSTRUCTIONS FOR WRITING IN STUDY IDENTIFIER…11  
XL184-IST Pharmacy Manual Version 3.0  CONFIDENTIAL            Page 4 of 10  
1 SITE PERSONNEL RESPONSIBILITIES 
The Principal Investigator (PI) should assign responsibility for the investigational product 
(IP) management to one primary study staff member. This person must be a licensed 
healthcare professional, preferably a pharmacist or a nurse. This manual will refer to 
this person as the Investigational Product Manager (IPM). It is recommended that a 
back-up person also be identified to cover in the absence of the primary IPM.  
2 STUDY DESCRIPTION 
Please refer to the study protocol for a detailed description of the study. 
3 INVESTIGATIONAL PRODUCT DESCRIPTION AND PACKAGING 
Exelixis will provide approved investigative sites with adequate supplies of labeled IP 
(refer to Attachment 2.0 for example label) .   
3.1   Cabozantinib (XL184) Description 
Cabozan
tinib is supplied as 60 mg and 20 mg yellow film-coated tablets. The 60 mg 
tablets are oval shaped and the 20 mg tablets are round. The components of the tablets 
are listed in the following table:  
Ingredient   Function  % w/w 
Cabozantinib Drug Substance (25% dru g load as free base)  Active Ingredient  31.7 
Microcrystalline Cellulose (Avicel PH -102) Filler  38.9 
Lactose Anhydrous (60M)  Filler  19.4 
Hydroxypropyl Cellulose (EXF)  Binder  3.0 
Croscarmellose Sodium (Ac -Di-Sol) Disintegrant  6.0 
Colloidal Silicon Dioxide,  Glidant  0.3 
Magnesium Stearate  Lubricant  0.75 
Opadry Yellow Film Coating which includes:  
HPMC 2910 / Hypromellose 6 cp  
Titanium dioxide  
Triacetin  
Iron Oxide Yellow  Film Coating  4.00 
Refer to the Investigator Brochure for additional information on Cabozantinib. 
XL184-IST Pharmacy Manual Version 3.0  CONFIDENTIAL            Page 5 of 10 3.2  Cabozantinib (XL184) Packaging 
IP will 
be provided in 60cc HDPE white bottles containing 30 tablets each. Each bottle 
will be printed with a unique 7-digit bottle number and a lot number for tracking 
purposes. The IP label will have a blank line under the drug type and drug name where 
the site staff will need to write in the specific IST Study Identifier (see Attachment 2.0) .    
4 STORAGE AND HANDLING 
All IP must be stored in a secure location with access available only to authorized 
personnel. The IP must be stored at controlled room temperature (20-25 degrees 
Centigrade, or 68-77 degrees Fahrenheit); allowing for excursions between 15 and 30 
degrees Centigrade (59 and 86 degrees Fahrenheit) and inventoried according to 
applicable state and federal regulations. Please contact Exelixis Clinical Supplies at 
Clinical_Supplies@exelixis.com  immediately in case of any temperature excursions 
outside the accepted range. All affected IP will need to be quarantined until further 
notification. 
Refer to the Cabozantinib Material Safety Data Sheet (MSDS) for additional handling 
information if required.  
Subjects need to be instructed to: 
 Store the IP at controlled room temperature, away from direct sunlight or 
appliances/items that give off heat, and out of reach of children and/or pets.  
 Not store the study drug in a hot, unventilated car for a long period of time. 
5 DRUG SHIPMENTS 
5.1 Initial and Re-supply Shipments 
After IST site activation, the site is required to submit the completed Initial Exelixis 
Study Drug Shipment Request Form (see Attachment 1.0) by email to 
Clinical_Sup
plies@Exelixis.com . Subsequent re-supply shipments of IP will be made by 
following the same process outlined above.  
All Exelixis Study Drug Shipment Request Forms must be fully completed (see below) 
to avoid any delays: 
- Complete Section 1.0: Site Information 
o Investigator Name  
XL184-IST Pharmacy Manual Version 3.0  CONFIDENTIAL            Page 6 of 10 o Contact Name 
o Site Name and Address 
o Phone/Fax 
o Date Requested/Required  
o Requested By 
 
- Complete Section 2.0: Drug Request 
o Check the appropriate box for “Initial” or “Resupply” 
o Requested Quantity and Current Inventory 
o Current # of active patients and their current dose 
 
Note:  A
llow 3-5 business days for processing and delivery of shipments. 
 
5.2 Shipment Requests and Timelines 
General drug shipments will take place Monday through Thursday only. In case of 
emergency , a special request will need to be authorized by Exelixis Clinical Supplies in 
order to ship on Friday. If a special drug shipment request is needed, please contact 
Exelixis Clinical Supplies immediately.  The Exelixis Clinical Supplies team can be 
reached directly at the following email address: Clinical_Supplies@Exelixis.com  
5.3 Drug Expiry Date Notification 
Exelixis maintains an on-going stability program for all lots of cabozantinib being used in 
study trials
 and is responsible for the management of the expiry dates for the 
cabozantinib supplied. In addition, Exelixis provides notification letters to sites before 
the expiry date of the affected IP. All expiry date notification letters should be filed in the 
site study pharmacy binder. 
5.4 Drug Receipt and Confirmation 
The Study Pharmacist or assigned designee is responsible for proper inspection of each 
shipment of IP received.  At the time of receipt, the Study Pharmacist or assigned 
designee must provide confirmation that all supplies are intact and in good condition. 
Once IP is received and confirmed in good condition, write in the IST Study Identifier on 
the designated blank line available on the label of the IP bottle(s) (see Attachment 2.0).   
If the shipment is damaged, missing, shows signs of tampering, etc., quarantine the 
shipment in a secure location and contact Exelixis Clinical Supplies immediately. Once 
XL184-IST Pharmacy Manual Version 3.0  CONFIDENTIAL            Page 7 of 10 a final decision is made regarding the disposition of any IP placed on quarantine status, 
you will receive further information regarding the availability or unavailability of the IP. 
All IP shipment/receipt documentation must be filed in site study pharmacy binder. 
6 INVESTIGATIONAL PRODUCT DISPENSATION/ADMINISTRATION 
6.1 Dispensation and Administration 
6.1.1   Cabozantinib Dispensation 
All cabozantinib should be dispensed in the original container supplied by Exelixis and 
should not be repackaged at any time. 
6.1.2   Cabozantinib Administration 
For the doses of cabozantinib taken outside the clinic, subjects should fast (with the 
exception of water) for at least 2 hours after eating an evening meal before taking their 
dose. After the 2-hour fast and before going to bed, subjects are to take cabozantinib 
with a full glass of water (minimum of 8 ounces or 240 millilite rs) with no more food 
intake for a minimum of one hour post-dose. If the subject’s schedule requires taking 
cabozantinib during the day, the subject is to be instructed to follow the same fasting 
recommendations. The subject should take cabozantinib at approximately the same 
time every day and the subject is to adhere to the fasting requirements described in this 
section. 
6.2 Instructions on Dose Reduction and/or Hold 
Refer to the IST protocol for further details on dose reduction and dose holds.   
6.3 Subject Dosing Instructions 
Refer to Section 6.1.2 of this document for out-patient dosing instructions. Subject 
compliance with out-patient study treatment regimens will be assessed by the site using 
standard operating procedures.  
7 RECORD KEEPING  
All records must be retained and available per site procedures. At the end of the study, 
the IP records will be incorporated into the clinical study file for long-term storage. The 
site is responsible for maintaining the study documents for at least 2 years after 
cabozantinib receives marketing approval for the indication being investigated, or 2 
years after formal discontinuation of clinical development of cabozantinib and FDA 
notification of such (i.e., the IND is closed), or until further notification from Exelixis. 
XL184-IST Pharmacy Manual Version 3.0  CONFIDENTIAL            Page 8 of 10 8 INVESTIGATION AL PRODUCT ACCOUNTABILITY PROCEDURES 
The study investigator or assigned designee is required to maintain accurate IP 
accountability records per the site Standard Operating Procedures (SOP).   
9 INVESTIGATIONAL PRODUCT DISPOSITION  
At no time during the study should IP be returned to Exelixis. Please follow your site’s 
Standard Operating Procedure for destruction of IP. If site is unable to destroy IP on site , 
the IP will need to be returned to the depot for destruction. Please contact Exelixis 
Clinical Supplies at Clinical_Supplies@exelixis.com  for instructions on returning IP to 
the depot. 
10 PHARMACY MANUAL HISTORY 
Pharmacy 
Manual 
Version  Effective Date  Change Summary  
V3 24-Oct-2017  Revised Version  
 
 
 
 
 
 
 
 
 
  
XL184-IST Pharmacy Manual Version 3.0  CONFIDENTIAL            Page 9 of 10 ATTACHMENT 1.0 : SAMPLE OF DRUG REQUEST FORM      
 
 
SECTION 1: SITE INFORMATION 
 
 
STUDY DRUG ORDER FORM 
  
Investigator Name:   
 Contact Person:   
 Site Name &Address:   
   
   
 Phone/Fax:   
 Date Requested:   
 Date Required at Site:   
                              
Requested  By:  
 
SECTION 2: DRUG REQUEST:  
 
For Clinical Site Use Only:  For Exelixis Clinical Supplies Use Only:  
 Initial Supply           Resupply  Exelixis Order # _____ 
PRODUCT 
DESCRIPTION  
(30 Tablets per 
bottle) REQUESTED 
QUANTITY  CURRENT 
INVENTORY  APPROVED 
QUANTITY  LOT 
NUMBER  PART NUMBER  
XL184 20 mg Tab       
XL184 60 mg Tab       
Total # of Active Subjects  
20mg       
40mg       
60mg       
To avoid any delays on shipment order processing, the “Requester” must complete all 
information requested on the form.  
 
For Exelixis Clinical Supplies Use Only 
Shipment Request Approved By:  
 
  
PROTOCOL:  
 
  XL184  – IST______  
 
Print Name / 
Signature   Date:  
  
XL184-IST Pharmacy Manual Version 3.0  CONFIDENTIAL            Page 10 of 10 Attachment 2.0 : INSTRUCTIONS FOR WRITING IN STUDY 
IDENTIFIER ON STUDY DRUG BOTTLE  
 
1. Remove the drug bottle(s) from your drug shipment. 
 
2. On the label of the bottle, you will find an empty space under “XL184 
(Cabozantinib) 20mg Tablets” or “XL184 (Cabozantinib) 60mg Tablets”. (See 
below for sample label text) 
 
3. Fill in the space by writing in your IST Study Number.   
 Note :  The IST Study number is on your Exelixis Study Drug Shipment Request 
Form. 
 
Sample Labels: 
 
        
 
         
